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A B S T R A C T
Background
Respiratory tract infection with Pseudomonas aeruginosa occurs in most people with cystic ﬁbrosis. Once chronic infection is established,
Pseudomonas aeruginosa is virtually impossible to eradicate and is associated with increased mortality and morbidity. Early infection
may be easier to eradicate.
This is an update of a Cochrane review ﬁrst published in 2003, and previously updated in 2006 and 2009.
Objectives
To determine whether antibiotic treatment of earlyPseudomonas aeruginosa infection in children and adults with cystic ﬁbrosis eradicates
the organism, delays the onset of chronic infection, and results in clinical improvement. To evaluate whether there is evidence that a
particular antibiotic strategy is superior to or more cost-effective than other strategies and to compare the adverse effects of different
antibiotic strategies (including respiratory infection with other micro-organisms).
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identiﬁed from compre-
hensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.
Most recent search: 08 September 2014.
Selection criteria
We included randomised controlled trials of people with cystic ﬁbrosis, in whom Pseudomonas aeruginosa had recently been isolated
from respiratory secretions. We compared combinations of inhaled, oral or intravenous antibiotics with placebo, usual treatment or
other combinations of inhaled, oral or intravenous antibiotics. We excluded non-randomised trials, cross-over trials, and those utilising
historical controls.
Data collection and analysis
Both authors independently selected trials, assessed risk of bias and extracted data.
1Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Main results
The search identiﬁed 49 trials; seven trials (744 participants) with a duration between 28 days and 27 months were eligible for inclusion.
Three of the trials are over 10 years old and their results may be less applicable today given the changes in standard treatment. Some
of the trials had low numbers of participants and most had relatively short follow-up periods; however, there was generally a low risk
of bias from missing data. In most trials it was difﬁcult to blind participants and clinicians to treatment given the interventions and
comparators used. Two trials were supported by the manufacturers of the antibiotic used.
Evidence from two trials (38 participants) at the two-month time-point showed treatment of early Pseudomonas aeruginosa infection
with inhaled tobramycin results in microbiological eradication of the organism from respiratory secretions more often than placebo,
odds ratio 0.15 (95% conﬁdence interval 0.03 to 0.65) and data from one of these trials, with longer follow up, suggested that this
effect may persist for up to 12 months.
One randomised controlled trial (26 participants) compared oral ciproﬂoxacin and nebulised colistin versus usual treatment. Results
after two years suggested treatment of early infection results in microbiological eradication of Pseudomonas aeruginosa more often than
no anti-pseudomonal treatment, odds ratio 0.12 (95% conﬁdence interval 0.02 to 0.79).
One trial comparing 28 days to 56 days treatment with nebulised tobramycin solution for inhalation in 88 participants showed that
both treatments were effective and well-tolerated, with no notable additional improvement with longer over shorter duration of therapy.
However, this trial was not powered to detect non-inferiority or equivalence .
A trial of oral ciproﬂoxacin with inhaled colistin versus nebulised tobramycin solution for inhalation alone (223 participants) failed to
show a difference between the two strategies, although it was underpowered to show this. A further trial of inhaled colistin with oral
ciproﬂoxacin versus nebulised tobramycin solution for inhalation with oral ciproﬂoxacin also showed no superiority of the former, with
increased isolation of Stenotrophomonas maltophilia in both groups.
A recent, large trial in 306 children aged between one and 12 years compared cycled nebulised tobramycin solution for inhalation to
culture-based therapy and also ciproﬂoxacin to placebo. The primary analysis showed no difference in time to pulmonary exacerbation
or proportion of Pseudomonas aeruginosa positive cultures. An analysis performed in this review (not adjusted for age) showed fewer
participants in the cycled therapy group with one or more isolates of Pseudomonas aeruginosa, odds ratio 0.51 (95% CI 0.31 to 0.28).
Authors’ conclusions
We found that nebulised antibiotics, alone or in combination with oral antibiotics, were better than no treatment for early infection
with Pseudomonas aeruginosa. Eradication may be sustained for up to two years. There is insufﬁcient evidence to determine whether
antibiotic strategies for the eradication of early Pseudomonas aeruginosa decrease mortality or morbidity, improve quality of life, or are
associated with adverse effects compared to placebo or standard treatment. Four trials of two active treatments have failed to show
differences in rates of eradication of Pseudomonas aeruginosa.There have been no published randomised controlled trials that investigate
the efﬁcacy of intravenous antibiotics to eradicate Pseudomonas aeruginosa in cystic ﬁbrosis. Overall, there is still insufﬁcient evidence
from this review to state which antibiotic strategy should be used for the eradication of early Pseudomonas aeruginosa infection in cystic
ﬁbrosis.
P L A I N L A N G U A G E S U M M A R Y
Different ways of giving antibiotics to eradicate Pseudomonas aeruginosa infection in people with cystic fibrosis
Review question
We reviewed the evidence for the effectiveness of antibiotics in getting rid of a lung infection with a germ called Pseudomonas aeruginosa
in people with cystic ﬁbrosis.
Background
Cystic ﬁbrosis is an inherited condition where the airways often become blocked with mucus. It is associated with chest infections,
which can lead to progressive breathing failure and death. A germ called Pseudomonas aeruginosa is a frequent cause of infection and is
difﬁcult to treat effectively, once infection has become established.
Search date
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The evidence is current to September 2014.
Study characteristics
We wanted to compare different combinations of inhaled, oral and intravenous (IV) antibiotics for eliminating Pseudomonas aeruginosa
in people with cystic ﬁbrosis and ﬁnd out if any single treatment works best and is more cost-effective. We included seven trials with a
total of 744 individuals, but the treatments were mostly different so we could not combine the results. Two trials compared tobramycin
to placebo (a dummy treatment). Three trials used a combination of oral ciproﬂoxacin and inhaled colistin in one group of volunteers
and compared this combination to no treatment in one trial, to inhaled tobramycin in a second trial and to oral ciproﬂoxacin with
inhaled tobramycin in the third trial. Another trial compared 28 days of inhaled tobramycin to 56 days of inhaled tobramycin and
the ﬁnal included trial compared regular cycles of inhaled tobramycin (plus oral ciproﬂoxacin or placebo) to culture-based inhaled
tobramycin (plus oral ciproﬂoxacin or placebo). Trials included people with cystic ﬁbrosis of both sexes, any age and both mild and
more severe lung disease. The trials lasted from 28 days to 27 months.
Key results
Two small trials (38 volunteers) treating early infection showed that, after two months, nebulised antibiotics were better than no
treatment and eliminated Pseudomonas aeruginosa in most people. One of these trials reported results over a longer period and these
suggested that this effect may last for up to 12 months. Another small trial (26 volunteers) which lasted two years showed that treating
early infection with a combination of nebulised and oral antibiotics was better than no treatment at eliminating Pseudomonas aeruginosa.
A further trial (88 volunteers), which compared 28 days of nebulised tobramycin solution for inhalation to 56 days, showed both
were equally tolerated and effective at eliminating Pseudomonas aeruginosa. Four direct comparisons of oral or inhaled antibiotics (or
combinations of both), one of which reported on 223 volunteers, did not ﬁnd a difference between different antibiotic combinations. A
recent, large trial in 306 children (aged up to 12 years) compared a regular cycle of treatment to treatment only when it was shown that
a child was infected with Pseudomonas aeruginosa, the treatment used was either an antibiotic or a placebo. When we analysed the data
for this review, we found that when children were given a regular cycle of inhaled tobramycin (with either oral ciproﬂoxacin or placebo)
fewer of them grew Pseudomonas aeruginosa from their sputum. The ofﬁcial published results from this trial made an adjustment for
age and did not show any difference in the number of times Pseudomonas aeruginosa was grown from samples between the groups, nor
was there any difference in the length of time until the patients had their next chest infection.
Quality of the evidence
Some of the trials were conducted between 10 and 20 years ago and the results may not be applicable to patients today. Some trials
were small and all the trials had quite a short follow-up period. Therefore, we could not show whether treatment made people with
cystic ﬁbrosis feel better or live longer. Given the types of treatment used in most of the trials, it would have been easy for the volunteers
to guess which treatment they were receiving, which might have inﬂuenced some of the results. Two trials were supported by the
pharmaceutical industry. Further research is still needed to see whether eliminating the bacteria completely improves the well-being
and quality of life in people with cystic ﬁbrosis and to establish which antibiotic combination provides the best way of eliminating
Pseudomonas aeruginosa.
B A C K G R O U N D
Description of the condition
Cystic ﬁbrosis (CF) is the most common life-limiting, autoso-
mal recessively inherited disease in Caucasian populations. Al-
though this is a multisystem disease, the primary cause of death
in CF is respiratory failure resulting from chronic pulmonary in-
fection (FitzSimmons 1993). The most frequent cause of chronic
pulmonary infection beyond infancy in people with CF is Pseu-
domonas aeruginosa (P. aeruginosa) and, once established, appears
to be permanent in the majority of cases (Fitzsimmons 1996). A
number of deﬁnitions have been used for chronic P. aeruginosa
infection in CF.
1. The presence of P. aeruginosa in monthly specimens for six
successive months or the development of precipitating antibodies
to P. aeruginosa or both (Valerius 1991).
2. The culture of P. aeruginosa from the sputum or respiratory
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secretions, on two or more occasions extending over six months
or a shorter period if accompanied by a sustained rise of anti-
pseudomonal antibodies (UK CF Trust 2004).
3. The isolation of P. aeruginosa in more than 50% of months
over a 12-month period (Lee 2003) - the second and subsequent
positive specimens in the same month do not count. Conversely,
eradication is deﬁned as all monthly specimens negative for P.
aeruginosa over 12 months.
4. Three or more isolates of P. aeruginosa in a 12-month
period (UK CF Registry 2012).
We have used the ﬁrst deﬁnition in this systematic review.
The age-speciﬁc prevalence of P. aeruginosa in pre-school children
is under 5%, rising to 30% at aged 16 years (UK CF Registry
2013). Some authors have suggested that the use of prophylactic
anti-staphylococcal antibiotic therapy in early childhood may pre-
dispose to chronic P. aeruginosa infection (Ratjen 2001b; Stutman
2002). However, this effect was not seen in a systematic review
of prophylactic antibiotic use, including over 400 participants
(Smyth 2012).
In children who are too young to expectorate, cough swabs or
oropharyngeal swabs are the only respiratory specimens which
can be easily obtained. These do not reliably predict the presence
of P. aeruginosa in the lower respiratory tract (Armstrong 1996;
Rosenfeld 1999), whereas ﬂexible ﬁbreoptic bronchoscopy with
bronchoalveolar lavage (BAL) may detect positive P. aeruginosa
in children with negative cough swabs or oropharyngeal swabs
(Douglas 2009; Hilliard 2007). Sputum cultures have been shown
to accurately reﬂect lower respiratory tract organisms in expecto-
rating children and adults (Iacocca 1963; Thomassen 1984). Over
half of people with CF have chronic infection with P. aeruginosa
by their early twenties (UK CF Registry 2013), although prior to
chronic infectionP. aeruginosa is often isolated intermittently from
respiratory tract specimens. This may represent transient colonies
of P. aeruginosawithin the lower respiratory tract or alternatively it
may reﬂect the difﬁculties in accurately detecting P. aeruginosa in
the lungs of youngpeoplewithCF (Burns 2001). The quantity and
type of P. aeruginosa present in the lower respiratory tract changes
as infection becomes established. It is known that P. aeruginosa
has two major phenotypes - mucoid and non-mucoid. Following
ﬁrst isolation there is a progressive increase in the density of P.
aeruginosa colonies in the lower respiratory tract (Rosenfeld 2001).
Initial isolates often show a non-mucoid phenotype; however, as
infection progresses a mucoid phenotype may prevail and will be
more difﬁcult to eradicate. Douglas has reported a relatively high
prevalence (18.2%) of mucoid P. aeruginosa) at ﬁrst isolation in
newborn screened infants, speculating that the notion of transfor-
mation from non-mucoid to mucoid phenotype under environ-
mental pressure may be inaccurate in young children. (Douglas
2009). It has been reported that P. aeruginosa provokes an inﬂam-
matory response of the lower respiratory tract (Muhlebach 1999)
and there is a marked step up in this inﬂammatory response as the
number of P. aeruginosa colonies increases (Armstrong 1996).
The presence of P. aeruginosa in respiratory secretions is a major
predictor of mortality in children with CF (Emerson 2002). Indi-
viduals with CF infected with P. aeruginosa also suffer greater mor-
bidity with a more rapid deterioration in lung function (Emerson
2002; Pamukcu 1995) and a more rapid decline in chest radio-
graph score (Kosorok 2001), poor growth, reduced quality of life,
increased hospitalisation and increased need for antibiotic treat-
ment (Ballman 1998; Nixon 2001; Winnie 1991). Some stud-
ies suggest there is a temporal relationship between the onset of
chronic infection and increased morbidity (Abman 1991;Hudson
1993; Kosorok 2001; Parad 1999), whilst others do not support
these ﬁndings (Kerem 1990; Rosenfeld 2001). On balance, there
seems to be good evidence from well-designed non-experimen-
tal studies that clinical state deteriorates after ﬁrst isolation of P.
aeruginosa.
Description of the intervention
Several strategies exist to treat early infectionwithP. aeruginosa and
include the use of the inhaled antibiotics such as colistin and to-
bramycin (Littlewood 1985; Ratjen 2001a), oral quinolones such
as ciproﬂoxacin (Taccetti 2005) and intravenous antibiotics usu-
ally consisting of combination of an aminoglycoside with a beta-
lactam (Döring 2000; Douglas 2009).
How the intervention might work
As well as antibiotic treatment of P. aeruginosa given at the time
of ﬁrst isolation, other strategies have the potential to prevent or
delay infection of the respiratory tract. These include avoidance of
contact with people who carry P. aeruginosa (UK CF Trust 2004)
and the development of vaccines against P. aeruginosa (Johansen
2013). Uncontrolled series have indicated that a variety of anti-
pseudomonal antibiotics either singly (Littlewood 1985; Ratjen
2001a) or in combination (Vazquez 1993) at ﬁrst isolation may
delay the onset of chronic infection. A trial using historical con-
trols suggested that oral ciproﬂoxacin and nebulised colistin are
effective in delaying or preventing chronic infection (Frederiksen
1997). An uncontrolled pilot study of intravenous therapy sug-
gested that intravenous treatment alone was less effective in delay-
ing the onset of chronic infection (Steinkamp 1989). There is also
evidence supporting eradication therapy from long-term observa-
tional studies of chronic infection with P. aeruginosa in CF clinics
such as the study reported by Lee (Lee 2004).
Why it is important to do this review
There are differences in the approach to detection and manage-
ment of ﬁrst isolation of P. aeruginosa. Some CF centres advocate
frequent microbiological surveillance with attempts to eradicate P.
aeruginosawhen it ﬁrst appears in the lung (Döring 2000), whereas
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others treat only when clinical or radiological signs of pulmonary
infection are present (Ramsey 1996). There is evidence that, when
P. aeruginosa is cleared from respiratory secretions it is not simply
suppressed because, when infection recurs, this is with a geneti-
cally distinct organism inmost cases (Munck 2001). Evidence that
eradication strategies result in increased survival or improved qual-
ity of life for people with CF are from observational studies alone.
There are multiple different eradication regimens that have been
described using different anti-pseudomonal antibiotics in differ-
ent combinations of intravenous, oral or nebulised (or both) and
with varying doses and duration of therapy (Lee 2009). Given the
expense of chronic anti-pseudomonal suppressive therapy, there
is a clear rationale for early eradication from a cost-effectiveness
perspective and this is supported by observational data (Taccetti
2005); however, there has not been any formal evaluation of cost
effectiveness to date.
This is an update of a Cochrane review ﬁrst published in 2003,
and previously updated in 2006 and 2009 (Langton Hewer 2009;
Wood 2003; Wood 2006).
O B J E C T I V E S
To determine whether antibiotic treatment of early P. aeruginosa
infection in children and adults with CF alters clinical and micro-
biological outcome when compared to usual treatment.
To test the hypotheses that antibiotics against P. aeruginosa, given
at the time of ﬁrst isolation, reduce CF-related mortality; improve
quality of life; improve pulmonary function; nutritional status; and
reduce the need for subsequent hospitalisation and consumption
of antibiotics.
To investigate whether these antibiotics prevent or delay the onset
of chronic infection of the respiratory tract with P. aeruginosa;
increase the incidence of isolates of other micro-organisms from
the respiratory tract; and are associated with adverse effects which
are either important to the individual with CF or have long-term
sequelae.
To investigate whether there is evidence of superior P. aeruginosa
eradication efﬁcacy or improved cost-effectiveness between differ-
ent antibiotic strategies.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials.
Types of participants
Children and adults with CF, diagnosed clinically and by sweat or
genetic testing (or both) with a ﬁrst ever positive microbiological
isolate of P. aeruginosa from a respiratory tract specimen. Trials will
also be included where the participants have been proven to be free
of P. aeruginosa for at least six months before a new isolation and
should not be currently receiving Pseudomonas-suppressing treat-
ment such as daily inhaled antibiotic therapy. Participants should
be enrolled into a trial within six months (post hoc change - previ-
ously not more than two months) from isolation of P. aeruginosa.
In a further post hoc change, we have also altered our eligibility cri-
teria to allow trials where all participants receive some eradication
therapy before randomisation (see Differences between protocol
and review). People with CF of all ages and disease severity will be
included.
Types of interventions
Combinations of inhaled, oral or intravenous antibiotics with the
aim of eradicating ﬁrst pulmonary isolates of P. aeruginosa com-
pared with placebo or usual treatment (or both) or other combi-
nations of inhaled, oral or intravenous antibiotics.
Types of outcome measures
Primary outcomes
1. Eradication of P. aeruginosa from the respiratory tract as
deﬁned by
i) clearance of P. aeruginosa from bronchoalveolar lavage
(BAL), sputum or oropharyngeal cultures at 1, 2, 3, 6, 12 and 24
months after commencement of therapy
ii) time to next isolation of P. aeruginosa from BAL,
sputum or oropharyngeal cultures
Secondary outcomes
1. Mortality
2. Quality of life assessment
3. Spirometric lung function (e.g. forced expiratory volume in
one second (FEV1) and forced vital capacity (FVC)) expressed as
percentage predicted values for age, sex and height
4. Growth and nutritional status as measured by weight,
height (children), body mass index (BMI) or z score
5. Frequency of respiratory exacerbations as deﬁned by:
i) frequency of infective pulmonary exacerbations
expressed as the number of exacerbations per patient year
ii) time to next course of IV antibiotics from
commencement of therapy
5Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
iii) days in hospital expressed as days in hospital per
patient year
iv) days of antibiotic usage expressed as days of antibiotic
usage per patient year
6. Isolation of other micro-organisms from the respiratory
tract expressed as the number of positive cultures per patient year
(where available, the microbiology detection method will be
described in view of the differences in sensitivity and speciﬁcity
of oropharyngeal, sputum and BAL samples for bacteriology,
mycology and non-tuberculous mycobacteria)
7. Adverse effects to antibiotics, e.g. renal or auditory
impairment and hypersensitivity reactions
Additional outcomes which have arisen during the review
1. Time to chronic infection (as deﬁned above in Description
of the condition)
2. Clinical and radiological scores
3. Cost effectiveness (trials looking at cost effectiveness will be
compared, where possible)
Search methods for identification of studies
Relevant trials were identiﬁed from the Group’s Cystic Fibrosis
Trials Register using the terms: antibiotics AND (pseudomonas
aeruginosa OR mixed infections) AND (eradication OR un-
known).
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated each new issue of The Cochrane Library),
quarterly searches of MEDLINE, a search of Embase to 1995
and the prospective handsearching of two journals - Pediatric Pul-
monology and the Journal of Cystic Fibrosis. Unpublished work is
identiﬁed by searching the abstract books of three major CF con-
ferences: the International Cystic Fibrosis Conference; the Euro-
pean Cystic Fibrosis Conference and the North American Cystic
Fibrosis Conference. For full details of all searching activities for
the Trials Register, please see the relevant sections of the Cystic
Fibrosis and Genetic Disorders Group Module.
Date of the most recent search of the Group’s trials register: 08
September 2014.
We have also searched the relevant clinical trials databases
clinicaltrials.gov/ and ISRCTN. We used the search terms “cystic
ﬁbrosis” AND “Pseudomonas aeruginosa” AND “eradication”.
Date of last search: 01 September 2014.
Data collection and analysis
Selection of studies
For the original review, two authors (DW, AS) independently se-
lected the trials to be included in the review. From Issue 3, 2009
of The Cochrane Library two authors (SLH, AS) selected the trials
to be included in the review. Where there was disagreement on
the suitability of a trial for inclusion in the review, or on its risk of
bias, the authors reached a consensus by discussion.
Data extraction and management
Each author independently extracted data using standard data ac-
quisition forms. Where there was disagreement on the suitability
of a trial for inclusion in the review, or on its risk of bias, the
authors reached a consensus by discussion.
We planned to group outcome data into those measured at one,
three, six, twelve months and annually thereafter. In addition, we
previously stated that if outcome data were recorded at other time
periods as well, that we would also consider examining these data.
Some trials reported data at two months for some outcomes and
we have included these data within the review. In the Taccetti trial,
cumulative data were reported at six months and ﬁnal follow-up
data at a median of 16 months (range 12 to 28 months); we have
included both time points in our analysis (Taccetti 2012). In the
Treggiari trial, cumulative data for pulmonary exacerbations and
isolates of P. aeruginosa are presented for the 70-week follow-up
period and these have been reported and analysed in this review
(Treggiari 2011).
Assessment of risk of bias in included studies
For earlier versions of this review, in order to assess the risk of bias,
each author independently assessed the methodological quality
of each trial, based on the method described by Schulz (Schulz
1995). From the 2011 update, each author independently assessed
the risk of bias using the tool recommended by the Cochrane
Collaboration (Higgins 2011). The risk of bias was judged to be
high, unclear or low for the domains of:
• sequence generation;
• allocation concealment;
• blinding (risk of bias increased as the level of blinding
decreased);
• incomplete outcome data (the risk of bias increased if any
withdrawals were not adequately described and reasons for
withdrawals given, or if the withdrawals were not equal across
groups);
• selective outcome reporting (bias increased if stated
outcome measures were only partially reported or not reported at
all);
• other potential sources of bias.
Where there was disagreement on the quality and risk of bias of a
trial, the authors reached a consensus by discussion.
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Measures of treatment effect
For binary outcome measures, in order to allow an intention-to-
treat analysis, the authors sought data on the number of partici-
pants with each outcome event, by allocated treated group, irre-
spective of compliance andwhether or not the participant was later
thought to be ineligible or otherwise excluded from treatment or
follow up. We calculated a pooled estimate of the treatment effect
for each outcome across trials - the odds ratio (OR) or the ratio of
the odds of an outcome among treatment allocated participants
to the corresponding odds among controls with 95% conﬁdence
intervals (CIs).
For continuous outcomes, in order to allow an intention-to-treat
analysis, we sought outcome data by allocated treated group, ir-
respective of compliance and whether or not the participant was
later thought to be ineligible or otherwise excluded from treat-
ment or follow up.We recorded either mean change from baseline
for each group or mean post-treatment or intervention values and
standard deviation (SD). We calculated a pooled estimate of treat-
ment effect by calculating the mean difference (MD) with 95%
CIs.
The authors have reported longitudinal data as individual time
points. We realise that this method ignores any correlation be-
tween the participants; however, we have been unable to analyse
these data using more appropriate methods as we do not have the
correlation co-efﬁcient for these data. If in the future, we are able
to obtain the correlation co-efﬁcient, we will analyse these data
more appropriately.
In this version of the review, we entered time-to-event data into
the meta-analysis using the log hazard ratio. This was possible for
the outcome ’time to pulmonary exacerbation’ (severe or any), in
the comparison of cycled versus. culture-based therapy (Analysis
6.5; Analysis 6.7) and ciproﬂoxacin versus placebo (Analysis 7.5;
Analysis 7.7). We presented binary data on clearance of P. aerugi-
nosa from BAL, sputum or oropharyngeal cultures and occurrence
of chronic infection with P. aeruginosa at multiple time points. We
calculated the OR at each time point separately, thus ignoring the
correlation between time points. For future updates of this review,
for time-to-event data, such as time to next P. aeruginosa infection
or time to chronic infection, the authors will attempt to obtain
individual patient data (IPD). We will use these IPD to provide
estimates of the log hazard ratio and its standard error and plan
to combine time-to-event data from trials in a meta-analysis. We
used the generic inverse variance (GIV) to analyse the data for
time to next isolation of P. aeruginosa from the Ratjen trial (Ratjen
2010).
Unit of analysis issues
Cross-over trials are not eligible for inclusion within this review.
The natural history of infection with P. aeruginosa in CF com-
prises an initial infection with the organism usually in planktonic
form, followed by chronic infection (in which the P. aeruginosa
frequently exists in the mucoid state). In the planktonic form, an-
tibiotics can eradicate the organism; however, persistent infection
is associated with bioﬁlm growth and adaptive evolution medi-
ated by genetic variation. The development of mucoidy, hyper-
mutability and the acquisition of mutational antibiotic resistance
are important factors associated with persistent infection and are
associated with increased difﬁculty in eradication (Ciofu 2012).
In a cross-over trial comparing active treatmentwith placebo, given
the progression of infections due to of P.aeruginosa, the group re-
ceiving the active treatment after placebo will be at a disadvan-
tage compared with those receiving active treatment ﬁrst. TheP.
aeruginosa may form a bioﬁlm during placebo treatment and so
it would not be able to be eradicated during the active treatment
phase. Hence, a cross-over trial is an inappropriate design and the
authors have not included cross-over trials in this review.
Dealing with missing data
In trials where outcome data were unavailable for randomised
participants, the authors performed an available-case analysis. This
available-case analysis included data on only those participants
whose results are known, using as a denominator the total number
of people who completed the trial for the particular outcome in
question.
When data were incomplete, the authors imputed themissing data
to provide best-case and worst-case scenarios, in order to show the
range of possible results for the combined analysis (see Analysis
1.4; Analysis 1.5). The best-case scenario analysis is based on the
assumption that all the missing data points represented beneﬁcial
clinical outcomes, whereas the worst-case analysis assumes that all
missing data points had a negative clinical outcome.
Assessment of heterogeneity
For future updates of this review, if we are able to combine a suf-
ﬁcient number of trials (at least four), we will test for heterogene-
ity using the I2 statistic (Higgins 2003). We will consider values
of I2 up to 30% to indicate little or no heterogeneity, values be-
tween 30% and 60% to represent moderate heterogeneity, values
from 60% to 90% to represent substantial heterogeneity and val-
ues over 90% to represent considerable heterogeneity. We accept
that the importance of the observed value of I2 depends ﬁrstly on
the magnitude and direction of effects and secondly on strength
of evidence for heterogeneity (e.g. P value from the Chi2 test, or a
conﬁdence interval for I2). In a future version of this review (with
more trials included in the meta-analysis of individual treatment
comparisons), if we ﬁnd evidence of at least substantial clinical
heterogeneity (as deﬁned above) in the included trials, we will per-
form a random-effects analysis.
Assessment of reporting biases
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The authors sought evidence of reporting bias by comparison of
the reported outcomes with those listed in the trial’s methodolog-
ical description. Where important outcomes have not been iden-
tiﬁed, we have requested the original trial protocol from the au-
thors.
Data synthesis
The authors have analysed the data using a ﬁxed-effect model.
If, in future updates of this review, we ﬁnd evidence of at least
substantial clinical heterogeneity (as deﬁned above) in the included
trials, we plan to perform a random-effects analysis.
Subgroup analysis and investigation of heterogeneity
If we identify a moderate degree of heterogeneity or higher
(Higgins 2003) and are able to combine a sufﬁcient number of
trials (at least 10), thenwe will investigate this with subgroup anal-
yses. We plan to categorise participants if possible as P. aeruginosa-
free and P. aeruginosa-naive according to the deﬁnition by Lee (Lee
2003). These subgroups will be analysed separately.
Sensitivity analysis
We also plan to test the robustness of our results with the following
sensitivity analyses:
• trials where participants receive treatment within three
months of isolation of P. aeruginosa versus those where the
interval is between three and 12 months;
• trials with high risk of bias versus low risk of bias for
generation of allocation sequence;
• trials with a high risk of bias versus a low risk of bias for
concealment of allocation;
• multi-centre versus single centre trials.
R E S U L T S
Description of studies
Results of the search
Our search identiﬁed a total of 49 trials, none of these were cross-
over trials. Of these 49 trials, seven met our inclusion criteria
(Gibson 2003; Proesmans 2013; Ratjen 2010; Taccetti 2012;
Treggiari 2011; Valerius 1991; Wiesemann 1998); we identiﬁed
one trial which is still ongoing and will include data from this trial
in a future update of this review once they have been published
(TORPEDO Trial); 40 trials were excluded and one trial is listed
as ’Awaiting classiﬁcation’ (Noah 2010). We have contacted the
investigators of this trial for further information to allow us to
include or exclude it at a future update.
Included studies
The seven included trials enrolled a total of 744 participants
(Gibson 2003; Proesmans 2013; Ratjen 2010; Taccetti 2012;
Treggiari 2011; Valerius 1991; Wiesemann 1998).
Trial characteristics
All seven included trials were randomised controlled trials of par-
allel design. Two trials were placebo-controlled (Gibson 2003;
Wiesemann 1998); one trial compared active treatment tono treat-
ment (Valerius 1991); and three trials were open-label trials com-
paring different active treatments (Proesmans 2013; Ratjen 2010;
Taccetti 2012). The design of the Treggiari trial was complex, with
randomisation to cycled treatment with tobramycin solution for
inhalation (TSI) or culture-based treatment and further randomi-
sation to additional oral ciproﬂoxacin or placebo (Treggiari 2011).
One trial reported stratiﬁcation for age and participating centre
(Gibson 2003), another trial reported stratiﬁcation by age and
FEV1 values as an expression of illness severity (Taccetti 2012);
the remaining ﬁve trials did not use stratiﬁcation (Proesmans
2013; Ratjen 2010; Treggiari 2011; Valerius 1991; Wiesemann
1998). Two trials stated that theywere double-blind (Gibson 2003;
Wiesemann 1998); the Treggiari trial used placebo to blind for
ciproﬂoxacin but not for TSI (Treggiari 2011); the other trials
could not be blinded due to differing treatment regimens. Five
trials were multicentre (Gibson 2003; Ratjen 2010; Taccetti 2012;
Treggiari 2011; Wiesemann 1998) and the other two were single-
centre trials (Proesmans 2013; Valerius 1991). Five trials were
based in Europe (Proesmans 2013; Ratjen 2010; Taccetti 2012;
Valerius 1991; Wiesemann 1998) and two in North America (
Gibson 2003; Treggiari 2011). The number of participants in
each trial ranged from 21 to 306 and were as follows: 306 in the
Treggiari trial (Treggiari 2011); 223 in the Taccetti trial (Taccetti
2012); 88 in the Ratjen trial (Ratjen 2010); 26 in the Proesmans
trial (Proesmans 2013); 26 in the Valerius trial (Valerius 1991);
22 in the Wiesemann trial (Wiesemann 1998); and 21 in the
Gibson trial (Gibson 2003). The Gibson trial reported that the
planned sample size was 98 participants, but randomisation was
stopped after an early interim analysis by the Data Monitoring
Committee was undertaken due to poor accrual. This analysis
showed a statistically signiﬁcant treatment effect and so the trial
was stopped (Gibson 2003). The duration of the trials varied and
ranged from 28 days (Gibson 2003) to 27months (Valerius 1991).
Participant characteristics
All seven trials had approximately equal numbers of males and
females. Only two trials recruited adult participants; Taccetti re-
cruited participants aged from 1 to 35 years (Taccetti 2012) and
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in the Ratjen trial any patient over six months of age was eligible
for inclusion (Ratjen 2010). Two trials were restricted to younger
children: six months to six years (Gibson 2003) and 1 to 12 years
(Treggiari 2011). All seven trials speciﬁed that participants had to
have microbiological evidence of recent onset of airway infection
with P. aeruginosa. However, the interval allowed between isola-
tion of P. aeruginosa and randomisation to study treatment var-
ied greatly, from four weeks (Proesmans 2013; Wiesemann 1998)
to as long as six months (Treggiari 2011). Two trials additionally
speciﬁed that individuals with raised titres to anti-pseudomonal
antibodies were excluded from the trial (Ratjen 2010; Wiesemann
1998). Other data from the EPIC study have shown that raised
antibodies to P. aeruginosa (anti-alkaline protease and anti-exo-
toxin A) are associated with an increased risk of recurrence in the
60 weeks following eradication treatment (Anstead 2013). Studies
excluding participants with raised antibodies might therefore be
expected to achieve higher eradication rates.
Intervention
Trials have used various combinations of inhaled tobramycin, in-
haled colistin, oral ciproﬂoxacin, placebo and no treatment. The
duration of the intervention has varied greatly, from three weeks
(Valerius 1991) to one year (Wiesemann 1998). Two trials com-
pared tobramycin to placebo (Gibson 2003; Wiesemann 1998).
One trial used tobramycin solution for inhalation (TSI) TOBI®
(nowmarketed by Novartis) at a dose of 300 mg twice-daily for 28
days (Gibson 2003); the second trial used aerosolised tobramycin
parenteral preparation (Eli Lilly, Bad Homburg, Germany) at a
dose of 80 mg twice-daily for 12 months (Wiesemann 1998). Rat-
jen evaluated a short (28 days) versus a longer (56 days) TSI course
(Ratjen 2010). Participants in the Treggiari trial were randomised
to receive either cycles of four weeks of treatment with nebulised
TSI in every 12-week period or TSI only when respiratory culture
was positive for P. aeruginosa (Treggiari 2011). In this trial, partic-
ipants were also randomised to receive either oral ciproﬂoxacin or
placebo for two weeks, commencing at the same time as TSI. This
design resulted in a four-arm trial where all trial participants had
an initial 28-day course of TSI, with an additional 28 days given if
the patient remained positive after initial treatment. Ciproﬂoxacin
or placebo was not given with second course of TSI and follow
up was for 18 months from randomisation and ﬁrst treatment
with TSI (Treggiari 2011). Three trials evaluated inhaled colistin
in combination with oral ciproﬂoxacin (Proesmans 2013; Taccetti
2012;Valerius 1991). Proesmans compared colistin 2millionunits
(MU) twice daily for three months (in combination with oral ci-
proﬂoxacin 30 mg/kg/day) to TSI 300 mg twice daily for 28 days
(Proesmans 2013). The Taccetti trial compared 28 days of inhaled
colistin with 28 days TSI; both arms also had oral ciproﬂoxacin 30
mg/kg/day for 28 days (Taccetti 2012). Valerius compared colistin
1 MU (plus ciproﬂoxacin 250 mg to 750 mg), both given twice
daily for three weeks, for initial and any subsequent isolate of P.
aeruginosa to no treatment (Valerius 1991).
Outcome measures
The most widely used primary outcome measure was eradication
of P. aeruginosa from respiratory secretions, though deﬁnitions of
eradication differ considerably between trials. In the Gibson trial,
the primary outcome was the change in P. aeruginosa density, on
BAL, from baseline to 28 days (Gibson 2003). However, the trial
also looked at eradication, deﬁned as a density of P. aeruginosa
in BAL of less than 20 colony forming units (CFU) at 28 days
from baseline. Proesmans deﬁned eradication as a negative culture
result for P. aeruginosa (from sputum, cough swab or BAL) at 28
days or three months (depending on which intervention the par-
ticipant received) (Proesmans 2013). Both trials based successful
eradication on a single specimen (Gibson 2003; Proesmans 2013).
In contrast, Taccetti used a more stringent deﬁnition of eradica-
tion as per guidance published by the UK CF Trust of three neg-
ative cultures in a six-month period (Taccetti 2012; UK CF Trust
2004). Ratjenused themedian time to recurrence of any strain ofP.
aeruginosa during a 27-month follow-up period (Ratjen 2010). In
the oldest trial, the primary outcome measure was time to chronic
infection with P. aeruginosa, deﬁned as the presence of P. aerugi-
nosa in monthly sputum samples for six consecutive months or the
development of precipitating serum antibodies against P. aerugi-
nosa or both (seeDescription of the condition for other deﬁnitions
of chronic infection) (Valerius 1991). There were two primary
outcomes in the Treggiari trial, time to pulmonary exacerbation
requiring intravenous antibiotics and proportion of P. aeruginosa
positive cultures over the 18-month trial period (Treggiari 2011).
Other measured outcomes included less severe pulmonary exac-
erbations, Pseudomonas antibody levels, lung function, nutritional
status, modiﬁed Shwachman score and monitoring for adverse
clinical and microbiological effects.
Excluded studies
We excluded 40 trials from our analysis for a number of reasons.
Three trials were excluded because therapy was not randomised
(Gibson 2007; Postnikov 2000; Schelstraete 2010) and one trial
was excluded because it was an observational study (Ballman
1998). Four trials were excluded as they did not have a control
group (Heinzl 2002; Littlewood 1985; Ratjen 2001a; Steinkamp
1989) and a further ﬁve because they used a historical control
group (Frederiksen 1997; Griese 2002; Kenny 2009; Taccetti
2005; Vazquez 1993). A total of 16 trials were excluded as they
involved participants with chronic P. aeruginosa infection (Clancy
2013; Coates 2011; Goss 2009; Konstan 2010; Latzin 2008;
Lenoir 2007; Mazurek 2012; Oermann 2009; Postnikov 2007;
Prayle 2013; Ramsey 1999; Retsch-Bogart 2008; Retsch-Bogart
2009; Steinkamp 2007; Trapnell 2012; Wainwright 2011b). Two
trials were excluded as they were designed to evaluate a diagnostic
technique forP. aeruginosa (Brett 1992;Wainwright 2011a). A fur-
ther two trials were excluded as they evaluated symptomatic rather
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than eradication treatment (Church 1997; Schaad 1997) and one
was of a prophylactic antibiotic regimen to prevent infection with
P. aeruginosa (Tramper-Stranders 2009). Five trials looked at phar-
macokinetics and drug tolerability (Alothman 2002; Alothman
2005; Geller 2007; Rietschel 2009; Schuster 2013) and the ﬁnal
trial was excluded as it looked at antibiotic sinonasal nebulisation
aiming to eradicate from the sinuses only (Mainz 2014).
Risk of bias in included studies
Please see further information in the risk of bias sections of the
tables (Characteristics of included studies) and the graphical risk
of bias summary (Figure 1).
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Figure 1. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
All seven trials were described as randomised controlled trials; in
four, the method of generation of allocation sequence was not
stated; hence the trials are judged to have an unclear risk of bias
(Gibson 2003; Proesmans 2013; Ratjen 2010; Valerius 1991).
The remaining three trials are judged to have a low risk of bias
(Taccetti 2012; Treggiari 2011; Wiesemann 1998). In the ﬁrst of
these, Taccetti describes a balanced randomisation sequence that
was created using statistical software using permuted blocks of
size 10 (Taccetti 2012). Treggiari employed a computer random
number generator to assign treatments within permuted blocks
of 12 (Treggiari 2011). In the Wiesemann trial, the allocation
sequencewas generated using a coinﬂip (Wiesemann 1998). There
is no information as to who was responsible for the coin ﬂip or
what controls were in place to ensure validity of the result of the
coin ﬂip; however we have still judged this to have a low risk of
bias.
In ﬁve trials it was not reported how allocation was concealed and
we judged these to have an unclear risk of bias (Gibson 2003;
Proesmans 2013; Ratjen 2010; Valerius 1991; Wiesemann 1998).
In the Taccetti trial, the staff involved in randomisation and in
treatment assignments were “kept separate” and we judged this
trial to have a low risk of selection bias (Taccetti 2012). In the
Treggiari trial, randomisation was remote and so allocation was
concealed (Treggiari 2011).
Blinding
Two trials were reported as double-blind trials (Gibson 2003;
Wiesemann 1998). Gibson did not provide any details in the pub-
lished paper regarding who was blinded or the method of blind-
ing (Gibson 2003). However, in response to a request for further
information, Dr Gibson conﬁrmed that drugs and placebo were
sufﬁciently masked that neither participants or clinicians were able
to differentiate between them. Wiesemann reported that partici-
pants were blinded by providing a placebo inhalation with a simi-
lar taste to the treatment inhalation, but it is not clear whether the
clinicians administering the treatment were blinded to treatment
allocation; however, we still judged this to have a low risk of bias
(Wiesemann 1998).
In the Treggiari trial, the oral ciproﬂoxacin treatment was blinded
but the TSIwas open label and sowe judged this to have an unclear
risk of bias (Treggiari 2011).
The remaining four trials did not utilise blinding and were judged
to have a high risk of bias (Proesmans 2013; Ratjen 2010; Taccetti
2012; Valerius 1991). The Proesmans trial compared an inhaled
intervention to a combination of inhaled and oral treatment, so
blinding of participants and clinicians was not possible; there is
no information available as to whether the outcome assessors were
blinded (Proesmans 2013). The Ratjen trial was open label com-
paring 28 or 56 days of nebulised therapy and made no attempt
at blinding (Ratjen 2010). The Taccetti trial was also open label
comparing 28 days of inhaled colistin with 28 days of TSI, both
groups also receiving 28 days of oral ciproﬂoxacin (Taccetti 2012).
Valerius compared a combination of inhaled and oral treatment
to no treatment, so again blinding of participants and clinicians
was not possible and no information is available with regards to
the outcome assessors (Valerius 1991).
Incomplete outcome data
Six trials were judged to have a low risk of bias (Gibson 2003;
Proesmans 2013; Ratjen 2010; Taccetti 2012; Treggiari 2011;
Valerius 1991). Four trials were analysed on an intention-to-treat
basis; all four reported data on all participants who were ran-
domised (Gibson 2003; Proesmans 2013; Taccetti 2012; Valerius
1991). In the Ratjen trial, 65 of the 88 randomised participants
were included in the primary outcome (time to recurrence of P.
aeruginosa). A total of 52 participants were prematurely withdrawn
from the trial, but these were approximately evenly distributed
across the two treatment groups and reasons were given for each
withdrawal; we therefore judge there to be a low risk of bias (Ratjen
2010). In the Treggiari trial only two of 306 randomised partic-
ipants were excluded from the analysis (because they did not re-
ceive treatment) (Treggiari 2011).
One trial had an unclear risk of bias (Wiesemann 1998). Five par-
ticipants withdrew from this trial after randomisation and only
baseline data at entry to the trial were presented for these partici-
pants; to date we have been unable to obtain further outcome data.
The trial was therefore analysed on an available-case basis and we
judged it to have an unclear risk of bias (Wiesemann 1998).
Selective reporting
It is current practice for newer trials to publish a protocol, but we
have not been able to locate a published protocol for the Taccetti
trial and have therefore judged this trial to have an unclear risk of
bias (Taccetti 2012).
We judged three trials to have a high risk of bias (Proesmans
2013; Ratjen 2010; Wiesemann 1998). Although a protocol for
the Proesmans trial was available online and we were able to con-
ﬁrm from the full paper that all outcomes from the protocol
were measured, the paper did not provide actual data for BMI
z score, weight z score or frequency of exacerbations and simply
reported that none of these changed signiﬁcantly for trial par-
ticipants (Proesmans 2013). Ratjen reported that there were no
major short-term (at three months) or long-term (at 27 months)
changes in spirometry, but did not record the ﬁgures for either
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of the two groups. In addition, only summary statements and no
numerical data were provided for weight, height or BMI (Ratjen
2010). Wiesemann reported no change in spirometric pulmonary
function during or after the treatment period, but again no data
were given (Wiesemann 1998).
We judged three trials to have a low risk of bias from selective
reporting (Gibson 2003; Treggiari 2011; Valerius 1991). The trial
protocol for the EPIC trial was published as a separate paper;
primary and secondary outcome measures were clearly described
in the protocol and data on all of these outcomes were presented in
either the main paper, related papers or in the online supplement
(Treggiari 2011). We have compared the ’Methods’ sections of
the reports from the remaining trials with the ’Results’ sections of
the same and have not found any evidence of selective reporting
(Gibson 2003; Valerius 1991).
Other potential sources of bias
We judged one trial to have a high risk due to other potential
sources of bias (Gibson 2003). The Gibson trial planned to recruit
to a sample size of 98 participants, but was stopped early by the
Data Monitoring Committee after interim analysis of the ﬁrst 21
participants showed a statistically signiﬁcantmicrobiological effect
in favour of the tobramycin-treated group (Gibson 2003). This
trial was supported in part by Chiron, the manufacturer of the
inhaled tobramycin (Gibson 2003).
We judged the Ratjen trial to have an unclear risk due to other po-
tential sources of bias (Ratjen 2010). This trial recruited fewer par-
ticipants than planned, the total number of planned randomised
participants was 100, but 35 from the recruited cohort of 123
were not randomised: 31 because of high P. aeruginosa antibody
levels (which led the investigators to believe that they were chron-
ically infected with P aeruginosa); one for an adverse event; one
where consent was withdrawn; one for a protocol deviation; and
one ’other’ (unspeciﬁed) reason (Ratjen 2010). Therefore the trial
investigators actually randomised 88 participants and the primary
outcome was evaluable in 65 of these (Ratjen 2010). The trial re-
sults cannot be generalised to a populationwhere anti-Pseudomonas
antibodies are not measured. Furthermore, like the earlier Gibson
trial, this trial was initially supported by Chiron and later Novartis
Pharma, the manufacturer of TSI (Ratjen 2010).
The Proesmans study was judged to have an unclear risk of bias in
view of the different time-points at which the primary outcome
was measured - at 28 days in the inhaled tobramycin group and
three months in the colistin with ciproﬂoxacin group (Proesmans
2013).
In four trials no other potential source of bias was identiﬁed and
thesewere judged tohave a low risk of bias (Taccetti 2012;Treggiari
2011; Valerius 1991; Wiesemann 1998).
Effects of interventions
Inhaled tobramycin versus placebo
This comparison included two trials with 43 participants (Gibson
2003; Wiesemann 1998).
Primary outcome
1. Eradication of P. aeruginosa from the respiratory tract
a. Clearance of P. aeruginosa from BAL, sputum or
oropharyngeal cultures
The intervention (inhaled tobramycin) was given in a very differ-
ent dose in the Wiesemann trial (80 mg twice daily) compared to
the Gibson trial (300 mg twice daily) (Gibson 2003; Wiesemann
1998). In the Gibson trial, signiﬁcantly fewer children who re-
ceived TSI had a positive BAL at one month, OR 0.01 (95% CI
0.00 to 0.30), but not at two months, OR 0.21 (95% CI 0.03 to
1.47) (Analysis 1.1). Results were not available for all the partici-
pants in theWiesemann trial, thereby precluding an intention-to-
treat analysis (Wiesemann 1998).Wiesemann was able to demon-
strate a statistically signiﬁcant reduction in the odds of a positive
culture from the respiratory tract specimen only after six months,
OR 0.06 (95% CI 0.00 to 0.92) and 12 months of treatment, OR
0.02 (95% CI 0.00 to 0.67) but not at one, two or three months
(Analysis 1.2). An available-case analysis of the data presented in
the Wiesemann trial showed that, when combined with the data
from the Gibson trial, there was a reduction in the odds of a posi-
tive culture in the treatment group compared to the placebo group
at one month, OR 0.06 (95% CI 0.01 to 0.33); and two months,
OR 0.15 (95% CI 0.03 to 0.65) both of which were statistically
signiﬁcant (Analysis 1.3).
A sensitivity analysis following imputation of the missing data
to provide best-case and worst case-scenarios for the combined
analysis showed a range of possible results. The best-case scenario
showed a reduction in the odds of a positive culture of P. aeruginosa
in the treatment group at both one month, OR 0.06 (95% CI
0.01 to 0.30); and two months, OR 0.14 (95% CI 0.03 to 0.60)
(Analysis 1.4). Furthermore, these imputed data also showed a
signiﬁcant difference in favour of tobramycin at six months, OR
0.04 (95% CI 0.00 to 0.48) and 12 months, OR 0.01 (95% CI
0.00 to 0.26), but not at threemonths (Analysis 1.4). In the worst-
case scenario the odds of a positive culture was reduced at one
month, OR 0.08 (95% CI 0.02 to 0.38) and two months, OR
0.18 (95% CI 0.04 to 0.73), but was not statistically signiﬁcant
for Wiesemann alone at three, six or 12 months (Analysis 1.5).
b. Time to next isolation of P. aeruginosa from BAL, sputum
or oropharyngeal cultures
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Neither trial assessed or reported on this outcome.
Secondary Outcomes
1. Mortality
Mortality was not included as an outcome in either trial, but there
were no reported deaths during any of the trial periods (Gibson
2003; Wiesemann 1998).
2. Quality of life
Neither trial assessed or reported on this outcome.
3. Spirometric lung function
Wiesemann reported no change in spirometric pulmonary func-
tion during or after the treatment period, but no data were given
(Wiesemann 1998). Gibson did not assess or report on spiromet-
ric lung function; most of the participants in this trial were too
young to perform spirometry reliably (Gibson 2003).
4. Growth and nutritional status
Only the trial by Gibson presented data on weight (Gibson 2003).
There was no signiﬁcant difference found between the two groups
in the change in weight from baseline (measured at trial entry)
and subsequent weights measured at one month and two months
(Analysis 1.6).
5. Frequency of respiratory exacerbations
Neither trial assessed or reported on this outcome.
6. Isolation of other micro-organisms
Gibson reported no changes in the prevalence of other micro-or-
ganisms, including multi-resistant organisms, cultured from respi-
ratory secretions (Gibson 2003). Wiesemann did not collect data
on this outcome (Wiesemann 1998).
7. Adverse effects of antibiotics
Gibson reported cough in association with inhalation in seven out
of eight participants in the treatment group and in 12 out of 13 in
the placebo group, but this result was not statistically signiﬁcant
(Analysis 1.7) . There was no evidence of a difference in serum
creatinine levels or auditory threshold between the groups, how-
ever the numbers of participants was small (Gibson 2003). Wiese-
mann reported one withdrawal from the placebo group because
of cough, however the authors did not report on the presence or
absence of cough in other participants (Wiesemann 1998).
Additional outcomes which have arisen during the review
1. Time to chronic infection
Neither trial assessed or reported on this outcome.
2. Clinical and radiological scores
Only the Gibson trial reported modiﬁed Shwachmann scores,
which were recorded at one month and two months from enrol-
ment and were expressed as both mean scores with SDs and mean
change from baseline with SDs (Gibson 2003). There were no
signiﬁcant differences between the two groups in changes in ei-
ther mean scores or modiﬁed Schwachman scores from baseline
at either one month or two months (Analysis 1.8).
3. Cost
Neither trial reported a health economic analysis.
Oral ciprofloxacin and inhaled colistin versus no
treatment
This intervention included only one trial with 26 participants
(Valerius 1991).
Primary outcome
1. Eradication of P. aeruginosa from the respiratory tract
a. Clearance of P. aeruginosa from BAL, sputum or
oropharyngeal cultures
The included trial did not report on this outcome.
b. Time to next isolation of P. aeruginosa from BAL, sputum
or oropharyngeal cultures
The included trial did not report on this outcome.
Secondary Outcomes
1. Mortality
The included trial did not report on this outcome.
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2. Quality of life
The included trial did not report on this outcome.
3. Spirometric lung function
The included trial did not report on this outcome.
4. Growth and nutritional status
The included trial did not report on this outcome.
5. Frequency of respiratory exacerbations
The included trial did not report on this outcome.
6. Isolation of other micro-organisms
The included trial did not report on this outcome.
7. Adverse effects of antibiotics
Valerius did not describe cough speciﬁcally, but reported that there
were no adverse effects in either group (Valerius 1991).
Additional outcomes which have arisen during the review
1. Time to chronic infection
We deﬁned this as the presence of P. aeruginosa in each monthly
sputum sample for six consecutive months or the presence of pre-
cipitating antibodies to P. aeruginosa or both. In the Valerius trial,
from the data provided, it was possible to calculate the propor-
tion of participants in each group who were deﬁned as chroni-
cally colonised with P. aeruginosa from respiratory secretions at 3,
6, 12 and 24 month time points (Valerius 1991). The odds of
being chronically infected with P. aeruginosa were reduced in the
treatment group compared to the placebo group after 24 months,
OR 0.12 (95% CI 0.02 to 0.79) (Analysis 2.1). No signiﬁcant
difference was detected between the two groups at the other time
points. No other trials in the review used this outcome measure
to express their ﬁndings.
2. Clinical and radiological scores
The included trial did not report on this outcome.
3. Cost
The Valerius trial did not include a health economic analysis.
Oral ciprofloxacin and inhaled colistin versus inhaled
tobramycin
This intervention comparing oral ciproﬂoxacin and inhaled col-
istin (three months) with inhaled tobramycin (28 days) included
only one trial including 58 participants (29 in each treatment
group) (Proesmans 2013).
Primary outcome
1. Eradication of P. aeruginosa from the respiratory tract
a. Clearance of P. aeruginosa from BAL, sputum or
oropharyngeal cultures
At some point in the six months following treatment, P. aeruginosa
was isolated in 10 out of 29 participants enrolled to the inhaled
colistin with oral ciproﬂoxacin arm compared to 16 out of 29 in
the TSI arm. The difference between groups was not statistically
signiﬁcant (Analysis 3.1).
b. Time to next isolation of P. aeruginosa from BAL, sputum
or oropharyngeal cultures
The included trial did not report on this outcome.
Secondary Outcomes
1. Mortality
There were no deaths in either arm (Proesmans 2013).
2. Quality of life
The included trial did not report on this outcome.
3. Spirometric lung function
The median change from baseline in FEV1 (% predicted) for all
the participants was -1%. The changes are not reported separately
for each treatment arm (Proesmans 2013).
4. Growth and nutritional status
Both BMI z score and weight z score were reported not to have
changed signiﬁcantly for trial participants as a whole, but numer-
ical data are not reported (Proesmans 2013).
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5. Frequency of respiratory exacerbations
The authors report that, during the ﬁrst six months of follow
up, there was no difference between the two treatment arms in
number of oral antibiotic treatment days. These oral antibiotics
were given for symptoms and not because of failed eradication.
However, numerical data are not reported (Proesmans 2013).
6. Isolation of other micro-organisms
The included trial did not report on this outcome.
7. Adverse effects of antibiotics
One participant is reported to have developed a severe cough with
TSI, but this result was not statistically signiﬁcant (Analysis 3.2).
No other adverse effects are reported.
Additional outcomes which have arisen during the review
1. Time to chronic infection
The included trial did not report on this outcome.
2. Clinical and radiological scores
The included trial did not report on this outcome.
3. Cost
The included trial did not include a health economic analysis.
Inhaled tobramycin (28 days) versus inhaled
tobramycin (56 days)
This intervention comparing 28 days TSI with 56 days TSI in-
cluded one trial of 123 participants, of whom 88 were randomised
(Ratjen 2010).
Primary outcome
1. Eradication of P. aeruginosa from the respiratory tract
a. Clearance of P. aeruginosa from BAL, sputum or
oropharyngeal cultures
This outcome was not evaluated; data are presented in the paper
at one month when participants were all given the initial 28 days
of TSI before randomisation and were excluded if they had raised
anti P. aeruginosa antibody levels (Ratjen 2010).
b. Time to next isolation of P. aeruginosa from BAL, sputum
or oropharyngeal cultures
The median time to recurrence was 26.12 months in the 28-day
treatment group and 25.82months in the 56-day treatment group.
Differences between groups were not signiﬁcant (Analysis 4.1).
Secondary Outcomes
1. Mortality
There were no deaths reported (Ratjen 2010).
2. Quality of life
The included trial did not report on this outcome.
3. Spirometric lung function
The paper presented data in a table for the median change from
baseline to three months and to 27 months for FEV1% predicted,
FVC % predicted and FEF25−75 % predicted; however, presented
data were combined for both the 28-day and the 56-day treatment
groups. The paper states that there were “no major short- or long-
term changes in spirometric parameters observed during the study
period” (Ratjen 2010).
4. Growth and nutritional status
No signiﬁcant differences in weight, height or body mass index
were reported. Only a summary statement was presented, indicat-
ing that the no signiﬁcant difference was found in weight, height
or body mass index. No data were provided (Ratjen 2010).
5. Frequency of respiratory exacerbations
Two participants allocated to the 56-day treatment group were
hospitalised on one occasion, each for a pulmonary exacerbation.
One of these isolatedP. aeruginosa andwas treatedwith intravenous
ceftazidime and tobramycin. When entered into the analysis this
gave a non-signiﬁcant result (Analysis 4.2).
6. Isolation of other micro-organisms
There were no consistent trends reported in the isolation of non-
P. aeruginosa organisms (one isolate only of Stenotrophomonas mal-
tophilia (S. maltophilia) which was seen in the 28-day arm).
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7. Adverse effects of antibiotics
Adverse events up to threemonths that were considered possibly or
probably related to treatment were reported by 14 participants in
each treatment group,with themajority being related todysphonia
in both treatment groups (11% and 14%, respectively) and cough
in the 28-day group (9%). There were no signiﬁcant differences
between treatment groups for any of the reported adverse events
at any time-point (Analysis 4.3; Analysis 4.4).
Additional outcomes which have arisen during the review
1. Time to chronic infection
The included trial did not report on this outcome.
2. Clinical and radiological scores
The included trial did not report on this outcome.
3. Cost
The included trial did not have a health economic analysis.
Inhaled colistin plus oral ciprofloxacin versus inhaled
tobramycin plus oral ciprofloxacin
This comparison of inhaled colistin plus oral ciproﬂoxacin with
inhaled tobramycin plus oral ciproﬂoxacin included one trial with
223 participants (Taccetti 2012).
Primary outcome
1. Eradication of P. aeruginosa from the respiratory tract
a. Clearance of P. aeruginosa from BAL, sputum or
oropharyngeal cultures
In the inhaled colistin plus oral ciproﬂoxacin group, P. aeruginosa
was isolated within the ﬁrst six months from 39 out of 105 partic-
ipants (37.1%) and in the the inhaled tobramycin plus oral cipro-
ﬂoxacin group from 41 out of 118 participants (34.7%) (Taccetti
2012). When data were analysed, the rate of isolation of P. aerugi-
nosa between the two arms was not signiﬁcantly different (Analysis
5.1). At a median follow-up period of 16 months, P. aeruginosa
had been isolated from 36 out of 97 participants in the colistin
with ciproﬂoxacin arm for whom data were available and from 24
out of 108 participants in the tobramycin with ciproﬂoxacin arm;
the two arms were not signiﬁcantly different. The trial authors
report that subgroup analyses by gender, age (one to ﬁve years; ﬁve
to twelve years and over twelve years), lung function (FEV1 less
than or greater than 70%) and participants with ﬁrst ever isolation
of P. aeruginosa failed to show any signiﬁcant differences between
groups (Taccetti 2012).
b. Time to next isolation of P. aeruginosa from BAL, sputum
or oropharyngeal cultures
The trial did not report on this outcome.
Secondary Outcomes
1. Mortality
No deaths were reported (Taccetti 2012).
2. Quality of life
The trial did not report on this outcome.
3. Spirometric lung function
Following treatment, after a mean (SD) time of observation of 54
(39) days, themean (SD) relative change (percentage of predicted)
in FEV1 from baseline was 2.15 (8.50)% in the inhaled colistin
plus oral ciproﬂoxacin group compared to 4.55 (11.54)% in the
the inhaled tobramycin plus oral ciproﬂoxacin group (not statis-
tically signiﬁcant) (Analysis 5.2).
4. Growth and nutritional status
The trial did not report these outcomes.
5. Frequency of respiratory exacerbations
The trial did not report this outcome.
6. Isolation of other micro-organisms
There was an observation that S. maltophilia was isolated more
frequently in the follow-up period than before eradication treat-
ment. There were no differences during follow up between the two
groups for isolation of: S. maltophilia, Achromobacter xylosoxidans
or Aspergillus species (Analysis 5.3).
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7. Adverse effects to antibiotics
There were a total of 38 out of 223 randomised participants (17%)
who discontinued treatment early; of these 17 were from the in-
haled colistin plus oral ciproﬂoxacin group and 21 from the in-
haled tobramycin plus oral ciproﬂoxacin group (Analysis 5.4).
There were a number of reasons for these discontinuations includ-
ing vomiting, photosensitivity, wheeze, pulmonary exacerbation
and lack of compliance.
Additional outcomes which have arisen during the review
1. Time to chronic infection
The trial did not report on this outcome.
2. Clinical and radiological scores
The trial did not report on this outcome.
3. Cost
A health economic analysis was not undertaken in the included
trial.
Cycled inhaled tobramycin versus culture-based
inhaled tobramycin
This comparison of cycled inhaled tobramycin (with oral cipro-
ﬂoxacin or placebo) with culture-based inhaled tobramycin (with
oral ciproﬂoxacin or placebo) included one trial, with 306 par-
ticipants randomised and data analysed on 304 participants who
received treatment (Treggiari 2011).
Primary outcome
1. Eradication of P. aeruginosa from the respiratory tract
a. Clearance of P. aeruginosa from BAL, sputum or
oropharyngeal cultures
Treggiari reported 43 out of 148 children on cycled therapy had
one or more isolates of P. aeruginosa compared to 67 out of 150
children on culture-based therapy giving a statistically signiﬁcant
effect in favour of cycled therapy, OR 0.51 (95% CI 0.31 to 0.82)
(Analysis 6.1). The main trial publication reports an age-adjusted
OR, using generalised estimating equations, with robust variance,
specifying a logit link and assuming an independence working cor-
relation (Treggiari 2011). This may explain the difference between
the trial publication and the ﬁndings of this review.
b. Time to next isolation of P. aeruginosa from BAL, sputum
or oropharyngeal cultures
This was not reported in the included trial.
Secondary Outcomes
1. Mortality
No deaths were reported in either arm (Treggiari 2011).
2. Quality of life
This outcome was not reported in the included trial.
3. Spirometric lung function
The included trial reports the mean 70-week change in FEV1 %
predicted, but the mean difference between the two arms was not
signiﬁcant (Analysis 6.2).
4. Growth and nutritional status
The Treggiari trial reports themean 70-week change from baseline
in weight (kg) for each treatment arm, but the MD between arms
was not signiﬁcant (Analysis 6.3). The trial also reports data for the
change from baseline in height (cm) for each arm at the same time
point; again the MD between arms was not signiﬁcant (Analysis
6.4).
5. Frequency of respiratory exacerbations
A primary outcome in the Treggiari trial was the time to a se-
vere pulmonary exacerbation (i.e. an exacerbation requiring in-
travenous antibiotics or hospitalisation or both) (Treggiari 2011).
The analysis shows no signiﬁcant difference in time to a severe
exacerbation (Analysis 6.5).
Data on the frequency of severe exacerbations, during the 70-
week follow-up period, are also presented in the paper. From our
analysis, the data indicate no signiﬁcant difference between groups
(Analysis 6.6).
Treggiari also reported a secondary outcome of time to pulmonary
exacerbation of any severity (including any exacerbation treated
with intravenous, inhaled or oral antibiotics or requiring hospital-
isation). The results of our analysis are slightly different to those
reported in the paper, but still show no statistically signiﬁcant dif-
ference in time to any exacerbation (Analysis 6.7).
Finally, the number of exacerbations of any severity was also re-
ported. In our analysis, the OR was not signiﬁcantly different be-
tween cycled and culture-based therapy (Analysis 6.8).
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6. Isolation of other micro-organisms
The Treggiari trial reported the number of participants in
each arm with one or more isolates of the emerging pathogen
Stenotrophomonas maltophilia (Treggiari 2011). There was no
signiﬁcant difference between cycled and culture-based therapy
(Analysis 6.9).
7. Adverse effects to antibiotics
With regards to the incidence of adverse effects, Treggiari did not
report any signiﬁcant difference between treatment arms, although
adverse events attributable to antibiotic therapy were not recorded
separately from adverse events which were unlikely to be related
to the study intervention (Treggiari 2011). Our results were also
not statistically signiﬁcant (Analysis 6.10).
Additional outcomes which have arisen during the review
1. Time to chronic infection
This was not reported in the one included trial.
2. Clinical and radiological scores
These outcomes were not reported in the one included trial.
3. Cost
Ahealth economic analysiswas not undertaken in the one included
trial.
Ciprofloxacin versus placebo added to cycled and
culture-based inhaled tobramycin therapy
As discussed under Description of studies, the Treggari trial ran-
domised participants to cycled versus culture-based inhaled to-
bramycin therapy and then to oral ciproﬂoxacin versus placebo for
two weeks with each 28-day course of TSI (Treggiari 2011). This
section presents the comparison of outcomes in the ciproﬂoxacin
and placebo arms.
Primary outcome
1. Eradication of P. aeruginosa from the respiratory tract
a. Clearance of P. aeruginosa from BAL, sputum or
oropharyngeal cultures
Treggiari reported that 49 out of 146 children on oral ciproﬂoxacin
had one ormore isolates ofP. aeruginosa compared to 55 out of 150
children on placebo (Treggiari 2011). The data for this outcome
show a non-statistically signiﬁcant effect. Age group-adjusted ORs
are reported in the trial paper; in our analysis, we did not adjust
for age.
b. Time to next isolation of P. aeruginosa from BAL, sputum
or oropharyngeal cultures
This was not reported in the included trial.
Secondary Outcomes
1. Mortality
No deaths were reported in either arm (Treggiari 2011).
2. Quality of life
This outcome was not reported in the included trial.
3. Spirometric lung function
The included trial reports the mean 70-week change in FEV1 %
predicted, but the MD between the two arms was not signiﬁcant
(Analysis 7.2).
4. Growth and nutritional status
The Treggiari trial reports themean 70-week change from baseline
in weight (kg) for each treatment arm; the MD between arms was
not signiﬁcant (Analysis 7.3). The trial also reports data for the
change from baseline in height (cm) for each arm; again the MD
between arms was not signiﬁcant (Analysis 7.4).
5. Frequency of respiratory exacerbations
A primary outcome in the Treggiari trial was the time to a se-
vere pulmonary exacerbation (i.e. an exacerbation requiring intra-
venous antibiotics or hospitalisation, or both) (Treggiari 2011).
Again, for the ciproﬂoxacin versus placebo comparison, there was
no signiﬁcant difference in time to a severe exacerbation (Analysis
7.5).
Data on the frequency of severe exacerbations, during the 70-
week follow-up period, are also presented in the paper. From our
analysis, the OR is not signiﬁcantly different between groups (
Analysis 7.6).
We analysed the outcome ’time to pulmonary exacerbation (any
severity)’, including any exacerbation treated with intravenous,
inhaled or oral antibiotics or requiring hospitalisation (Analysis
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7.7). There was no difference between ciproﬂoxacin and placebo
in time to exacerbation (any severity).
Finally, the number of exacerbations of any severity was not sig-
niﬁcantly different between ciproﬂoxacin and placebo (Analysis
7.8).
6. Isolation of other micro-organisms
In the Treggiari trial, there was no signiﬁcant difference between
ciproﬂoxacin and placebo in the number of isolates of S. mal-
tophilia (Analysis 7.9).
7. Adverse effects to antibiotics
Treggiari did not report any signiﬁcant difference between treat-
ment arms in the incidence of adverse events, although adverse
events attributable to antibiotic therapy were not recorded sep-
arately from adverse events which were unlikely to be related to
the trial intervention (Treggiari 2011). Our analysis showed no
difference between arms in the number of participants with one
or more serious adverse events (Analysis 7.10).
Additional outcomes which have arisen during the review
1. Time to chronic infection
This was not reported in the one included trial.
2. Clinical and radiological scores
These outcomes were not reported in the one included trial.
3. Cost
Ahealth economic analysiswas not undertaken in the one included
trial.
D I S C U S S I O N
Summary of main results
Our review includes seven trials (with data from 744 participants)
of antibiotic strategies for the eradication of P. aeruginosa infection
in CF, conducted over a period of over 20 years. Each trial used a
different intervention and only two trials could be combined in a
meta-analysis of the same treatment comparison. An early interim
analysis was performed due to slow accrual in one trial (Gibson
2003).
Cumulative data from 43 participants in two of the seven included
trials indicate that P. aeruginosa was more frequently eradicated
from the respiratory secretions in the participants receiving antibi-
otics than from those receiving placebo (Gibson 2003;Wiesemann
1998). This reduction in the number of isolates of P. aeruginosa
was noted at both one month and two months after the start of
treatment. A further trial suggests that the onset of chronic infec-
tion with P. aeruginosa is delayed in those individuals who have re-
ceived antibiotic therapy compared to those receiving no therapy
(Valerius 1991). There was evidence from the trials by Valerius
and Wiesemann that this effect may persist for up to 24 months
(Valerius 1991; Wiesemann 1998). We found no difference in ad-
verse events. In two trials, an increased incidence of the emerging
pathogen S. maltophilia was reported following treatment, but no
difference was found between eradication regimens in either of
these trials (Taccetti 2012; Treggiari 2011) .
The trial by Proesmans, which randomised 58 participants, was
associated with a low rate of short-term eradication of P. aeruginosa
from both groups of children treated with nebulised high-dose
tobramycin and a combination of oral ciproﬂoxacin with inhaled
colistin (Proesmans 2013). The numbers of participants in each
group were too low to allow comparisons of superiority between
the two eradication regimens to be made. A further possible cause
of the low eradication rate in this trial may be that participants
were recruited if they had been free of P. aeruginosa for at least
six months (with negative microbiology samples for at least six
months), which is shorter than the 12-month P. aeruginosa-free
interval used by the Leeds deﬁnition of ’Pseudomonas-free’ (Lee
2003).
The trial by Ratjen took place in 21 centres in Germany, France,
The Netherlands, UK, Spain and Austria from November 2003
until January 2008. The trial has reported that 28-day and 56-
day treatment with inhaled tobramycin to be effective and safe;
with no additional advantage to 56 days of therapy over 28 days
(Ratjen 2010). The authors of this trial concluded that head-to-
head comparisons will clarify whether adding either oral ciproﬂo-
xacin or intravenous antibiotic therapy can further increase treat-
ment success in people with CF with early P. aeruginosa infection.
The Taccetti trial randomised 223 participants and failed to
demonstrate superiority of inhaled tobramycin with oral cipro-
ﬂoxacin over inhaled colistin with oral ciproﬂoxacin, both treat-
ments given over 28 days (Taccetti 2012). As in the Ratjen trial,
the included participants had been free of P. aeruginosa for at least
six months, again at variance with the Leeds deﬁnition of Pseu-
domonas-free (Lee 2003).
The Treggiari trial was the largest trial of P. aeruginosa eradication
in CF reported so far and randomised 306 children (aged 1 to 12
years) and reported data on 304 children (Treggiari 2011). The
trial used a complex, four-arm design, comparing cycled with cul-
ture-based treatment with TSI and also additional oral ciproﬂo-
xacin versus placebo. The trial was adequately powered for its two
primary outcome measures (time to severe pulmonary exacerba-
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tion and proportion of P. aeruginosa positive cultures) and found
no difference between arms for either outcome. In contrast, our
analysis (which was not corrected for age) did ﬁnd a signiﬁcant
difference in the proportion of P. aeruginosa positive cultures in
favour of cycled therapy. There was no difference between cipro-
ﬂoxacin and placebo for this outcome.
No deaths were reported in any of the trials.
Overall completeness and applicability of
evidence
The aim of antibiotic therapy for earlyP. aeruginosa infection inCF
should be both eradication of the micro-organism and improve-
ment in (or slowing in the rate of decline of ) clinical parameters,
whilst minimising adverse effects and the isolation of new micro-
organisms. If P. aeruginosa is successfully eradicated, but there is
no measurable clinical beneﬁt, it is likely that current measures of
clinical status are not sufﬁciently sensitive or that the duration of
follow up is too short to show a difference.
There are differences in the type and dose of drug administered to
the treatment groups in the two trials where nebulised tobramycin
was compared to placebo. In the Wiesemann trial, tobramycin
injectable solution was administered by nebuliser, at a low dose
(80 mg twice daily) for a long duration (12 months) (Wiesemann
1998); whereas Gibson used TSI TOBI® (now marketed by No-
vartis) at a high dose (300 mg twice daily) for a short duration (28
days) (Gibson 2003). This is a potential source of heterogeneity
between the trials. It is of interest that signiﬁcant heterogeneity
was detected between the trials at the one-month time point but
this was not detected at the two-month time point.
The Proesmans andTaccetti trials included patients that werePseu-
domonas-naive and those that had not isolated P. aeruginosa for
at least six months (Proesmans 2013; Taccetti 2012), which is at
variance with the 12-month deﬁnition proposed by Lee to deﬁne
a patient as ’Pseudomonas-free’ (Lee 2003). It was not possible for
the authors of this review to extract IPD for those patients that
ﬁt this longer deﬁnition of Pseudomonas-free. The Treggiari trial
required patients to have been free of P. aeruginosa for at least two
years (Treggiari 2011).
Eradication of isolates of P. aeruginosa is easiest in people with CF
with recent onset of P. aeruginosa infection of the respiratory tract,
in particular in those who have non-mucoid isolates of P. aerug-
inosa as they seem particularly susceptible to antibiotic therapy.
Two trials included in this review have recruited adult patients
suggesting that early P. aeruginosa infection can be eradicated from
adults as well as from children and therefore adults should be in-
cluded in future studies.
Finally, it should be noted that some of the trials were conducted
between 10 and 20 years ago and the results may be less applicable
to patients today.
Quality of the evidence
The quality of the trials was variable with important deﬁciencies
identiﬁed in some. For example, in four out of the seven included
trials we judged there to be a high risk from a lack of blinding
of participants and clinicians; in two of these trials the different
interventions used in the treatment and control groups precluded
blinding (Proesmans 2013; Valerius 1991) and two trials were
open label and no attempt was made at blinding. We also judged
there to be a high risk of bias due to selective reporting in three of
the trials, which only reported summary statements with no actual
data for a number of outcomes (Proesmans 2013; Ratjen 2010;
Wiesemann 1998).
While we generally judged there to be a low risk of bias due
to incomplete outcome data, there was incomplete follow up of
a number of participants in one of the older and smaller trials
(Wiesemann 1998). The absence of these data has complicated
the combined analysis of the two trials that compare inhaled to-
bramycin with placebo (Gibson 2003; Wiesemann 1998); one
trial was analysed on an intention-to-treat basis (Gibson 2003)
and another on an available-case basis (Wiesemann 1998). A sen-
sitivity analysis based on best- and worst-case scenarios demon-
strated similar results to the available-case analysis. The available-
case analysis revealed a reduction in the odds of a positive culture
for P. aeruginosa in the group treated with tobramycin inhalation
when compared to the odds in the placebo group at both one and
two months from the start of treatment (Wiesemann 1998).
The Gibson trial was stopped early because of evidence of signif-
icant treatment effect (Gibson 2003). It has been suggested that
the results of randomised controlled trials stopped early for beneﬁt
should be interpreted with caution particularly when the number
of events is small (Montori 2005).
In the Ratjen trial, the authors wished to enrol 120 participants in
order to randomise 100 patients. They succeeded in recruiting 123
individuals ofwhom88were randomised and65 could be included
in the analysis of the primary outcome (time to recurrence of P.
aeruginosa). This trial is potentially subject to bias because of the
exclusion of non-randomised individuals, including 31 people in
whom there were elevated antibody titres to P. aeruginosa (Ratjen
2010).
The relationship between the presence of P. aeruginosa in secre-
tions from the upper respiratory tract and the isolation of P. aerug-
inosa from the lower respiratory tract is inconsistent. Reporting of
the presence of organisms in respiratory secretions is difﬁcult to
standardise, dependent on the sampling methods used and on the
number of samples taken. The trials included in this review used
a heterogeneous mix of methods to sample respiratory secretions
from both the lower and upper respiratory tracts. No two trials
used the samemethods andmore than onemethodwas used in two
trials. There was no subgroup analysis based on sampling method
in any of the trials, probably owing to relatively small numbers of
participants in individual trials. Wiesemann used a combination
of oropharyngeal swabs and sputum samples, whereasGibson used
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oropharyngeal swabs and BAL ﬂuid (Gibson 2003; Wiesemann
1998). Proesmans used sputum, throat swab and BAL (Proesmans
2013). The Taccetti study did not describe the technique used
for culture collection (Taccetti 2012). The Treggiari trial enrolled
younger children and used oropharyngeal swabs or sputum sam-
ples (Treggiari 2011). Armstrong has shown that the results of
oropharyngeal specimens are poorly predictive of the presence of
organisms in the lower respiratory tract (Armstrong 1996). Va-
lerius relied on sputum samples which can be of poor quality in
younger children (Valerius 1991).
Potential biases in the review process
The original review stated that trials would be included only where
eradication begins within two months of isolation of P. aerugi-
nosa. In a post hoc change, this has now been altered to include
those where eradication has been initiated up to six months since
isolation. Whilst prompt treatment of new P. aeruginosa infection
is recommended (Smyth 2014), there is no robust evidence for a
speciﬁc time limit for initiation of treatment.
The review now also includes patients from two distinct groups,
those that are Pseudomonas-naive and those that are Pseudomonas-
free.
Agreements and disagreements with other
studies or reviews
We are not aware of any other studies or reviewswhich recommend
speciﬁc eradication treatment.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Signiﬁcantly more children with cystic ﬁbrosis (CF) show clear-
ance of Pseudomonas aeruginosa (P. aeruginosa) from their respira-
tory secretions up to three months after commencing antibiotic
therapy aimed at eradication of the organism from their respira-
tory tract when compared to placebo. This effect may last for sev-
eral months. This review has not established any improvement in
clinical outcome measures following treatment. The small num-
bers of participants in some trials and the short duration of follow
up mean that this review may have insufﬁcient statistical power
to detect changes in these clinical outcomes. However, there are
many observational studies which have shown a decline in clinical
status once chronic P. aeruginosa infection occurs and so clinical
beneﬁt from eradication is likely. There was no signiﬁcant differ-
ence in the rate of common adverse effects detected. An increased
incidence of the emerging pathogen Stenotrophomonas maltophilia
(S. maltophilia) was seen after eradication treatment in two trials,
but there was no statistically signiﬁcant difference between regi-
mens (Taccetti 2012; Treggiari 2011).
We found that nebulised antibiotics (or a combinationof nebulised
and oral antibiotics) were better than no treatment in treating early
infection with P. aeruginosa, which was eliminated in the majority
of individuals. Eradication may be sustained in the short term.We
were unable to determine whether there is an associated clinical
beneﬁt to people with CF, though data from observational studies
suggest that beneﬁt is likely. Overall, there is insufﬁcient evidence
from this review to state which antibiotic strategy should be used
for the eradication of early P. aeruginosa infection in CF.
Implications for research
Whilst there is evidence that eradication treatment is more effec-
tive than placebo or no treatment, there is no evidence to help the
clinician choose which regimen to use. There remains an urgent
need for well-designed and well-executed trials, comparing erad-
ication regimens. Where possible these should evaluate whether
eradication results in appreciable clinical beneﬁt to patients, with-
out causing them harm. Trials should also explore the inﬂuence of
prior infection with P. aeruginosa (“Pseudomonas-free” compared
to “Pseudomonas-naive”) and whether there is an advantage in early
institution of therapy (within weeks rather than within months).
This might be accomplished, using a stratiﬁed trial design. Con-
sideration should be given to appropriate outcome measures, par-
ticularly spirometric lung function, nutritional status, socio-eco-
nomic outcomes (including quality of life) and duration of follow
up. Long-term follow-up trials with careful clinical and bacterio-
logical surveillance are required. These trials will be challenging
to design and deliver. Randomisation should include two active
treatments that are both believed to be effective and safe andwould
still need to recruit a sufﬁcient number of patients to show differ-
ences in efﬁcacy with adequate power. Adult participants as well
as children should be included in such trials.
A C K N OW L E D G E M E N T S
Hazel Bunn assisted in formulation of the review protocol. We
would also like to thank Dr Damian Wood for his input into
the original version of this review and subsequent updates until
November 2007.
22Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
R E F E R E N C E S
References to studies included in this review
Gibson 2003 {published data only}
Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld
M, Yunker A, et al.A randomized, controlled trial of
inhaled tobramycin in young children with cystic ﬁbrosis:
Eradication of pseudomonas from the lower airway
[abstract]. Pediatric Pulmonology 2002;Suppl 24:300.
[CFGD Register: PI151c]
Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld
M, Yunker A, et al.Online Supplement to ’Signiﬁcant
microbiological effect of inhaled tobramycin in young
children with cystic ﬁbrosis’. [online]. American Journal of
Respiratory and Critical Care Medicine 2003;167(6):841
Online. [CFGD Register: PI151e]
∗ Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld
M, Yunker A, et al.Signiﬁcant microbiological effect of
inhaled tobramycin in young children with cystic ﬁbrosis.
American Journal of Respiratory and Critical Care Medicine
2003;167(6):841–9. [CFGD Register: PI151d]
Rosenfeld M. Serum and lower respiratory tract tobramycin
concentrations produced by inhaled tobramycin (TOBI)
in young children with cystic ﬁbrosis [abstract]. Pediatric
Pulmonology 1999;Suppl 19:106–8. [CFGD Register:
PI151b]
Rosenfeld M, Borowitz D, Emerson J, Gibson R, McCoy
K, McNamara S, et al.Serum pharmacokinetics and safety
of inhaled tobramycin in very young CF patients [abstract].
Pediatric Pulmonology 1999;Suppl 19:262. [CFGD
Register: PI151a]
Proesmans 2013 {published data only}
Proesmans M, Boulanger L, Vermeulen F, De Boeck K.
Eradication of recent Pseudomonas aeruginosa isolation:
TOBI versus colistin/ciproﬂoxacin [abstract]. Journal of
Cystic Fibrosis 2008;7(S2):S64. [CFGD Register: PI208a]
Proesmans M, Boulanger L, Vermeulen F, De Boeck K.
Eradication of recent Pseudomonas aeruginosa isolation:
TOBI versus colistin/ciproﬂoxacin [abstract]. Pediatric
Pulmonology 2009;44(S32):321, Abstract no: 311. [CFGD
Register: PI208b; MEDLINE: 96296083]
Proesmans M, Boulanger L, Vermeulen F, De Boeck K.
Eradication of recent pseudomonas aeruginosa infection:
TOBI versus Colistineb®/ ciproﬂoxacin [abstract]. Journal
of Cystic Fibrosis 2011;10 Suppl 1:S26, Abstract no: 102.
[CFGD Register: PI208c]
∗ Proesmans M, Vermeulen F, Boulanger L, Verhaegen
J, De Boeck K. Comparison of two treatment regimens
for eradication of Pseudomonas aeruginosa infection in
children with cystic ﬁbrosis. Journal of Cystic Fibrosis 2013;
12(1):29–34. [CFGD Register: PI208d]
Ratjen 2010 {published data only}
Ratjen F, Munck A, Campello V. Inhaled tobramycin
nebuliser solution for treatment of early Pseudomonas
aeruginosa infection: ﬁrst results from the Elite study
[abstract]. Pediatric Pulmonlogy 2006;41(S29):318.
[CFGD Register: PI197b]
Ratjen F, Munck A, Campello V. Safety of inhaled
tobramycin nebuliser solution for treatment of early
pseudomonas aeruginosa infection: ﬁrst results from the
ELITE study [abstract]. Journal of Cystic Fibrosis 2006;5
Suppl 1:S22. [CFGD Register: PI197a]
Ratjen F, Munck A, Kho P. Short and long-term efﬁcacy of
inhaled tobramycin in early P. Aeruginosa infection: the
ELITE study [abstract]. Pediatric Pulmonology 2008;43
(S31):319. [CFGD Register: PI197d]
∗ Ratjen F, Munck A, Kho P, Angyalosi G, for the ELITE
Study Group. Treatment of early Pseudomonas aeruginosa
infection in patients with cystic ﬁbrosis: the ELITE trial.
Thorax 2010;65(4):286–91. [CFGD Register: PI197e]
Ratjen F, Stenglein S, Munck A. Inhaled tobramycin
nebulizer solution for treatment of early Pseudomonas
aeruginosa infection; the ELITE study [abstract]. Journal
of Cystic Fibrosis 2008;7 Suppl 2:S26. [CFGD Register:
PI197c]
Taccetti 2012 {published data only}
Cariani L, Deﬁlippi G, Costantini D, Claut L, Clarizia
G, D’accico M, et al.Semi-automated rep-pcr genotyping
of pseudomonas aeruginosa in Italian CF patients in
eradication therapy [abstract]. Pediatric Pulmonology 2010;
45 Suppl 33:348, Abstract no: 360. [CFGD Register:
PI230c]
Dolce D, Cariani L, Ravenni N, Mergni G, Bifﬁ A,
Colombo C, et al.Anti-P.aeruginosa antibodies and
microbiological outcome in patients treated with early
eradication therapy [abstract]. Pediatric Pulmonology 2013;
48 Suppl 36:288, Abstract no: 231. [CENTRAL: 921692;
CFGD Register: PI230i; CRS: 5500125000000403]
Taccetti G, Bianchini E, Zavataro L, Campana S, Deﬁlippi
G, Ravenni N, et al.Pseudomonas aeruginosa eradication
in cystic ﬁbrosis: preliminary data from a randomized
multicenter study of two different early antibiotic treatment
protocols [abstract]. Pediatric Pulmonology 2010;45(S33):
337, Abstract no: 332. [CFGD Register: PI230d]
Taccetti G, Bianchini E, Zavataro L, Campana S,
Deﬁlippi G, Ravenni N, et al.Pseudomonas aeruginosa
microbiological status and emergence of other pathogens
after early eradication treatment in cystic ﬁbrosis: a post-
trial follow-up [abstract]. Pediatric Pulmonology 2011;46
(S34):317, Abstract no: 292. [CFGD Register: PI230e]
Taccetti G, Bianchini E, Zavataro L, Campana S,
Ravenni N, Boni V, et al.Early antibiotic treatment for
Pseudomonas aeruginosa eradication in cystic ﬁbrosis
patients: a randomized multicenter study of two different
protocols [abstract]. Pediatric Pulmonology 2009;44(S32):
354, Abstract no: 406. [CFGD CF Register: PI230a;
MEDLINE: 96296083]
Taccetti G, Bianchini E, Zavataro L, Costantini D, Galici
V, Campana S, et al.Pseudomonas aeruginosa eradication
in cystic ﬁbrosis: ﬁnal results of a randomized multicenter
23Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
study of two different early antibiotic treatment protocols
[abstract]. Pediatric Pulmonology 2011;46(S34):317,
Abstract no: 291. [CFGD Register: PI230f ]
Taccetti G, Cocchi P, Dolce D, Galici V, Mergni G,
Gagliardini R, et al.Is early eradication treatment against
P.aeruginosa associated with the emergence of other
non-fermenter gram negatives [abstract]. Pediatric
Pulmonology 2013;48 Suppl 36:328, Abstract no: 338.
[CENTRAL: 921671; CFGD Register: PI230h; CRS:
5500125000000398]
∗ Taccetti G, Bianchini E, Cariani L, Buzzetti R,
Costantini D, Trevisan F, et al.Early antibiotic treatment for
Pseudomonas aeruginosa eradication in patients with cystic
ﬁbrosis: a randomised multicentre study comparing two
different protocols. Thorax 2012;67(10):853–9. [CFGD
Register: PI230g]
Zavataro L, Taccetti G, Cariani L, Ravenni N, Braccini
G, Bresci S, et al.Epidemiology of ﬁrst/new Pseudomonas
aeruginosa infection in cystic ﬁbrosis patients [abstract].
Journal of Cystic Fibrosis 2010;9 Suppl 1:S29, Abstract no:
110. [CFGD Register: PI230b]
Treggiari 2011 {published data only}
Anstead M, Lymp J, Khan U, Barbieri J, Langkamp M,
Doring G, et al.Pseudomonas aeruginosa serology predicts
response to treatment and re-infection in the EPIC clinical
study [abstract]. Pediatric Pulmonology 2011;46(S34):303,
Abstract no: 254. [CFGD Register: PI202g]
Hamblett NM, Retsch-Bogart GZ, Treggiari M, Kronmal
RA, Khan U, Williams J, et al.Safety and efﬁcacy
of anti-pseudomonal therapy for early eradication of
Pseudomonas aeruginosa: the EPIC study [abstract].
Pediatric Pulmonology 2009;44(S32):183. [CFGD CF
Register: PI202b; MEDLINE: 96296083]
Hoffman LR, Ramsey BW, Kulasekara HD, Retsch-Bogart
GZ, Wolter DJ, Pope CE, et al.Pseudomonas aeruginosa
(PA) phenotypes associated with persistent early infection in
CF patients in the EPIC Clinical Trial [abstract]. Pediatric
Pulmonology 2012;47(S35):317, Abstract no: 266. [CFGD
Register: PI202j]
Khan U, Mayer-Hamblett N, Retsch-Bogart G, Treggiari
M, Ramsey B. Association between baseline pseudomonas
aeruginosa positivity in EPIC clinical trial participants &
prior antibiotic exposure [abstract]. Pediatric Pulmonology
2010;45(S33):335, Abstract no: 326. [CFGD Register:
PI202f ]
Mayer-Hamblett N, Kronmal RA,Gibson RL, Rosenfeld M,
Retsch-Bogart G, Treggiari MM, et al.Initial Pseudomonas
aeruginosa treatment failure is associated with exacerbations
in cystic ﬁbrosis. Pediatric Pulmonology 2012;47(2):125–34.
[CFGD Register: PI202i; DOI: 10.1002/ppul.21525]
Mayer-Hamblett N, Rosenfeld M, Treggiari MM, Konstan
MW, Retsch-Bogart G, Morgan W, et al.Standard care
versus protocol based therapy for new onset Pseudomonas
aeruginosa in cystic ﬁbrosis. Pediatric Pulmonology 2013;
48(10):943–53. [CENTRAL: 916577; CFGD Register:
PI202k; CRS: 5500125000000727; PUBMED: 23818295]
Ramsey B. TOBI use in infants and children with early
Pseudomonas Aeruginosa infection - duration of effect and
epic update [abstract]. Pediatric Pulmonology 2005;40(S28):
146. [CFGD CF Register: PI202a]
Treggiari M, Retsch-Bogart G, Mayer-Hamblett N, Khan
U, Kronmal R, Ramsey B, et al.Comparative efﬁcacy
and safety of four randomized regimens to treat early
Pseudomonas aeruginosa infection in children with cystic
ﬁbrosis [abstract]. Journal of Cystic Fibrosis 2010;9 Suppl 1:
S54, Abstract no: 209. [CFGD Register: PI202e]
Treggiari M, Retsch-Bogart GZ, Mayer-Hamblett N,
Kronmal R, Khan U, Williams J, et al.Early anti-
pseudomonal infection in children with CF: study
population and conduct of the “EPIC” clinical trial
[abstract]. Pediatric Pulmonology 2009;44(S32):316,
Abstract no: 299. [CFGD CF Register: PI202c;
MEDLINE: 96296083]
∗ Treggiari MM, Retsch-Bogart G, Mayer-Hamblett
N, Khan U, Kulich M, Kronmal R, et al.Comparative
efﬁcacy and safety of 4 randomized regimens to treat early
Pseudomonas aeruginosa infection in children with cystic
ﬁbrosis. Archives of Pediatrics and Adolescent Medicine 2011;
165(9):847–56. [CFGD Register: PI202h]
Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-
Bogart G, Gibson RL, Williams J, et al.Early anti-
pseudomonal acquisition in young patients with cystic
ﬁbrosis: rationale and design of the EPIC clinical trial and
observational study. Contempory Clinical Trials 2009;30
(3):256–68. [CFGD CF Register: PI202d; MEDLINE:
96296083]
Valerius 1991 {published data only}
∗ Valerius NH, Koch C, Høiby N. Prevention of chronic
Pseudomonas aeruginosa colonisation in cystic ﬁbrosis by
early treatment. Lancet 1991;338(8769):725–6. [CFGD
Register: PI70b]
Valerius NH, Koch C, Høiby N. Prevention of chronic
colonization with Pseudomonas aeruginosa in patients
with CF by early treatment with ciproﬂoxacin and colistin
aerosol inhalations [abstract]. Pediatric Pulmonology 1990;9
(Supplement S5):248. [CFGD Register: PI70a]
Wiesemann 1998 {published data only}
Ratjen F, Steinkamp G, Döring G, Bauernfeind A,
Wiesemann HG, Von Der Hardt H. Prevention of chronic
pseudomonas aeruginosa infection by early inhalation
therapy with tobramycin [abstract]. Pediatric Pulmonology
1994;Suppl 10:250. [CFGD Register: PI101a]
∗ Wiesemann HG, Steinkamp G, Ratjen F, Baurnfeind A,
Przyklenk B, Döring G, et al.Placebo-controlled, double-
blind, randomised study of aerosolised tobramycin for early
treatment of Pseudomonas aeruginosa colonization in cystic
ﬁbrosis. Pediatric Pulmonology 1998;25(2):88–92. [CFGD
Register: PI101b]
References to studies excluded from this review
Alothman 2002 {published data only}
Alothman GA, Alsaadi MM, Ho BL, Ho SL, Dupuis A,
Corey M, et al.Evaluation of bronchial constriction in
children with cystic ﬁbrosis after inhaling two different
24Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
preparations of tobramycin. Chest 2002;122(3):930–4.
[CENTRAL: 398028; CFGD Register: PI157b; CRS:
5500100000002196; PUBMED: 12226034]
Alothman GA, Coates AL, Corey M, Dupuis A, Ho SL,
Ho BL, et al.In cystic ﬁbrosis (CF) patients, does the
inhalation of an intravenous tobramycin preparation result
in more bronchospasm than a preservative free tobramycin
preparation? [abstract]. Pediatric Pulmonology 2000;Suppl
20:298–9. [CFGD Register: PI157a]
Alothman 2005 {published data only}
Alothman GA, Ho B, Alsaadi MM, Ho SL, O’Drowsky
L, Louca E, et al.Bronchial constriction and inhaled
colistin in cystic ﬁbrosis. Chest 2005;127(2):522–9.
[CENTRAL: 502709; CFGD Register: PI190; CRS:
5500100000002670; PUBMED: 15705991]
Ballman 1998 {published data only}
Ballman M, Rabsch P, von der Hardt H. Long term follow
up of changes in FEV1 and treatment intensity during
Pseudomonas aeruginosa colonisation in patients with cystic
ﬁbrosis. Thorax 1998;53(9):732–7.
Brett 1992 {published data only}
Brett MM, Simmonds EJ, Ghonheim ATM, Littlewood
JM. The value of serum IgG titres against Pseudomonas
aeruginosa in the management of early infection in cystic
ﬁbrosis. Archives of Disease in Childhood 1992;67(9):
1086–8. [CFGD Register: PI73]
Church 1997 {published data only}
Church DA, Kanga JF, Kuhn RJ, Rubio TT, Spohn
WA, Stevens JC, et al.Sequential ciproﬂoxacin therapy in
pediatric cystic ﬁbrosis: comparative study vs. ceftazidime/
tobramycin in the treatment of acute pulmonary
exacerbations. The Cystic Fibrosis Study Group.
Pediatric Infectious Disease Journal 1997;16(1):97–105.
[CENTRAL: 135891; CFGD Register: PI115 ; CRS:
5500100000000803; PUBMED: 9002118]
Clancy 2013 {published data only}
∗ Clancy JP, Dupont L, Konstan MW, Billings J, Fustik
S, Goss CH, et al.Phase II studies of nebulised Arikace
in CF patients with Pseudomonas aeruginosa infection.
Thorax 2013;68(9):818–25. [CENTRAL: 876398; CFGD
Register: PI207e // PI222c ; CRS: 5500050000000084;
PUBMED: 23749840]
Clancy JP, Minic P, Dupont L, Goss CH, Quittner AL,
Lymp JF, et al.Full analysis of data from two phase II
blinded & placebo-controlled studies of nebulized liposomal
amikacin for inhalation (Arikace) in the treatment of CF
patients with pseudomonas aeruginosa lung infection
[abstract]. Pediatric Pulmonology 2010;45 Suppl 33:299,
Abstract no: 227. [CENTRAL: 848916; CFGD Register:
PI207d // PI222b; CRS: 5500100000010628]
Dupont L, Minic P, Fustic S, Mazurek H, Solyom E,
Feketova A, et al.A randomised placebo-controlled study of
nebulized liposomal amikacin (Arikace) in the treatment of
cystic ﬁbrosis patients with chronic Pseudomonas aeruginosa
lung infection [abstract]. Journal of Cystic Fibrosis 2008;
7 Suppl 2:S26. [CENTRAL: 790820; CFGD Register:
PI207a; CRS: 5500100000003531]
Dupont LJ, Minic P, Fustik S, Mazurek H, Solyom E,
Feketeova A, et al.A randomized placebo-controlled study
of nebulized liposomal amikacin (Arikace) in the treatment
of cystic ﬁbrosis patients with chronic Pseudomonas
Aeruginosa lung infection [abstract]. Pediatric Pulmonology
2008;43 Suppl 31:301. [CENTRAL: 790939; CFGD
Register: PI207b; CRS: 5500100000003535]
Gupta R, Dupont L, Minin P, Fustik S, Mazurek H, Solyom
E, et al.A randomized placebo-controlled study of nebulized
liposomal amikacin (Arikace) in the treatment of cystic
ﬁbrosis patients with chronic Pseudomonas aeruginosa
lung infection (protocol TR02-105) [abstract]. American
Journal of Respiratory and Critical Care Medicine 2009;
179:Abstract no: A1199. [CENTRAL: 790940; CFGD
Register: PI207c; CRS: 5500100000003536]
Coates 2011 {published data only}
∗ Coates AL, Denk O, Leung K, Ribeiro N, Chan J, Green
M, et al.Higher tobramycin concentration and vibrating
mesh technology can shorten antibiotic treatment time in
cystic ﬁbrosis. Pediatric Pulmonology 2011;46(4):401–8.
[CENTRAL: 786190; CFGD Register: PI241b; CRS:
5500100000006333]
Denk O, Caotes AL, Keller M, Leung K, Green M, Chan J,
et al.Lung delivery of a new tobramycin nebuliser solution
(150mg/1.5ml) by an investigational eFlow® nebuliser is
equivalent to TOBI® but in a fraction of time [abstract].
Journal of Cystic Fibrosis 2009;8 Suppl 2:S66, Abstract no:
264. [CENTRAL: 794467; CFGD Register: PI241c; CRS:
5500100000003576]
Keller M, Coates AL, Griese M, Denk O, Schierholz J,
Knoch M. In-vivo data support equivalent therapeutic
efﬁcacy of a new tobramycin inhalation solution (150mg/
1.5ml) administered by the eFlow® electronic nebuliser
compared to TOBI® in the PARI LC PLUS® [abstract].
Journal of Cystic Fibrosis 2010;9 Suppl 1:S22, Abstract no:
84. [CENTRAL: 794286; CFGD Register: PI241a; CRS:
5500100000003569]
Frederiksen 1997 {published data only}
Frederiksen B, Koch C, Høiby N. Antibiotic treatment of
initial colonisation with Pseudomonas aeruginosa postpones
chronic infection and prevents deterioration of pulmonary
function in cystic ﬁbrosis. Pediatric Pulmonology 1997;23
(5):330–5.
Geller 2007 {published data only}
Geller DE, Howenstine M, Conrad C, Smith J, Mulye S,
Shrewsbury SB. A phase 1 study to assess the tolerability of a
novel tobramycin powder for inhalation (TPI) formulation
in cystic ﬁbrosis subjects [abstract]. Pediatric Pulmonology
2004;38(Suppl 27):250. [CENTRAL: 507896; CFGD
Register: PI187a ; CRS: 5500100000002694]
Geller DE, Konstan MW, Smith J, Noonberg SB,
Conrad C. Novel tobramycin inhalation powder in cystic
ﬁbrosis subjects: Pharmacokinetics and safety. Pediatric
Pulmonology 2007;42(4):307–13. [CENTRAL: 587235;
25Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
CFGD Register: PI187c ; CRS: 5500100000002919;
PUBMED: 17352404]
Rodriguez CA, Shrewsbury SB, Potter SN, Nardella P,
Geller DE. Single dose pharmacokinetics of tobramycin
after administration of a novel dry powder formulation
(TPI) in subjects with cystic ﬁbrosis (cf ) [abstract]. Pediatric
Pulmonology 2004;38 Suppl 27:250. [CENTRAL: 526254;
CFGD Register: PI187b ; CRS: 5500100000002754]
Gibson 2007 {published data only}
Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL,
McNamara S, Accurso FJ, et al.Duration of treatment effect
after tobramycin solution for inhalation in young children
with cystic ﬁbrosis. Pediatric Pulmonology 2007;42(7):
610–23.
Goss 2009 {published data only}
Goss CH, Clancy JP, Nick JA, Billings J, Rubenstein RC,
Young KR, et al.A phase 2 blinded and placebo-controlled
study of nebulized liposomal amikacin (arikace) in the
treatment of CF patients with Pseudomonas aeruginosa
lung infection [abstract]. Pediatric Pulmonology 2009;44
(S32):295. [CFGD CF Register: PI222]
Griese 2002 {published data only}
Griese M, Mueller I, Reinhardt D. Eradication of initial
Pseudomonas aeruginosa colonisation in patients with cystic
ﬁbrosis. European Journal of Medical Research 2002;7(2):
79–80.
Heinzl 2002 {published data only}
Heinzl B, Eber E, Oberwaldner B, Haas G, Zach M.
Effects of inhaled gentamicin prophylaxis on acquisition of
Pseudomonas aeruginosa in children with cystic ﬁbrosis: a
pilot study. Pediatric Pulmonology 2002;33(1):32–7.
Kenny 2009 {published data only}
Kenny S, Hall V, Goldsmith C, Moore J, Rendall JC,
Elborn JS. Eradication of Pseudomonas aeruginosa in adults
with CF [abstract]. Journal of Cystic Fibrosis 2009;8 Suppl
2:S39, Abstract no: 158. [CFGD CF Register: PI229a;
MEDLINE: 96296083]
Kenny SL, Shaw TD, Downey DG, Moore JE, Rendall JC,
Elborn JS. Eradication of Pseudomonas aeruginosa in adults
with cystic ﬁbrosis. BMJ Open Respiratory Research 2014;1:
e000021.
Konstan 2010 {published data only}
Konstan MW, Geller DE, Brockhaus F, Zhang J, Angyalosi
G. Tobramycin inhalation powder is effective and safe in the
treatment of chronic pulmonary Pseudomonas aeruginosa
(Pa) infection in patients with cystic ﬁbrosi [abstract].
American Journal of Respiratory and Critical Care Medicine
2009;179:Abstract no: A1186. [CENTRAL: 744126;
CFGD Register: PI227a; CRS: 5500100000003455]
Konstan MW, Geller DE, Minic P, Brockhaus F,
Zhang J, Angyalosi G. Effective treatment of chronic
Pseudomonas aeruginosa (Pa) infection with tobramycin
inhalation powder in CF patients [abstract]. Journal of
Cystic Fibrosis 2009;8 Suppl 2:S27, Abstract no: 105.
[CENTRAL: 744127; CFGD Register: PI227b; CRS:
5500100000003456]
Konstan MW, Geller DE, Minic P, Brockhaus F,
Zhang J, Angyalosi G. Tobramycin inhalation powder
for P. aeruginosa infection in cystic ﬁbrosis: The
EVOLVE trial. Pediatric Pulmonology 2010;46:230–8.
[CENTRAL: 867122; CFGD Register: PI227e; CRS:
5500100000011272; PUBMED: 20963831]
McColley S, Rietschel E, Brockhaus F, Angyalosi G, Higgins
M. Safety of inhaled tobramycin in patients with cystic
ﬁbrosis [abstract]. Pediatric Pulmonology 2011;46 Suppl
34:344, Abstract no: 365. [CENTRAL: 848919; CFGD
Register: PI227d // PI239h; CRS: 5500100000010634]
Novartis (NCT00125346). Tobramycin Inhalation
Powder (TIP) in Cystic Fibrosis Subjects (EVOLVE).
Http://clinicaltrials.gov/ct2/show/NCT00125346 2010.
[CENTRAL: 867467; CFGD Register: PI227c ; CRS:
5500100000006168]
Latzin 2008 {published data only}
Latzin P, Fehling M, Bauernfeind A, Reinhardt D, Kappler
M, Griese M. Efﬁcacy and safety of intravenous meropenem
and tobramycin versus ceftazidime and tobramycin in cystic
ﬁbrosis. Journal of Cystic Fibrosis 2008;7(2):142–6. [CFGD
Register: PI209]
Lenoir 2007 {published data only}
∗ Lenoir G, Antypkin YG, Miano A, Moretti P, Zanda M,
Varoli G, et al.Efﬁcacy, safety, and local pharmacokinetics
of highly concentrated nebulized tobramycin in patients
with cystic ﬁbrosis colonized with Pseudomonas aeruginosa.
Paediatric Drugs 2007;9 Suppl:11–20. [CFGD Register:
Pi196c]
Lenoir G, Aryayev N, Varoli G, Monici Preti P. Aerosolized
tobramycin in the treatment of patients with cystic ﬁbrosis
and pseudomonas aeruginosa infection [abstract]. Journal
of Cystic Fibrosis 2006;5 Suppl 1:S42. [CFGD Register:
PI196b]
Lenoir G, Aryayev N, Varoli G, Monici Preti P. Highly
concentrated aerosolized tobramycin in the treatment of
patients with cystic ﬁbrosis and Pseudomonas aeruginosa
infection [abstract]. European Respiratory Journal 2005;26
Suppl 49:620s. [CFGD Register: PI196a]
Littlewood 1985 {published data only}
Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH.
Nebulised colomycin for early pseudomonal colonisation in
cystic ﬁbrosis [letter]. Lancet 1985;1(8433):865.
Mainz 2014 {published data only}
Mainz JG, Schadlich K, Schien C, Michl R, Schelhorn-
Neise P, Koitschev A, et al.Sinonasal inhalation of
tobramycin vibrating aerosol in cystic ﬁbrosis patients with
upper airway Pseudomonas aeruginosa colonization: results
of a randomized, double-blind, placebo-controlled pilot
study. Drug Design, Development and Therapy 2014;8:
209–17. [CENTRAL: 981442; CFGD Register: PI248b ;
CRS: 5500125000000721; PUBMED: 24596456]
Mainz JG, Schien C, Schadlich K, Pﬁster W, Schelhorn-
Neise P, Koitschev A, et al.Sinonasal inhalation of
tobramycin in cystic ﬁbrosis patients with P. aeruginosa
26Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
colonization of the upper airways - results of a multicentric
placebo-controlled pilot study [abstract]. Journal of
Cystic Fibrosis 2011;10 Suppl 1:S21, Abstract no: 83.
[CENTRAL: 848866; CFGD Register: PI248a ; CRS:
5500100000010543]
Mazurek 2012 {published data only}
Mazurek H, Chiron R, Pelikan L, Geidel C, Bolbas
K, Antipkin Y, et al.Comparison of two inhaled
tobramycin solutions in cystic ﬁbrosis patients with chronic
pseudomonas aeruginosa infection: results in different age
subgroups [abstract]. Journal of Cystic Fibrosis 2011;10
Suppl 1:S28, Abstract no: 111. [CENTRAL: 848929;
CFGD Register: PI249b; CRS: 5500100000010714]
Mazurek H, Chiron R, Varoli G, Santoro D, Cicirello H,
Antipkin Y. Efﬁcacy on lung function and safety of multiple
courses of tobramycin 300mg/4 ml nebuliser solution
(Bramitob) in patients with cystic ﬁbrosis and chronic
pseudomonas aeruginosa infection: results from a 48-week
extension phase [abstract]. Journal of Cystic Fibrosis 2012;
11 Suppl1:S74, Abstract no: 69. [CENTRAL: 867264;
CFGD Register: PI249c; CRS: 5500100000011290]
Mazurek H, Lenoir G, Pelikan L, Geidel C, Bolbas K,
Antipkin Y, et al.Head-to-head comparison of two inhaled
tobramycin solutions in cystic ﬁbrosis (CF) patients with
chronic pseudomonas aeruginosa (Pa) infection [abstract].
Journal of Cystic Fibrosis 2011;10 Suppl 1:S28, Abstract no:
110. [CENTRAL: 848928; CFGD Register: PI249a; CRS:
5500100000010713]
Oermann 2009 {published data only}
Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson R,
McKevitt M, Montgomery B. Antibiotic susceptibility in
Pseudomonas Aeruginosa (PA) isolates following exposure
to aztreonam for inhalation solution (AZLI) in patients with
cystic ﬁbrosis [abstract]. Pediatric Pulmonology 2009;44
(S32):309, Abstract no: 278. [CFGD CF Register: PI220a]
Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson R,
McKevitt M, Montgomery B. Effect of repeated exposure
to aztreonam for inhalation solution (AZLI) therapy on
cystic ﬁbrosis respiratory pathogens [abstract]. Pediatric
Pulmonology 2009;44(Suppl 32):335, Abstract no: 353.
[CFGD Register: PI220d]
Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL,
Montgomery AB. Effect of multiple courses of Aztreonam
Lysine for inhalation (AZLI) on FEV1 and weight in
patients with cystic ﬁbrosis (CF) and Pseudomonas
aeruginosa (PA): analysis of 18 month data from CP-AI-
006 [abstract]. Journal of Cystic Fibrosis 2009;8 Suppl 2:
S28, Abstract no: 107. [CFGD CF Register: PI220c]
Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL,
Quittner AL, Montgomery AB. Adherence over multiple
courses of Aztreonam for inhalation (AZLI): effect on
disease- related endpoints in patients with cystic ﬁbrosis
(CF) and Pseudomonas aeruginosa (PA) [abstract]. Journal
of Cystic Fibrosis 2009;8 Suppl 2:S28, Abstract no: 109.
[CFGD CF Register: PI220b]
Oermann CM, Retsch-Bogart GZ, Quittner AL, Gibson
RL, McCoy KS, Montgomery AB, et al.An 18-month study
of the safety and efﬁcacy of repeated courses of inhaled
aztreonam lysine in cystic ﬁbrosis. Pediatric Pulmonology
2010;45(11):1121–34. [CFGD Register: PI220e]
Quitnner AL, Henig NR, Lewis S, Derchak PA, McCoy
KS, Oermann CM, et al.Effects of chronic intermittant
aztreonam for inhalation solution (AZLI) on health-
related quality of life (HRQOL) in persons with cystic
ﬁbrosis (CF) and P. aeruginosa [abstract]. Pediatric
Pulmonology 2011;46 Suppl 34:299, Abstract no: 240.
[CENTRAL: 867260; CFGD Register: PI220f/PI213j;
CRS: 5500100000011261]
Postnikov 2000 {published data only}
Postnikov SS, Semykin SYU, Kapranov NI, Perederko LV,
Polikarpova SV, Khamidullina KF. Evaluation of peﬂoxacin
efﬁcacy and tolerability in the treatment and prophylaxis
of severe infections at the children with mucoviscidosis and
aplastic anaemia. Antibiotiki i Khimioterapiia 2000;45(8):
25–30. [CFGD Register: PI171]
Postnikov 2007 {published data only}
Postnikov SS, Semykin SY, Polikarpova SV, Dubovik LG,
Gracheva LA, Sagatelyan. A prospective trial on the efﬁcacy
and tolerability of twice-daily dosing (TDD) versus once-
daily dosing (ODD) amikacin in cystic ﬁbrosis patients
[abstract]. Journal of Cystic Fibrosis 2007;6 Suppl 1:S34.
[CFGD CF Register: PI204]
Prayle 2013 {published data only}
Prayle A, Jain K, Watson A, Smyth AR. Are morning doses
of intravenous tobramycin less nephrotoxic than evening?
Evidence from urinary biomarkers in the critic study
[abstract]. Pediatric Pulmonology 2013;48 Suppl 36:299,
Abstract no: 261. [CENTRAL: 980338; CFGD Register:
CO55 ; CRS: 5500125000000420]
Ramsey 1999 {published data only}
Birnbaum HG, Greenberg P, Finkelstein S, Berndt E,
Otto KL, Montgomery AB, et al.Economic analysis of
hospitalization and home IV anti-pseudomonal antibiotic
use in CF patients on tobramycin solution for inhalation
(TOBI®) [abstract]. Pediatric Pulmonology 1998;Suppl 17:
273. [CENTRAL: 792738; CRS: 5500100000003553]
Bowman CM. The long-term use of inhaled tobramycin in
patients with cystic ﬁbrosis. Journal of Cystic Fibrosis 2002;1
Suppl 2(Suppl 2):S194–8. [CENTRAL: 451888; CFGD
Register: PI120cc ; CRS: 5500100000002389]
Burns JL, Van Dalfsen JM, Shawar RM, Otto KL,
Garber RL, Quan JM, et al.Effect of chronic intermittent
administration of inhaled tobramycin on respiratory
microbial ﬂora in patients with cystic ﬁbrosis. Journal of
Infectious Diseases 1999;179(5):1190–6. [CENTRAL:
161606; CRS: 5500100000000895; PUBMED:
10191222]
Casey S, Ramsey B, Borowitz D. Nutritional beneﬁts
of chronic intermittent Pseudomonas aeruginosa
suppression with tobramycin solution for inhalation in
adolescents [abstract]. 13th International Cystic Fibrosis
27Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Congress; 2000 June 4-8; Stockholm, Sweden. 2000:172.
[CENTRAL: 302945; CRS: 5500100000001685]
Enger C, Rothman K, Kylstra JW. Mortality rates
during 2 years of treatment with intermittent inhaled
tobramycin (TOBI) in CF [abstract]. Pediatric Pulmonology
1999;Suppl 19:339–40. [CENTRAL: 291292; CRS:
5500100000001353]
Fiel SB. Long term effect of tobramycin solution for
inhalation on reduction of hospitalization of CF patients
[abstract]. European Respiratory Journal 2000;16(Suppl 31):
1545. [CENTRAL: 415647; CRS: 5500100000002265]
Fiel SB. Long term effect of tobramycin solution for
inhalation on reduction of hospitalization of CF patients
[abstract]. European Respiratory Journal 2000;16(Suppl 31):
1545. [CENTRAL: 415647; CFGD Register: PI120dd ;
CRS: 5500100000002265]
Geller DE, Pitlick WH, Nardella PA, Tracewell WG,
Ramsey BW. Pharmacokinetics and bioavailability of
aerosolized tobramycin in cystic ﬁbrosis. Chest 2002;122
(1):219–26. [ CFGD Register: PI120bb ; CENTRAL:
404033; CRS: 5500100000002214]
Graff GR, Gordon DC, Van Dalfsen JM, Burns JL.
Epidemiology of Stenotrophomonas maltophilia culture
in cystic ﬁbrosis (CF) patients during the tobramycin
solution for inhalation (TOBI®) study [abstract]. Pediatric
Pulmonology 2000;Suppl 20:283. [CENTRAL: 793580;
CRS: 5500100000003564]
Hazinski TA. Intermittent administration of inhaled
tobramycin in patients with cystic ﬁbrosis. Journal of
Pediatrics 1999;135(1):130. [CENTRAL: 165714; CRS:
5500100000000909; EMBASE: 1999019576; PUBMED:
10428654]
Konstan MW, VanDevanter DR. Peripheral white blood cell
count as a surrogate marker for progression of lung disease in
cystic ﬁbrosis [abstract]. Pediatric Pulmonology 2001;Suppl
22:305. [CENTRAL: 362193; CRS: 5500100000001991]
Kylstra JW, Bowman CM, Meyer U, Montgomery AB,
Schaefﬂer B, Stewart P, et al.Who beneﬁts more? An age-
stratiﬁed analysis of lung function and weight gain in CF
patients using inhaled tobramycin [abstract]. Netherlands
Journal of Medicine 1999;54(Suppl):S83. [CENTRAL:
291415; CRS: 5500100000001449]
LeLorier J, Perreault S, Birnbaum H, Greenberg P,
Sheehy O. Savings in direct medical costs from the
use of tobramycin solution for inhalation in patients
with cystic ﬁbrosis. Clinical Therapeutics 2000;22(1):
140–51. [CENTRAL: 275378; CRS: 5500100000001232;
PUBMED: 10688397]
LiPuma JJ. Microbiological and immunologic
considerations with aerosolized drug delivery. Chest 2001;
120(3 Suppl):118S–23S. [CENTRAL: 356379; CRS:
5500100000001971; PUBMED: 11555566]
MacLeod DL, Nelson LE, Shawar RM, Lin BB, Lockwood
LG, Dirk JE, et al.Aminoglycoside-resistance mechanisms
for cystic ﬁbrosis Pseudomonas aeruginosa isolates are
unchanged by long-term, intermittent, inhaled tobramycin
treatment. Journal of Infectious Diseases 2000;181(3):
1180–4. [CENTRAL: 302968; CRS: 5500100000001702]
Moss R, Kylstra JW, Montgomery AB, Gibson R. Who
beneﬁts more? An analysis of FEV1 and weight in adolescent
(age 13-<18) CF patients using inhaled tobramycin (TOBI)
[abstract]. Pediatric Pulmonology 1999;Suppl 19:243.
[CENTRAL: 291469; CRS: 5500100000001497]
Moss RB. Administration of aerosolized antibiotics in cystic
ﬁbrosis patients. Chest 2001;120(3 Suppl):107S–13S.
[CENTRAL: 368291; CRS: 5500100000002023]
Moss RB. Long-term beneﬁts of inhaled tobramycin in
adolescent patients with cystic ﬁbrosis. Chest 2002;121(1):
55–63. [CENTRAL: 377132; CRS: 5500100000002049;
PUBMED: 11796432]
Nickerson B, Montgomery AB, Kylstra JW, Ramsey BW.
Safety and effectiveness of 2 years of treatment with
intermittent inhaled tobramycin in CF patients [abstract].
Pediatric Pulmonology 1999;Suppl 19:243–4. [CENTRAL:
291479; CRS: 5500100000001506]
Otto KL, Montgomery AB, Lin A, Ramsey BW. Seasonality
of hospitalization for pulmonary exacerbations and
lower respiratory tract infections in Phase III tobramycin
solution for inhalation (TOBI®) trials [abstract]. Pediatric
Pulmonology 1998;Suppl 17:273. [CENTRAL: 795752;
CRS: 5500100000003601]
Quan JM, Vasiljev M, Schaefﬂer B, Phelps C, Burrington
C, Meyer U. Treatment for exacerbation only does not
arrest progressive lung function decline in CF [abstract].
Netherlands Journal of Medicine 1999;54(Suppl):S84.
[CENTRAL: 291523; CRS: 5500100000001545]
Quittner A, Gordon D, Yu X. Convergence of quality of life
assessments and clinical outcomes in patients enrolled in the
tobramycin solution for inhalation (TSI) trials [abstract].
24th European Cystic Fibrosis Conference; 2001 June 6-9;
Vienna, Austria. 2001:P326. [CENTRAL: 614345; CRS:
5500100000003153]
Quittner AL, Buu A. Effects of tobramycin solution for
inhalation on global ratings of quality of life in patients
with cystic ﬁbrosis and Pseudomonas aeruginosa infection.
Pediatric Pulmonology 2002;33(4):269–76. [CENTRAL:
379174; CRS: 5500100000002059; PUBMED:
11921456]
Quittner AL, Buu A, Gordon D. Longitudinal changes in
global ratings of quality of life for patients in the tobramycin
solution for inhalation (TSI) trials [abstract]. Pediatric
Pulmonology 2001;Suppl 22:349. [CENTRAL: 362214;
CRS: 5500100000002002]
Ramsey B, Burns J, Smith A. Safety and efﬁcacy of
Tobramycin Solution for Inhalation in patients with
cystic ﬁbrosis: The results of two phase III placebo
controlled clinical trials [abstract]. Pediatric Pulmonology
1997;Suppl 14:137–8. [CENTRAL: 385760; CRS:
5500100000002121]
Ramsey BW, Bowman MC, Montgomery AB, Smith AR,
TOBIStudy G. Design of phase 3 aerosolized tobramycin
studies for chronic intermittent therapy [abstract]. 21st
European Cystic Fibrosis Conference; 1997 June 1-6;
Davos, Switzerland. 1997:144. [CENTRAL: 291527;
28Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
CRS: 5500100000001548]
Ramsey BW, Bowman MC, Vasiljev-KM, Smith AR,
TOBIStudy G. Results of phase 3 aerosolized tobramycin
studies for chronic intermittent therapy [abstract]. 21st
European Cystic Fibrosis Conference; 1997 June 1-6;
Davos, Switzerland. 1997:144. [CENTRAL: 291528;
CRS: 5500100000001549]
Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery
AB, Williams Warren J, et al.Intermittent administration of
inhaled tobramycin in patients with cystic ﬁbrosis. cystic
ﬁbrosis Inhaled Tobramycin Study Group. New England
Journal of Medicine 1999;340(1):23–30. [CENTRAL:
158508; CRS: 5500100000000883; PUBMED: 9878641]
Rosenfeld M, Emerson J, Williams-Warren J, Pepe M,
Smith A, Montgomery AB, et al.Deﬁning a pulmonary
exacerbation in cystic ﬁbrosis. Journal of Pediatrics
2001;139(3):359–65. [CENTRAL: 384105; CRS:
5500100000002077; PUBMED: 11562614]
Taylor CJ. Nebulised high dose Tobramycin (TOBI)
in adolescents with cystic ﬁbrosis [abstract]. Pediatric
Pulmonology 2001;Suppl 22:291. [CENTRAL: 362226;
CRS: 5500100000002008]
VanDevanter D, Hou K, Yu X. Effect of tobramycin
solution for inhalation (TOBI®) on long term rates of
lung function decline in Pseudomonas aeruginosa infected
cystic ﬁbrosis (CF) patients with mild to moderate lung
disease [abstract]. Pediatric Pulmonology 2000;Suppl 20:
298. [CENTRAL: 793150; CRS: 5500100000003557]
VanDevanter D, Yu X, Konstan MW. Effect of tobramycin
solution for inhalation on circulating white blood cell
counts in exacerbating and stable CF patients [abstract].
24th European Cystic Fibrosis Conference; 2001 June 6-9;
Vienna, Austria. 2001:P172. [CENTRAL: 354463; CRS:
5500100000001964]
Ratjen 2001a {published data only}
Ratjen F, Döring G, Nikolaizik WH. Effect of inhaled
tobramycin on early Pseudomonas aeruginosa colonisation
in patients with cystic ﬁbrosis. Lancet 2001;358(9286):
983–4.
Retsch-Bogart 2008 {published data only}
Burns JL, Stapp J, Loﬂand D, AIPhase 2SG. Microbiology
results from a phase 2 clinical study of aztreonam lysinate for
inhalation (AI): a new inhaled antibiotic to treat CF patients
with Pseudomonas aeruginosa (PA) [abstract]. Journal of
Cystic Fibrosis 2005;4 Suppl:S55. [CENTRAL: 548338;
CFGD Register: PI211a ; CRS: 5500100000002786]
∗ Retsch-Bogart GZ, Burns JL, Otto KL, Liou TG, McCoy
K, Oermann C, et al.A phase 2 study of aztreonam lysine
for inhalation to treat patients with cystic ﬁbrosis and
Pseudomonas aeruginosa infection. Pediatric Pulmonology
2008;43(1):47–58. [CENTRAL: 628521; CFGD Register:
PI211c; CRS: 5500100000003193; PUBMED: 18041081]
Retsch-Bogart GZ, Gibson RL, AIPhase 2SG. A phase 2
study of aztreonam lysinate for inhalation to treat cystic
ﬁbrosis patients with Pseudomonas aeruginosa infection
[abstract]. American Thoracic Society International
Conference; 2005 May 20-25; San Diego, USA. 2005:
A576. [CENTRAL: 592963; CFGD Register: PI211b ;
CRS: 5500100000002930]
Retsch-Bogart GZ, McCoy KS, Gibson RL, Oermann
CM. Sustained improvement in pulmonary function
following a 28-day course of 75mg azli tid therapy
[abstract]. Pediatric Pulmonology 2008;43 Suppl 31:320.
[CENTRAL: 675920; CFGD Register: PI211d // PI213b;
CRS: 5500100000003286]
Retsch-Bogart 2009 {published data only}
McCoy K, Retsch-Bogart G, Gibson RL, Oermann C,
Braff M, Montgomery AB. Investigation of susceptibility
breakpoints for inhaled antibiotic therapies in cystic ﬁbrosis
[abstract]. Pediatric Pulmonology 2010;45 Suppl 33:341,
Abstract no: 340. [CENTRAL: 848913; CFGD Register:
PI212g // PI213i ; CRS: 5500100000010623]
McCoy KS, Retsch-Boagrt GZ, Gibson RL, Oermann CM,
McKevitt M, Montgomery AB. Efﬁcacy of Aztreonam
Lysine for inhalation (AZLI) in patients with cystic ﬁbrosis
and drug resistant P. aeruginosa (DRPA) [abstract]. Journal
of Cystic Fibrosis 2009;8 Suppl 2:S28. [CENTRAL:
744120; CFGD Register: PI212e // PI213e ; CRS:
5500100000003449]
McCoy KS, Retsch-Bogart GZ, Gibson R, Oermann C,
Braff MH, Montgomery AB. Relevance of established
susceptibility breakpoints to clinical efﬁcacy of inhaled
antibiotic therapies in cystic ﬁbrosis [abstract]. Pediatric
Pulmonology 2008;43 Suppl 31:351. [CENTRAL:
677646; CFGD Register: PI212b // PI213c; CRS:
5500100000003289]
Plosker GL. Aztreonam lysine for inhalation solution: in
cystic ﬁbrosis. Drugs 2010;70(14):1843–55. [CENTRAL:
848912; CFGD Register: PI212f // PI213h ; CRS:
5500100000010622]
Quittner AL, Henig NR, Lewis S, Derchak PA, McCoy
KS, Oermann CM, et al.Effects of chronic intermittent
aztreonam for inhalation solution (AZLI) on health-related
quality of life (HRQOL) in persons with cystic ﬁbrosis
(CF) and P. aeruginosa [abstract]. Pediatric Pulmonology
2011;46 Suppl 34:299, Abstract no: 240. [CENTRAL:
867260; CFGD Register: PI213j // PI220f; CRS:
5500100000011261]
Quittner AL, Retsch-Bogart GZ, McCoy KS, Oermann
CM, Gibson R, Lewis S, et al.Effect of a 28-day course
of aztreonam for inhalation solution (AZLI) on responses
to individual CFQ-R respiratory symptoms score
questions among patients with CF [abstract]. Pediatric
Pulmonology 2009;44 Suppl 32:305, Abstract no: 266.
[CENTRAL: 744128; CFGD Register: PI213f ; CRS:
5500100000003457]
Retsch-Bogart GZ, McCoy KS, Gibson RL, Oermann C,
Montgomery AB. Source of improvements in lung function
in patients with cystic ﬁbrosis (CF) following treatment with
aztreonam lysine for inhalation (AZLI) [abstract]. Pediatric
Pulmonology 2008;43 Suppl 31:320. [CENTRAL: 744116;
CFGD Register: PI213d; CRS: 5500100000003445]
Retsch-Bogart GZ, McCoy KS, Gibson RL, Oermann
CM. Sustained improvement in pulmonary function
29Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
following a 28-day course of 75mg azli tid therapy
[abstract]. Pediatric Pulmonology 2008;43 Suppl 31:320.
[CENTRAL: 675920; CFGD Register: PI211d // PI213b;
CRS: 5500100000003286]
Retsch-Bogart GZ, Montgomery B, Gibson R, McCoy
K, Oermann CM, Cooper P. Phase 3 trial (AIR-CF 1)
measuring improvement in respiratory symptoms in patients
with cystic ﬁbrosis (CF) following treatment with aztreonam
lysine for inhalation [abstract]. Pediatric Pulmonology 2007;
42 Suppl 30:310. [CENTRAL: 623759; CFGD Register:
PI213a; CRS: 5500100000003182]
Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann
CM, McCoy KS, Montgomery AB, et al.Efﬁcacy
and safety of inhaled aztreonam lysine for airway
pseudomonas in cystic ﬁbrosis. Chest 2009;135(5):
1223–32. [CENTRAL: 698536; CFGD Register: PI213g ;
CRS: 5500100000010621]
Rietschel 2009 {published data only}
Rietschel E, Posselt HG, Heuer HE, Merkel N, Staab D.
Pharmacokinetics of tobramycin (TOBI) after 4 and 8
weeks of continuous once daily or twice daily inhalation
[abstract]. Journal of Cystic Fibrosis 2009;8 Suppl 2:S27,
Abstract no: 106. [CENTRAL: 795021; CFGD Register:
PI232a; CRS: 5500100000003587]
Rietschel E, Staab D, Merkel N, van Konigsbruggen S,
Posselt H. Pharmacokinetics of continuous treatment with
O.D. or B.I.D inhalation of tobramycin (TOBI™) via Pari
Eﬂow™ Rapid [abstract]. Pediatric Pulmonology 2010;45
Suppl 33:320, Abstract no: 283. [CENTRAL: 849031;
CFGD Register: PI232c; CRS: 5500100000010629]
Rietschel E, Staab D, von Konigsbruggen S, Merkel N,
Heuer HE, Posselt HG. Pharmacokinetics of continuous
treatment with o.d. or b.i.d. inhalation of tobramycin
(TOBITM) [abstract]. Journal of Cystic Fibrosis 2010;9
Suppl 1:S23, Abstract 106. [CENTRAL: 795018; CFGD
Register: PI232b; CRS: 5500100000003586]
Schaad 1997 {published data only}
Schaad UB, Wedgwood J, Ruedeberg A, Kraemer R,
Hampel B. Ciproﬂoxacin as antipseudomonal treatment
in patients with cystic ﬁbrosis. Pediatric Infectious Diseases
Journal 1997;16(1):106–11. [CFGD Register: PI116]
Schelstraete 2010 {published data only}
Schelstraete P, Deschaght P, Van Daele S, Haerynck F,
Van Simaey L. Genotype based evaluation of eradication
treatment of new P. aeruginosa infections in CF patients
[abstract]. Journal of Cystic Fibrosis 2009;8 Suppl 2:
S39, Abstract no: 156. [CFGD CF Register: PI228;
MEDLINE: 96296083]
Schelstraete P, Deschaght P, Van Simaey L, Van Daele
S, Haerynck F, Vaneechoutte M, et al.Genotype based
evaluation of Pseudomonas aeruginosa eradication
treatment success in cystic ﬁbrosis patients. Journal of Cystic
Fibrosis 2010;9(2):99–103. [CFGD Register: PI228]
Schuster 2013 {published data only}
Goldman M, Schuster A, Halliburn C, Döring G, The
FSG. A randomised, open label phase 3 study to evaluate the
efﬁcacy and safety of a dry powder formulation of inhaled
colistimethate sodium (Colobreathe®) versus tobramycin
nebuliser solution (TNS) in cystic ﬁbrosis subjects with
chronic Pseudomonas aeruginosa lung infection [abstract].
Journal of Cystic Fibrosis 2012;11, Suppl 1:S12, Abstract no:
WS5.5. [CENTRAL: 848917; CFGD Register: PI214b ;
CRS: 5500100000010630]
Goldman MH, Pitt T. Lack of emergence of antimicrobial
resistance of Pseudomonas Aeruginosa after six months
inhalation of dry powder colistimethate [abstract]. Pediatric
Pulmonology 2008;43 Suppl 31:331. [CFGD Register:
PI214a]
Goldman MH, Shuster A, Haliburn C, Doring G.
A randomised, open label phase 3 study to evaluate
the efﬁcacy and safety of a dry powder formulation of
colistimethate sodium (Colobreathe®) versus tobramycin
nebuliser solution (TNS) in cystic ﬁbrosis subjectes with
chronic Pseudomonas aeruginosa lung infection [abstract].
Pediatric Pulmonology 2012;47(S35):353, Abstract no: 363.
[CENTRAL: 849030; CFGD Register: PI214c ; CRS:
5500100000010631]
Goldman MH, Werner T, Schuster A. Does persistence
with inhaled dry powder antibiotic treatment improve
tolerability? [abstract]. Pediatric Pulmonology 2013;48
Suppl 36:347, Abstract no: 389. [CENTRAL: 921669;
CFGD Register: PI214f; CRS: 5500125000000396]
Schuster A, Haliburn C, Doring G, Goldman MH,
FSG. Online Data Supplement to ’Safety, efﬁcacy and
convenience of colistimethate sodium dry powder for
inhalation (Colobreathe DPI) in patients with cystic ﬁbrosis:
a randomised’ [online] study. Thorax 2013;68(4):344-350
Online. [CENTRAL: 867327; CFGD Register: PI214e;
CRS: 5500100000011299]
∗ Schuster A, Haliburn C, Doring G, Goldman MH, FSG.
Safety, efﬁcacy and convenience of colistimethate sodium
dry powder for inhalation (Colobreathe DPI) in patients
with cystic ﬁbrosis: a randomised study. Thorax 2013;
68(4):344–50. [CENTRAL: 864435; CFGD Register:
PI214d; CRS: 5500100000011298; PUBMED: 23135343]
Steinkamp 1989 {published data only}
Steinkamp G, Tummler B, Malkotte R, Von der Hardt
H. Treatment of Pseudomonas aeruginosa colonisation in
cystic ﬁbrosis. Archives of Disease in Childhood 1989;64(7):
1022–8.
Steinkamp 2007 {published data only}
Steinkamp G, Schmitt-Grohe S, Doring G, Stabb D,
Schubert R, Zielen S. Once weekly azithromycin in cystic
ﬁbrosis: a double-blind, randomised trial in patients with
chronic Pseudomonas aeruginosa infection [abstract].
Pediatric Pulmonology 2007;42(S30):300. [CFGD Register:
MA19b]
Steinkamp G, Schmitt-Grohe S, Doring G, Worlitzsch D,
Staab D, Schubert R, et al.Clinical and immunomodulatory
effects of once weekly azithromycin treatment in cystic
ﬁbrosis patients chronically infected with Pseudomonas
aeruginosa [abstract]. Journal of Cystic Fibrosis 2006;5
Suppl 1:S25. [CFGD Register: MA19a]
30Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Taccetti 2005 {published data only}
Taccetti G, Campana S, Festini F, Mascherini M, Doring G.
Early eradication therapy against Pseudomonas aeruginosa
in cystic ﬁbrosis patients. European Respiratory Journal
2005;26(3):1–4.
Tramper-Stranders 2009 {published data only}
Tramper-Stranders G, Wolfs TFW, van Aalderen W,
Kouwenberg J, Nagelkerke A, van der Ent CK. Prevention
of initial P. aeruginosa infection in children with cystic
ﬁbrosis: a multi-centre double-blind randomised controlled
trial [abstract]. Journal of Cystic Fibrosis 2009;8 Suppl
2:S37, Abstract no: 148. [CFGD Register: PI231a;
MEDLINE: 96296083]
Tramper-Stranders GA, Wolfs TF, van Haren Noman
S, van Aalderen WM, Nagelkerke AF, Nuijsink M, et
al.Controlled trial of cycled antibiotic prophylaxis to
prevent initial Pseudomonas aeruginosa infection in
children with cystic ﬁbrosis. Thorax 2010;65(10):915–20.
[CENTRAL: 761942; CFGD Register: PI231b; CRS:
5500125000000359; PUBMED: 20729233]
Trapnell 2012 {published data only}
McColley SA, Trapnell B, Kissner D, McKevitt M,
Montgomery B, Rosen J, et al.Fosfomycin/tobramycin
for inhalation (FTI): microbiological results of a phase
2 placebo-controlled trial in patients with cystic ﬁbrosis
and pseudomonas aeruginosa [abstract]. Pediatric
Pulmonology 2010;45 Suppl 33:338, Abstract no: 334.
[CENTRAL: 848865; CFGD Register: PI247c; CRS:
5500100000010542]
Trapnell BC, Kissner D, Montgomery AB, Newcomb T,
Geller D. Fosfomycin/tobramycin for inhalation FTI):
safety results of a phase 2 placebo-controlled trial in patients
with cystic ﬁbrosis and pseudomonas aeruginosa [abstract].
Pediatric Pulmonology 2010;45 Suppl 33:302, Abstract no:
234. [CENTRAL: 848864; CFGD Register: PI247b; CRS:
5500100000010541]
Trapnell BC, McColley SA, Kissner DG, Rolfe MW,
Rosen JM, McKevitt M, et al.Fosfomycin/tobramycin for
inhalation in patients with cystic ﬁbrosis with pseudomonas
airway infection. American Journal of Respiratory and Critical
Care Medicine 2012;185(2):171–8. [CENTRAL: 814492;
CFGD Register: PI247d; CRS: 5500100000010632]
Trapnell BC, Rolfe M, McColley S, Montgomery
AB, Moorehead L, Geller D. Fosfomycon/tobramycin
for inhalation (FTI): efﬁcacy results of a phase 2
placebo-controlled trial in patients with cystic ﬁbrosis
and pseudomonas aeruginosa [abstract]. Pediatric
Pulmonology 2010;45 Suppl 33:302, Abstract no: 233.
[CENTRAL: 848927; CFGD Register: PI247a; CRS:
5500100000010712]
Vazquez 1993 {published data only}
Vazquez C, Municio M, Corera M, Gaztelurrutia L, Sojo
A, Vitoria JC. Early treatment of Pseudomonas aeruginosa
colonisation in cystic ﬁbrosis. Acta Paediatrica Scandanavia
1993;82(3):308–9.
Wainwright 2011a {published data only}
Byrnes CA, Vidmar S, Cheney JL, Carlin JB, Armstrong
DS, Cooper PJ, et al.Prospective evaluation of respiratory
exacerbations in children with cystic ﬁbrosis from newborn
screening to 5 years of age. Thorax 2013;68(7):643–51.
[CENTRAL: 904924; CFGD Register: PE167i; CRS:
5500125000000477; PUBMED: 23345574]
Cheney J, Vidmar S, Grimwood K, Carlin JB, Wainwright
C, on behalfofACFBALSG. Interim outcomes of a
Pseudomonas aeruginosa (Pa) eradication protocol in young
children in the Australian Cystic Fibrosis Bronchoalveolar
Lavage (ACFBAL) Study [abstract]. Journal of Cystic Fibrosis
2009;8(Suppl 2):S39, Abstract no:157. [CFGD Register:
PE167c]
Cheney J, Wainwright C, ACFBAL SG. Trials, tribulations
and triumphs of a cystic ﬁbrosis study - a behind the scenes
look at the workings of an international multi-centre study
[abstract]. Journal of Cystic Fibrosis 2010;9 Suppl 1:S118,
Abstract no: 452. [CENTRAL: 790042; CFGD Register:
PE167g; CRS: 5500125000000092]
Wainwright C, Carlin J, Cooper P, Byrnes C, Martin J,
Grimwood K, et al.Australasian cystic ﬁbrosis BAL study
interim analysis [abstract]. Pediatric Pulmonology 2006;41
Suppl 29:317. [CFGD Register: PE167a]
Wainwright CE, Carlin J, Cooper P, Byrnes C, Whitehead
B, Martin J, et al.Early infection with pseudomonas
aeruginosa can be cleared in young children with cystic
ﬁbrosis [abstract]. Pediatric Pulmonology 2002;34 Suppl
24:300–1. [CFGD Register: PI167d]
Wainwright CE, Kidd TJ, Ramsey KA, Bell SC, Grimwood
K. Australasian CF bronchoalveolar lavage (ACFBAL)
study: P.Aeruginosa (PA) genotypes in pre-school CF
children [abstract]. Pediatric Pulmonology 2011;46 Suppl
34:320, Abstract no: 299. [CENTRAL: 874662; CFGD
Register: PE167h; CRS: 5500125000000093]
Wainwright CE, Vidmar S, Armstrong DS, Byrnes CA,
Carlin JB, Cheney J, et al.Effect of bronchoalveolar lavage-
directed therapy on Pseudomonas aeruginosa infection and
structural lung injury in children with cystic ﬁbrosis: a
randomized trial. JAMA 2011;306(2):163–71. [CFGD
Register: PI167e]
Wainwright CE, Vidmar S, Armstrong DS, Byrnes CA,
Carlin JB, Cheney J, et al.Online Supplement to ’Effect of
bronchoalveolar lavage-directed therapy on Pseudomonas
aeruginosa infection and structural lung injury in children
with cystic ﬁbrosis: a randomized trial’ [online]. JAMA
2011;306(2):163-171 Online. [CENTRAL: 788878;
CFGD Register: PE167f; CRS: 5500100000011126;
PUBMED: 21750293]
Wainwright CE, Grimwood K, Carlin JB, Vidmar S,
Cooper PJ, Francis PW, et al.Safety of bronchoalveolar
lavage in young children with cystic ﬁbrosis. Pediatric
Pulmonology 2008;43(10):965–72. [CFGD Register:
PI167b]
Wainwright 2011b {published data only}
Wainwright CE, Quittner AL, Geller DE, Nakamura C,
Wooldridge JL, Gibson RL, et al.Aztreonam for inhalation
solution (AZLI) in patients with cystic ﬁbrosis, mild lung
impairment, and P. aeruginosa. Journal of Cystic Fibrosis
31Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2011;10(4):234–42. [CENTRAL: 801029; CFGD
Register: PI273 ; CRS: 5500100000011273; PUBMED:
21441078]
References to studies awaiting assessment
Noah 2010 {published data only}
Noah T, Ivins S, Abode K, Harris W, Henry M, Leigh
M. Comparison of antibiotics for early pseudomonas
infection in CF: interim data analysis [abstract]. Pediatric
Pulmonology 2007;42(S30):332. [CFGD Register: PI205a]
∗ Noah TL, Ivins SS, Abode KA, Stewart PW, Michelson
PH, Harris WT, et al.Inhaled versus systemic antibiotics
and airway inﬂammation in children with cystic ﬁbrosis and
Pseudomonas. Pediatric Pulmonology 2010;45(3):281–90.
[CFGD Register: PI205b]
References to ongoing studies
TORPEDO Trial {published data only}
Langton Hewer S. TORPEDO-CF. http://www.controlled-
trials.com/ISRCTN02734162/torpedo-cf accessed 10
October 2011. [: ISRCTN02734162]
Additional references
Abman 1991
Abman SH, Ogle JW, et al.Early bacteriologic, immunologic
and clinical courses of young infants with cystic ﬁbrosis
identiﬁed by neonatal screening. Journal of Pediatrics 1991;
119(2):211–7.
Anstead 2013
Anstead M, Heltshe S, Khan U, Barbieri JT, Langkamp M,
Doring G, et al.Pseudomonas aeruginosa serology and risk
for re-isolation in the EPIC trial. Journal of Cystic Fibrosis
2013;12(2):147–53.
Armstrong 1996
Armstrong D, Grimwood K, Carlin J, Carzino R, Olinsky
A, Phelan P. Bronchoalveolar lavage or oropharyngeal
cultures to identify lower respiratory pathogens in infants
with cystic ﬁbrosis. Pediatric Pulmonology 1996;21(5):
267–75.
Burns 2001
Burns JL, Gibson RL, McNamara S, Yim D, Emerson J,
Rosenfeld M, et al.Longitudanal assessment of Pseudomonas
aeruginosa in young children with cystic ﬁbrosis. Journal of
Infectious Diseases 2001;183(3):444–52.
Ciofu 2012
Ciofu O, Mandsberg LF, Wang H, Hoiby N. Phenotypes
selected during chronic lung infection in cystic ﬁbrosis
patients: implications for the treatment of Pseudomonas
aeruginosa bioﬁlm infections. FEMS Immunology and
Medical Microbiology 2012;65(2):215–25.
Douglas 2009
Douglas TA, Brennan S, Gard S, Berry L, Gangell C, Stick
SM, et al.Acquisition and eradication of P. aeruginosa in
young children with cystic ﬁbrosis. European Respiratory
Journal 2009;33(2):305–11.
Döring 2000
Döring G, Conway S, Heijerman H, Hodson M, Høiby
N, Smyth A, et al.Antibiotic therapy against Pseudomonas
aeruginosa: a European consensus. European Respiratory
Journal 2000;16(4):749–67.
Döring 2012
Döring G, Flume P, Heijerman H, Elborn JS. Treatment
of lung infection in patients with cystic ﬁbrosis: Current
and future strategies. Journal of Cystic Fibrosis 2012;11(6):
461–79.
Emerson 2002
Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson
RL. Pseudomonas aeruginosa and other predictors of
mortality and morbidity in young children with cystic
ﬁbrosis. Pediatric Pulmonology 2002;34(2):91–100.
FitzSimmons 1993
FitzSimmons SC. The changing epidemiology of cystic
ﬁbrosis. Journal of Pediatrics 1993;122(1):1–9.
Fitzsimmons 1996
Fitzsimmons S. The Cystic Fibrosis Foundation Patient
Registry Report 1996. Pediatric Pulmonology 1996;Suppl
21:267–75.
Higgins 2003
Higgins JPT, Thompson SG, Deeks JJ, Altman DG.
Measuring inconsistency in meta-analyses. BMJ 2003;327
(7414):557–60.
Higgins 2011
Higgins JPT, Altman DG. Chapter 8: Assessing risk
of bias in included studies. In: Higgins JPT, Green S
(editors). Cochrane Handbook of Systematic Reviews
of Interventions. Version 5.1 [updated March 2011].
The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Hilliard 2007
Hilliard TN, Sukhani S, Francis J, Madden N, Rosenthal
M, Balfour-Lynn I, et al.Bronchoscopy following diagnosis
with cystic ﬁbrosis. Archives of Disease in Childhood 2007;
92(10):989–9.
Hudson 1993
Hudson V, Wielinski C, Regelmann W. Prognostic
implications of initial oropharyngeal bacterial ﬂora in
patients with cystic ﬁbrosis diagnosed before the age of two
years. Journal of Pediatrics 1993;122(6):854–60.
Iacocca 1963
Iacocca VF, Sibinga M, Barbero G. Respiratory Tract
Bacteriology in Cystic Fibrosis. American Journal of Disease
in Childhood 1963;106(3):115–24.
Johansen 2013
Johansen HK, Gøtzsche PC. Vaccines for preventing
infection with Pseudomonas aeruginosa in cystic ﬁbrosis.
Cochrane Database of Systematic Reviews 2013, Issue 6.
[DOI: 10.1002/14651858.CD001399.pub3]
Kerem 1990
Kerem E, Corey M, Stein R, Gold R, Levison H. Risk
factors for Pseudomonas aeruginosa colonisation in cystic
32Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ﬁbrosis patients. Pediatric Infectious Disease Journal 1990;9
(7):494–8.
Kosorok 2001
Kosorok MR, Zeng L, West SE, Rock MJ, Splaingard ML,
Laxova A, et al.Acceleration of lung disease in children with
cystic ﬁbrosis after Pseudomonas aeruginosa acquisition.
Pediatric Pulmonology 2001;32(4):277–87.
Lee 2003
Lee TWR, Brownlee KG, Conway SP, Denton M,
Littlewood JM. Evaluation of a new deﬁnition for chronic
Pseudomonas aeruginosa infection in cystic ﬁbrosis patients.
Journal of Cystic Fibrosis 2003;2(1):29–34.
Lee 2004
Lee TW, Brownlee KG, Denton M, Littlewood JM, Conway
SP. Reduction in prevalence of chronic Pseudomonas
aeruginosa infection at a regional pediatric cystic ﬁbrosis
center. Pediatric Pulmonology 2004;37(2):104–10.
Lee 2009
Lee TWR. Eradication of early Pseudomonas infection
in cystic ﬁbrosis. Chronic Respiratory Disease 2009;6(2):
99–107.
Montori 2005
Montori VM, Devereaux PJ, Adhikari NKJ, Burns KEA,
Eggert CH, Briel M, et al.Randomized Trials Stopped Early
for Beneﬁt: A Systematic Review. JAMA 2005;294(17):
2203–9.
Muhlebach 1999
Muhlebach M, Stewart P, Leigh M, Noah T. Quantitation
of inﬂammatory responses to bacteria in young cystic
ﬁbrosis and control patients. American Journal of Respiratory
& Critical Care Medicine 1999;160(1):186–91.
Munck 2001
Munck A, Bonacorsi S, Mariani-Kurkdjian P, Lebourgeois
M, GerardinM, Brahimi N, et al.Genotypic characterisation
of Pseudomonas aeruginosa strains recovered from patients
with cystic ﬁbrosis after initial and subsequent colonisation.
Pediatric Pulmonology 2001;32(4):288–92.
Nixon 2001
Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky
A, Robertson CF, et al.Clinical outcome after early
Pseudomonas aeruginosa infection in cystic ﬁbrosis. Journal
of Pediatrics 2001;138(5):699–704.
Pamukcu 1995
Pamukcu A, Bush A, Buchdal R. Effects of Pseudomonas
aeruginosa colonisation on lung function and
anthropomorphic variables in children with cystic ﬁbrosis.
Pediatric Pulmonology 1995;19(1):10–5.
Parad 1999
Parad RB, Gerard CJ, Zurakowski D, Nichols DP, Pier GB.
Pulmonary outcome in cystic ﬁbrosis is inﬂuenced primarily
by mucoid Pseudomonas aeruginosa infection and immune
status and only modestly by genotype. Infection & Immunity
1999;67(9):4744–50.
Ramsey 1996
Ramsey B. Drug therapy: Management of pulmonary
disease in patients with cystic ﬁbrosis. New England Journal
of Medicine 1996;335(3):179–88.
Ratjen 2001b
Ratjen F, Comes G, Paul K, Posselt H, Wagner T, Harms K.
Effect of continuous antistaphylococcal therapy on the rate
of P.aeruginosa acquisition in patients with cystic ﬁbrosis.
Pediatric Pulmonology 2001;31(1):13–6.
Rosenfeld 1999
Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castille
R, Grimwood K, et al.Diagnostic accuracy of oropharyngeal
cultures in infants and young children with cystic ﬁbrosis.
Pediatric Pulmonology 1999;28(5):321–8.
Rosenfeld 2001
Rosenfeld MR, Gibson RL, McNamara S, Emerson J,
Burns JL, Castile R, et al.Early pulmonary infection,
inﬂammation and clinical outcomes in infants with cystic
ﬁbrosis. Pediatric Pulmonology 2001;32(5):356–66.
Schulz 1995
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical
evidence of bias. Dimensions of methodological quality
associated with estimates of treatment effects in randomised
controlled trials. JAMA 1995;273(5):408–12.
Smyth 2012
Smyth AR, Walters S. Prophylactic anti-staphylococcal
antibiotics for cystic ﬁbrosis. Cochrane Database of
Systematic Reviews 2012, Issue 12. [DOI: 10.1002/
14651858.CD001912]
Smyth 2014
Smyth AR, Bell SC, Bojcin S, Bryon M, Duff A, Flume P,
et al.European Cystic Fibrosis Society Standards of Care:
Best Practice Guidelines. Journal of Cystic Fibrosis 2014;13
(Supplement 1):S23–S42.
Stutman 2002
Stutman HR, Lieberman JM, Nussbaum E, Marks MI.
Antibiotic prophylaxis in infants and young children with
cystic ﬁbrosis: a randomised controlled trial. Journal of
Pediatrics 2002;140(3):299–305.
Thomassen 1984
Thomassen MJ, Klinger JD, Badger SJ, Van Herckren BW,
Stern RC. Cultures of thoracotomy specimens conﬁrm
usefulness of sputum cultures in cystic ﬁbrosis. Journal of
Pediatrics 1984;104(3):352–6.
UK CF Registry 2012
UK CF Trust. Cystic Fibrosis Trust Patient Registry User’s
Guide. Bromley: UK CF Trust, 2012.
UK CF Registry 2013
UK Cystic Fibrosis Trust. UK CF Registry: Annual Data
Report 2013. Bromley: Cystic Fibrosis Trust, 2014.
UK CF Trust 2004
UK CF Trust Control of Infection Group. Pseudomonas
aeruginosa infection in people with cystic ﬁbrosis:
33Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
suggestions for prevention and control (2nd edition). UK
CF Trust 2004.
Winnie 1991
Winnie GB, Cowan RG. Respiratory tract colonisation
with Pseudomonas aeruginosa in cystic ﬁbrosis: correlations
between anti-Pseudomonas aeruginosa antibody levels and
pulmonary function. Pediatric Pulmonology 1991;10(2):
92–100.
References to other published versions of this review
Langton Hewer 2009
Langton Hewer SC, Smyth AR. Antibiotic strategies for
eradicating Pseudomonas aeruginosa in people with cystic
ﬁbrosis. Cochrane Database of Systematic Reviews 2009, Issue
4. [DOI: 10.1002/14651858.CD004197.pub3]
Wood 2003
Wood DM, Smyth A. Antibiotic strategies for eradicating
Pseudomonas aeruginosa in people with cystic ﬁbrosis.
Cochrane Database of Systematic Reviews 2003, Issue 2.
[DOI: 10.1002/14651858.CD004197]
Wood 2006
Wood DM, Smyth AR. Antibiotic strategies for eradicating
Pseudomonas aeruginosa in people with cystic ﬁbrosis.
Cochrane Database of Systematic Reviews 2006, Issue 1.
[DOI: 10.1002/14651858.CD004197.pub2]
∗ Indicates the major publication for the study
34Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Gibson 2003
Methods Double-blind RCT.
Placebo-controlled.
Parallel design.
Duration: 28 days.
Multicentre based in USA.
Participants 21 participants with a recent positive oropharyngeal culture and isolation of P. aeruginosa
from BAL at study entry.
Age: 6 months - 6 years.
Gender: 11 males, 10 females.
Interventions Treatment: Tobramycin solution for inhalation (300 mg 2x daily for 28 days)
Control: placebo inhalations.
Outcomes Eradication of P. aeruginosa, nutritional status, modiﬁed Shwachman score, adverse ef-
fects
Notes Oropharyngeal cultures performed at entry and on days 14, 28, 42 and 56 of the study.
BAL from the same lobar segment on entry and day 28
Enrolement was discontinued due to an interim analysis, precipitated by poor accrual of
participants, which showed a statistically signiﬁcant microbiological effect of treatment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as a randomised controlled trial
stratiﬁed by study centre and age (
<
= 36
months; > 36 months), but the method of
generation of allocation sequence was not
stated
Allocation concealment (selection bias) Unclear risk Did not report how allocation was con-
cealed.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Reported as double blind, but paper did
not provide any details regarding who was
blinded or the method of blinding
We received the following helpful response
from trial authors, regarding placebo:
Active: Preservative free tobramycin sulfate,
60 mg/mL in 5 mL excipient (1/4 normal
saline, pH 6.0) in low density polyethylene
plastic ampoules inside a foil pouch (Patho-
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Gibson 2003 (Continued)
Genesis Corporation)
Placebo: 5 mL of vehicle with 1.25 mg of
quinine sulfate added as a ﬂavouring agent,
packaged identically. PathoGenesis Corpo-
rationwere responsible for themanufacture
of the tobramycin and placebo for inhala-
tion
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analysed on an intention-to-treat basis. Re-
ported data on all participants who were
randomised. There were no dropouts re-
ported
Selective reporting (reporting bias) Low risk No evidence of selective reporting found.
Other bias High risk Study was stopped early by the Data Mon-
itoring Committee after recruitment of 21
froman anticipated 98participants because
of statistically signiﬁcant treatment effect
in favour of the tobramycin group
Study received sponsorship support from
Chiron, manufacturer of tobramycin for
inhalation as used in the study
Proesmans 2013
Methods RCT.
Parallel design.
Duration: 3 months.
Single centre based in Europe.
Participants 58 children with CF, all with new isolation of P. aeruginosa (sputum or cough swabs).
Age: median age 9 years, interquartile range (4.7 - 13.1 years)
Gender: 31 male, 27 female.
Lung function: median FEV1 at inclusion 98% predicted.
Interventions Treatment (n = 29): Inhaled TSI (300 mg 2x daily for 28 days)
Control (n = 29): 3 months combination therapy with inhaled colistin (2 MU 2x daily)
+ oral ciproﬂoxacin (10 mg/kg 3x daily)
Outcomes Primary outcomes
Eradication of P. aeruginosa at the end of treatment.
Secondary outcomes
Time to P. aeruginosa relapse; antibodies (Ab); IgG; FEV1; body mass index; and P.
aeruginosa status at 2-year follow up.
Notes Participants were then switched to the other arm or treatedwith IV antibiotics if clinically
indicated
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Proesmans 2013 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised in blocks of 10. No descrip-
tion given ofmethod of randomisation, nor
of any stratiﬁcation
Allocation concealment (selection bias) Unclear risk Did not report how allocation was con-
cealed.
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not possible for participants and
clinicians as treatments compared were in-
haled versus inhaled and oral. No details
regarding whether outcome assessors were
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis on all 58 ran-
domised participants
Selective reporting (reporting bias) High risk Protocol published on ClinicalTrials.gov
(identiﬁer: NCT01400750). All pre-speci-
ﬁed outcomes reported
BMI z score, weight z score and frequency
of exacerbations were reported not to have
changed signiﬁcantly for trial participants,
but numerical data are not reported
Other bias Unclear risk Primary outcome was assessed at end of
treatment which was different for the 2
treatment groups 28 days for TSI partici-
pants versus 3 months for colistin/ciproﬂo-
xacin participants
Ratjen 2010
Methods RCT.
Parallel design.
Duration: 27 months.
Multicentre (21 centres) based in Europe (Germany, France, Spain, Austria, UK,Nether-
lands)
Participants 123 participants with CF free of P. aeruginosa (88 randomised - 31 participants not
randomised because of high P. aeruginosa antibody titres and 4 for other reasons).
Age (mean (SD)): 28-day TIS 8.7 (7.2) years, 56-day TIS 8.7 (10.5) years
Gender: 28-day TIS 26 (58%) males, 19 (42%) females; 56-day TIS 22 (51%) males,
21 (49%) females
Lung function (mean (SD) FEV1 % predicted): 28-day TIS 80.2 (18.9), 56-day TIS 87.
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Ratjen 2010 (Continued)
0 (19.2)
Interventions Group 1 (n = 45): 28 days of tobramycin solution for inhalation (TSI) (300 mg 2x daily)
, then stopped treatment
Group 2 (n = 43): 28 days of tobramycin solution for inhalation (TSI) (300 mg 2x daily)
, then randomised to a further 28 days (56 days in total)
Outcomes Primary outcome
Median time to recurrence of any strain of P. aeruginosa.
Secondary outcomes
Proportion of patients free of P. aeruginosa 1 month after the end of treatment
Number and length of hospital admissions for respiratory indications
Occurrence of other pathogens
Changes in FEV1, FVC & FEF25−75
Weight, height and body mass index.
Notes Also known as ELITE trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, but no descrip-
tion of randomisation techniques given
Allocation concealment (selection bias) Unclear risk Did not report how allocation was con-
cealed.
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label study, no attempt at blinding.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 65 patients from 88 randomised achieved
primary outcome.A total of 52participants
prematurely withdrawn from trial
27 participants withdrew from the 28-day
treatment group with the following rea-
sons: loss to follow up (n = 1); protocol de-
viation (n = 4); recurrence/non-eradication
(n = 21); other (n = 1)
25 participants withdrew from the 56-day
treatment group for the following reasons:
withdrawn consent (n = 1); loss to follow
up (n = 2); protocol deviation (n = 2); re-
currence/no eradication (n = 19); abnormal
audiology test (n = 1)
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Ratjen 2010 (Continued)
Selective reporting (reporting bias) High risk Study reports there were no major short-
or long-term (3 and 27 months) changes in
spirometry, but does not record the ﬁgures
for either of the 2 groups. Also, only sum-
mary statements and no numerical data are
provided for weight, height or BMI
Other bias Unclear risk Recruited fewer participants than planned;
actually randomised 88 participants (pri-
mary outcome evaluable in 65) - planned
randomisation of 100 participants
Did not randomise 35 participants from
the recruited cohort of 123 participants:
31 because of high P. aeruginosa antibody
levels, one for an adverse event, one where
consent was withdrawn, one for a protocol
deviation and one ’other’ (unspeciﬁed) rea-
son. Participants with raised antibody lev-
els were not included because the investi-
gators believed that they were chronically
infected with P. aeruginosa based on their
antibody results.
This trial was initially supported by Chi-
ron and later Novartis Pharma, the manu-
facturer of TSI
Taccetti 2012
Methods RCT.
Parallel design.
Duration: 28 days.
Multicentre (13 centres) in Italy.
Participants 223 participants with ﬁrst ever or new P. aeruginosa infection. New infection deﬁned as
P. aeruginosa isolation following bacterial clearance documented by 3 negative cultures
within the previous 6 months
Age: over 1 year.
Gender: 116 male, 107 female.
Interventions Group A (n = 105; 52 male and 53 female): 28 days 2x daily inhalation of 2 MU colistin
with 2x daily doses of ciproﬂoxacin 15 mg/kg/dose.
Group B (n = 118; 64 male and 54 female): 28 days therapy with TSI (300 mg 2x daily)
with 2x daily doses of ciproﬂoxacin 15 mg/kg/dose
Outcomes Primary outcome
P. aeruginosa eradication deﬁned as 3 negative cultures over 6 months.
Secondary outcomes
Lung function (FEV1).
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Taccetti 2012 (Continued)
Period of time free of P. aeruginosa.
Isolation of other pathogens including gram-negative and aspergillus
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation sequence generated by sta-
tistical software within permuted blocks
of size 10, stratiﬁed according to age and
FEV1.
Allocation concealment (selection bias) Low risk Separation of individuals responsible for
randomisation and treatment assignment
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label trial so no blinding of partici-
pants nor researchers
Incomplete outcome data (attrition bias)
All outcomes
Low risk 38 of 223 randomised participants (17%)
dropped out of the trial. The biggest reason
for dropping out was lack of compliance
with follow up protocol (11 from Group A
and 13 from Group B) and identiﬁcation
of a pulmonary exacerbation during early
eradication therapy (4 fromGroup A and 5
from Group B). Analysis was by intention-
to-treat
Selective reporting (reporting bias) Unclear risk We have been unable to locate a published
protocol for this trial. The details pub-
lished on the EudraCT database (number
2008-006502-42) describe objectives but
not outcomes. In themain paper, themeth-
ods section does not describe all the trial
objectives. Only eradication, time free of
P. aeruginosa and spirometry are described
in the methods section. These outcomes
plus the additional outcomes of isolation
of other organisms and adverse events are
described in the results
Other bias Low risk No evidence of other bias identiﬁed.
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Treggiari 2011
Methods RCT.
Multi-centre (57 centres) in the USA.
Trial duration for each participant is 18 months.
Parallel design.
Inhaled tobramycin was provided in an open-label fashion, while oral ciproﬂoxacin was
provided in a double-blinded fashion
Participants 306 participants with CF, previously free of P. aeruginosa or had not had positive isolates
for 2 years or more.
Age: 1 year or older and 12 years and younger.
Gender: 150 male, 154 female.
Interventions All participants received eradication therapy with inhaled tobramycin (Novartis Phar-
maceutical Corp) for 28 days with or without ciproﬂoxacin (Bayer Healthcare AG). The
main randomised intervention of nebulised tobramycin, with or without oral ciproﬂo-
xacin, commenced after this initial 28 days of treatment:
Group A: cycled therapy;
Group B: culture-based therapy.
Furthermore, the time from isolation of P. aeruginosa to commencing trial therapy was
up to 6 months and in this interval, some participants received antimicrobial therapy
Outcomes Primary outcomes
Time to ﬁrst exacerbation requiring IV therapy.
Proportion of positive cultures in each group.
Secondary outcomes
Clinical
Time to pulmonary exacerbation not requiring IV antibiotic usage or hospitalization
Frequency of pulmonary exacerbations, hospitalizations, and use of concomitant oral,
inhaled, and IV antibiotics
Anthropometric measures (linear growth, weight gain).
Pulmonary function tests including FVC, FEF25%−75%, and FEV1 (participants 4 years
of age and older, able to reproducibly perform spirometry)
Total hospitalization days.
Microbiological
Changes in antibiotic susceptibility patterns (minimal inhibitory concentrations of 12
antibiotics)
Colony morphology.
Presence of mucoid isolates from baseline to the end of the trial
Emergence of intrinsically aminoglycoside and ciproﬂoxacin-resistant non-pseudomonal
organisms (e.g. B. cepacia, A. xylosoxidans, and S. maltophilia).
Adverse events.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Treggiari 2011 (Continued)
Random sequence generation (selection
bias)
Low risk Randomization was carried out by per-
muted blocks, and performed using a com-
puter-generated sequence
Allocation concealment (selection bias) Low risk Randomization assignmentwas available at
the sites via an interactive voice response
system with e-mail conﬁrmation of the
treatment assignment
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Inhaled tobramycin was provided in an
open-label fashion, while oral ciproﬂoxacin
was provided in a double-blinded fashion
All trial personnel and participants were
blinded to oral therapy assignment but not
to cycled or culture-based treatment allo-
cation. The core trial investigators were
blinded to all treatment allocation for the
entire study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 2 of 306 randomised participants ex-
cluded from the analysis (because they did
not receive study treatment)
Selective reporting (reporting bias) Low risk Data on all primary and secondary out-
comes reported.
Other bias Low risk No imbalance in baseline characteristics.
Central trial team (not local investigators)
blinded
Valerius 1991
Methods RCT.
Parallel design.
Duration: 27 months.
Single-centre trial based in Europe.
Participants 26 participants with a recent positive culture who have never received anti-pseudomonal
therapy
Age: 2 - 9 years.
Gender: 13 males, 13 females.
Interventions Treatment: oral ciproﬂoxacin (250 - 750 mg) 2x daily and inhaled colistin (1 MU) for
3 weeks at entry and each time P. aeruginosa isolated.
Control: no anti-pseudomonas chemotherapy.
42Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Valerius 1991 (Continued)
Outcomes Time to chronic colonisation with P. aeruginosa (deﬁned as the presence of P. aeruginosa
in monthly routine sputum specimens for 6 consecutive months and/or the development
of precipitating serum antibodies against P. aeruginosa).
Notes Monthly sputum samples.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as a RCT without stratiﬁcation,
but the method of generation of allocation
sequence was not stated
Allocation concealment (selection bias) Unclear risk Did not report how allocation was con-
cealed.
Blinding (performance bias and detection
bias)
All outcomes
High risk Did not use blinding, interventions differ-
ent.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analysed on an intention-to-treat basis. Re-
ported data on all participants who were
randomised. There were no dropouts re-
ported
Selective reporting (reporting bias) Low risk No evidence of selective reporting found.
Other bias Low risk No evidence of other bias identiﬁed.
Wiesemann 1998
Methods RCT.
Double-blind, placebo-controlled trial.
Parallel design.
Duration: 2 years.
Multicentre trial based in Europe.
Participants 22 children with P. aeruginosa-negative throat swabs or sputum cultures for > 1 year and
negative serum antibody titers were eligible
Age: 4 - 18 years.
Gender: 9 males, 13 females.
Interventions Treatment: nebulised tobramycin 80 mg inhaled 2x daily.
Control: inhaled placebo.
Outcomes Time to clearance of P. aeruginosa from the airway.
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Wiesemann 1998 (Continued)
Notes Monthly sputum or oropharyngeal swabs during trial period.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation sequence was generated using a
coin ﬂip for pairs of participants. There is
no information as to who was responsible
for the coin ﬂip or what controls were in
place to ensure validity of the result of the
coin ﬂip
Allocation concealment (selection bias) Unclear risk Did not report how allocation was con-
cealed.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Reported as double blind. Participantswere
blinded by providing a placebo inhalation
with a similar taste to the treatment in-
halation, but it is not clear whether the
clinicians administering the treatmentwere
blinded to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 2 out of 11 participants withdrew from
treatment group; 5 out of 11 participants
withdrew from placebo group. The trial
was analysed on an available case basis
Selective reporting (reporting bias) High risk Reported there was no change in spiromet-
ric pulmonary function during or after the
treatment period, but no data were given
Other bias Low risk No evidence of other bias identiﬁed.
BAL: bronchoalveolar lavage
FEF25−75: mid-forced expiratory ﬂow
FEV1: forced expiratory volume at one second
FVC: forced vital capacity
IgG: immunoglobulin G
IV: intravenous
MU: million units
P. aeruginosa: Pseudomonas aeruginosa
RCT: randomised controlled trial
TSI: tobramycin solution for inhalation
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alothman 2002 Drug tolerability study, not eradication therapy.
Alothman 2005 Drug tolerability study, not eradication therapy.
Ballman 1998 Eradication treatment not used. Observational study.
Brett 1992 Participants allocated to treatment by minimisation on the basis of IgG levels and clinical indications
compared to therapy based on clinical indications alone
Church 1997 Symptomatic treatment not eradication.
Clancy 2013 Participants chronically infected with P. aeruginosa.
Coates 2011 Participants chronically infected with P. aeruginosa.
Frederiksen 1997 Historical control group.
Geller 2007 Pharmacokinetic and drug tolerability study, not eradication therapy
Gibson 2007 Not randomised and with no allocation concealment.
Goss 2009 Participants chronically infected with P. aeruginosa.
Griese 2002 Case-control study.
Heinzl 2002 No control group.
Kenny 2009 Retrospective cohort study.
Konstan 2010 Participants chronically infected with P. aeruginosa.
Latzin 2008 The primary aim of this trial was not to evaluate eradication regimens for P. aeruginosa and 112 of 118
participants were treated for an acute exacerbation or suppression of chronic infection with P. aeruginosa.
Lenoir 2007 Trial not designed to look at eradication of P. aeruginosa. At baseline, 47 of 59 participants had chronic
infection with P. aeruginosa.
Littlewood 1985 No control group.
Mainz 2014 Sinonasal nebulisation of antibiotic aiming to eradicate from the sinuses only
Mazurek 2012 Participants chronically infected with P. aeruginosa.
Oermann 2009 Participants chronically infected with P. aeruginosa, not an eradication trial, no randomisation.
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(Continued)
Postnikov 2000 No control group and no randomisation.
Postnikov 2007 Not an eradication trial, participants chronically infected with P. aeruginosa.
Prayle 2013 Participants chronically infected with P. aeruginosa.
Ramsey 1999 Participants chronically infected with P. aeruginosa.
Ratjen 2001a No control group.
Retsch-Bogart 2008 Participants chronically infected with P. aeruginosa.
Retsch-Bogart 2009 Participants chronically infected with P. aeruginosa.
Rietschel 2009 Pharmacokinetic study of inhaled tobramycin, not eradication therapy
Schaad 1997 Symptomatic treatment not eradication.
Schelstraete 2010 No randomisation or eradication therapy.
Schuster 2013 Drug tolerability study in chronic P. aeruginosa infection, not eradication therapy.
Steinkamp 1989 No control group.
Steinkamp 2007 Participants chronically infected with P. aeruginosa.
Taccetti 2005 Primary outcome did not have a control group. Historical controls utilised for other outcomes. No
randomisation
Tramper-Stranders 2009 Study of prophylaxis against future infection with P. aeruginosa, not of eradication.
Trapnell 2012 Participants chronically infected with P. aeruginosa.
Vazquez 1993 Historical control group.
Wainwright 2011a Randomised to therapy directed by the results of bronchoalveolar lavage compared to therapy based on
clinical indications or upper respiratory samples
Wainwright 2011b Participants chronically infected with P. aeruginosa.
P. aeruginosa: Pseudomonas aeruginosa
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Characteristics of studies awaiting assessment [ordered by study ID]
Noah 2010
Methods Single-centre, randomised, prospective trial.
Participants Stable children with CF and positive surveillance cultures for P. aeruginosa.
Interventions Nebulised tobramycin 300 mg 2x daily for 4 weeks or intravenous ceftazidime with tobramycin for 2 weeks at
standard weight-adjusted doses
Outcomes Primary efﬁcacy endpointwas change inBALﬂuid percentage neutrophils from themost affected lobe at bronchoscopy
Secondary outcomes included change in BAL ﬂuid differential cell counts, cytokines and bacterial quantity
Notes 8 participants from a total of 15 had ﬁrst ever isolate of P. aeruginosa and can be included in this review. Outcome
data for these 8 participants not published, author contacted for them
BAL: bronchoalveolar lavage
CF: cystic ﬁbrosis
P. aeruginosa: Pseudomonas aeruginosa
Characteristics of ongoing studies [ordered by study ID]
TORPEDO Trial
Trial name or title TORPEDO-CF (Trial of Optimal Therapy for Pseudomonas Eradication in Cystic Fibrosis)
Methods Multi-centre, parallel group, RCT.
Participants Inclusion criteria
1. Diagnosis of CF
2. Children over the age of 28 days, older children and adult CF participants are all eligible with no upper
age limitation
3. Competent adults should provide fully informed written consent to participate in the trial
4.Minors should have proxy consent by the parent or legal guardian and should provide assentwhere applicable
to participate in the trial
5. The participant should have isolated P.aeruginosa and should be either:
a. P. aeruginosa-naïve (i.e. has never previously isolated P. aeruginosa) or
b. P. aeruginosa-free (i.e. a minimum of four consecutive cough or sputum samples should be P. aeruginosa-
free within a 12-month period)
6. The participant should be able to commence treatment no later than 21 days from the date of a P. aeruginosa
positive microbiology report
Interventions Objective: this trial will assess whether 10 days IV ceftazidime with tobramycin is superior to 3 months oral
ciproﬂoxacin. Both treatment regimes will be in conjunction with 3 months nebulised colistin
Arm A: 14 days IV ceftazidime 50 mg/kg/dose, to a maximum of 3 g 3x daily and IV tobramycin 10 mg/kg/
day either 1x daily or in divided doses (maximum 660 mg/day).
Arm B: 3 months oral ciproﬂoxacin 2x daily (ciproﬂoxacin dose will be 15 - 20 mg/kg/dose 2x daily for
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TORPEDO Trial (Continued)
children aged < 5 years and 20 mg/kg/dose 2x daily (maximum 750 mg 2x daily) for those aged ≥ 5 years).
Both treatment arms will receive 3 months of nebulised colistin in conjunction to the randomised treatment.
Colistin dose will be as recommended by the UK CF Trust: 1,000,000 units 2x daily for children aged ≤ 2
years and 2,000,000 units 2x daily for children aged > 2 years and adults
Outcomes Primary outcome
1. Successful eradication of P. aeruginosa infection 3 months after allocated treatment has started, remaining
infection-free through to 15 months after the start of allocated treatment
Secondary outcomes
1. Time to reoccurrence of original P. aeruginosa infection
2. Re-infection with a different genotype of P. aeruginosa
3. Lung function (FEV1 , FVC, FEF25−75)
4. O2 saturation
5. Growth and nutritional status - height, weight and body mass index
6. Number of pulmonary exacerbations
7. Admission to hospital
8. Number of days spent as inpatient in hospital over the 3-month period after allocated treatment has
ﬁnished, and between 3 months and 15 months after eradication treatment has ﬁnished (other than 14 days
spent on initial IV treatment)
9. Quality of life (CFQ)
10. Utility (EQ-5D)
11. Adverse events
12. Other sputum/cough microbiology (MRSA, B. cepacia complex, Aspergillus, candida infection)
13. Cost per patient (from NHS perspective)
14. Incremental cost effectiveness ratio (cost per successfully treated patient, cost per QALY)
15. Carer burden (absenteeism from school or work)
16. Participant burden (absenteeism from education or work)
Starting date 24/05/2010.
Contact information Dr Simon Langton Hewer
Bristol Royal Hospital for Children
Paul O’Gorman Building
Upper Maudlin Street
Bristol
BS2 8BJ
UK
Notes Anticipated end date: 01/11/2014
HTA 07/51/01
A. xylosoxidans: Alcaligenes xylosoxidans
B. cepacia: Burkholderia cepacia
CF: cystic ﬁbrosis
FEF25−75: mid-forced expiratory ﬂow
FEV1: forced expiratory volume at 1 second
FVC: forced vital capacity
IV: intravenous
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MRSA: Methicillin-resistant Staphylococcus aureus
NHS: National Health Service
O2: oxygen
od: once daily
P. aeruginosa: Pseudomonas aeruginosa
QALY: quality-adjusted life year
RCT: randomised controlled trial
S. maltophilia: Stenotrophomonous maltophilia
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D A T A A N D A N A L Y S E S
Comparison 1. Inhaled tobramycin versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Positive respiratory culture for P.
aeruginosa (300 mg 2x daily)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 At 1 month 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 At 2 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Positive respiratory culture for P.
aeruginosa (80 mg 2x daily)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 At 1 month 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 At 2 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 At 3 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 At 6 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.5 At 12 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Positive respiratory culture for P.
aeruginosa (combined available
case analysis)
2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 At 1 month 2 38 Odds Ratio (M-H, Fixed, 95% CI) 0.06 [0.01, 0.33]
3.2 At 2 months 2 38 Odds Ratio (M-H, Fixed, 95% CI) 0.15 [0.03, 0.65]
4 Positive respiratory culture for
P. aeruginosa (combined) - best
case
2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 At 1 month 2 39 Odds Ratio (M-H, Fixed, 95% CI) 0.06 [0.01, 0.30]
4.2 At 2 months 2 39 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.03, 0.60]
4.3 At 3 months 1 18 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.02, 1.16]
4.4 At 6 months 1 18 Odds Ratio (M-H, Fixed, 95% CI) 0.04 [0.00, 0.48]
4.5 At 12 months 1 18 Odds Ratio (M-H, Fixed, 95% CI) 0.01 [3.32, 0.26]
5 Positive respiratory culture for P.
aeruginosa (combined) - worst
case
2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 At 1 month 2 39 Odds Ratio (M-H, Fixed, 95% CI) 0.08 [0.02, 0.38]
5.2 At 2 months 2 39 Odds Ratio (M-H, Fixed, 95% CI) 0.18 [0.04, 0.73]
5.3 At 3 months 1 18 Odds Ratio (M-H, Fixed, 95% CI) 0.36 [0.05, 2.77]
5.4 At 6 months 1 18 Odds Ratio (M-H, Fixed, 95% CI) 0.16 [0.01, 1.83]
5.5 At 12 months 1 18 Odds Ratio (M-H, Fixed, 95% CI) 0.36 [0.05, 2.77]
6 Change in weight from baseline 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 At 1 month 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 At 2 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Adverse events 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
7.1 Cough 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Change in modiﬁed
Shwachmann score from
baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 At 1 month 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 At 2 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 2. Oral ciprofloxacin and inhaled colistin versus no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion colonised with P.
aeruginosa
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 At 3 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 At 6 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 At 12 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 At 24 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. Oral ciprofloxacin and inhaled colistin versus inhaled tobramycin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Positive respiratory culture for
P.aeruginosa
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 In ﬁrst 6 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 At 24 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Adverse events 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Severe cough 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 4. Nebulised tobramycin 28 days versus 56 days
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to next isolation of P.
aeruginosa from BAL, sputum
or oropharyngeal cultures
1 Hazard Ratio (Fixed, 95% CI) Totals not selected
2 Number of respiratory
exacerbations
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Until recurrence of P.
aeruginosa
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Adverse events (up to 3 months) 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Cough 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Productive cough 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Haemoptysis 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.4 Rhinitis 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.5 Sinusitis 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.6 Nasopharyngitis 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.7 Tonsilitis 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.8 Oropharyngeal pain 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.9 Dysphonia 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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3.10 Headache 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.11 URTI 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.12 Lung disorder 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.13 Bronchitis 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.14 P. aeruginosa infection 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.15 Inﬂuenza 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.16 Otitis media 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.17 Deafness 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.18 Drug level increased 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.19 Pyrexia 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.20 Vomiting 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.21 Varicella 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Adverse events (over 3 months) 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Cough 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Productive cough 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Haemoptysis 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 Rhinitis 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 Sinusitis 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.6 Nasopharyngitis 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.7 Tonsilitis 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.8 Oropharyngeal pain 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.9 Dysphonia 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.10 Headache 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.11 URTI 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.12 Lung disorder 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.13 Bronchitis 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.14 P. aeruginosa infection 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.15 Inﬂuenza 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.16 Otitis media 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.17 Deafness 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.18 Drug level increased 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.19 Pyrexia 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.20 Vomiting 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.21 Varicella 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 5. Inhaled colistin/oral ciprofloxacin versus inhaled tobramycin/oral ciprofloxacin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Positive respiratory culture for P.
aeruginosa
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 In ﬁrst 6 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 At end of follow up
(median 16 months)
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Relative change in % predicted
FEV1 from baseline (to mean
54 days)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Post-trial microbiology status 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
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3.1 Stenotrophomonas
maltophilia
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Achromobacter xylosoxidans 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Aspergillus species 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Adverse events leading to trial
discontinuation
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Vomiting 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Photosensitivity 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Wheeze 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 Pulmonary exacerbation
during early eradication
treatment
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 Lack of compliance 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 6. Cycled inhaled tobramycin versus culture-based inhaled tobramycin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participants with one or more
isolates of P. aeruginosa from
respiratory tract
1 Odds Ratio (IV, Fixed, 95% CI) Totals not selected
2 Mean 70-week change in FEV1
% predicted
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Mean 70-week change in weight
from baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4 Mean 70-week change in height
from baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5 Time to severe pulmonary
exacerbation
1 Hazard Ratio (Fixed, 95% CI) Totals not selected
6 Participants with one or more
severe pulmonary exacerbations
1 Odds Ratio (IV, Fixed, 95% CI) Totals not selected
7 Time to pulmonary exacerbation
(any severity)
1 Hazard Ratio (Fixed, 95% CI) Totals not selected
8 Participants with one or more
pulmonary exacerbations (any
severity)
1 Odds Ratio (IV, Fixed, 95% CI) Totals not selected
9 Participants with new isolates of
Stenotrophomonas maltophilia
1 Odds Ratio (IV, Fixed, 95% CI) Totals not selected
10 Participants with one or more
serious adverse event
1 Odds Ratio (IV, Fixed, 95% CI) Totals not selected
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Comparison 7. Ciprofloxacin versus placebo added to cycled and culture-based inhaled tobramycin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participants with one or more
isolates of P. aeruginosa from
respiratory tract
1 Odds Ratio (IV, Fixed, 95% CI) Totals not selected
2 Mean 70-week change in FEV1
% predicted
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Mean 70-week change in weight
from baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4 Mean 70-week change in height
from baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5 Time to severe pulmonary
exacerbation
1 Hazard Ratio (Fixed, 95% CI) Totals not selected
6 Participants with one or more
severe pulmonary exacerbations
1 Odds Ratio (IV, Fixed, 95% CI) Totals not selected
7 Time to pulmonary exacerbation
(any severity)
1 Hazard Ratio (Fixed, 95% CI) Totals not selected
8 Participants with one of more
pulmonary exacerbation (any
severity)
1 Odds Ratio (IV, Fixed, 95% CI) Totals not selected
9 Participants with new isolates of
Stenotrophomonas maltophilia
1 Odds Ratio (IV, Fixed, 95% CI) Totals not selected
10 Participants with one or more
serious adverse event
1 Odds Ratio (IV, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Inhaled tobramycin versus placebo, Outcome 1 Positive respiratory culture for
P. aeruginosa (300 mg 2x daily).
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 1 Inhaled tobramycin versus placebo
Outcome: 1 Positive respiratory culture for P. aeruginosa (300 mg 2x daily)
Study or subgroup Tobramycin Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 1 month
Gibson 2003 0/8 11/13 0.01 [ 0.00, 0.30 ]
2 At 2 months
Gibson 2003 2/8 8/13 0.21 [ 0.03, 1.47 ]
0.001 0.01 0.1 1 10 100 1000
Favours tobramycin Favours placebo
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Analysis 1.2. Comparison 1 Inhaled tobramycin versus placebo, Outcome 2 Positive respiratory culture for
P. aeruginosa (80 mg 2x daily).
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 1 Inhaled tobramycin versus placebo
Outcome: 2 Positive respiratory culture for P. aeruginosa (80 mg 2x daily)
Study or subgroup Tobramycin Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 1 month
Wiesemann 1998 3/8 7/9 0.17 [ 0.02, 1.44 ]
2 At 2 months
Wiesemann 1998 2/8 7/9 0.10 [ 0.01, 0.90 ]
3 At 3 months
Wiesemann 1998 2/8 4/7 0.25 [ 0.03, 2.24 ]
4 At 6 months
Wiesemann 1998 1/9 4/6 0.06 [ 0.00, 0.92 ]
5 At 12 months
Wiesemann 1998 1/8 4/4 0.02 [ 0.00, 0.67 ]
0.001 0.01 0.1 1 10 100 1000
Favours tobramycin Favours placebo
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Analysis 1.3. Comparison 1 Inhaled tobramycin versus placebo, Outcome 3 Positive respiratory culture for
P. aeruginosa (combined available case analysis).
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 1 Inhaled tobramycin versus placebo
Outcome: 3 Positive respiratory culture for P. aeruginosa (combined available case analysis)
Study or subgroup Tobramycin Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 1 month
Gibson 2003 0/8 11/13 67.4 % 0.01 [ 0.00, 0.30 ]
Wiesemann 1998 3/8 7/9 32.6 % 0.17 [ 0.02, 1.44 ]
Subtotal (95% CI) 16 22 100.0 % 0.06 [ 0.01, 0.33 ]
Total events: 3 (Tobramycin), 18 (Placebo)
Heterogeneity: Chi2 = 1.82, df = 1 (P = 0.18); I2 =45%
Test for overall effect: Z = 3.32 (P = 0.00091)
2 At 2 months
Gibson 2003 2/8 7/9 51.9 % 0.10 [ 0.01, 0.90 ]
Wiesemann 1998 2/8 8/13 48.1 % 0.21 [ 0.03, 1.47 ]
Subtotal (95% CI) 16 22 100.0 % 0.15 [ 0.03, 0.65 ]
Total events: 4 (Tobramycin), 15 (Placebo)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 2.54 (P = 0.011)
0.001 0.01 0.1 1 10 100 1000
Favours tobramycin Favours placebo
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Analysis 1.4. Comparison 1 Inhaled tobramycin versus placebo, Outcome 4 Positive respiratory culture for
P. aeruginosa (combined) - best case.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 1 Inhaled tobramycin versus placebo
Outcome: 4 Positive respiratory culture for P. aeruginosa (combined) - best case
Study or subgroup Tobramycin Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 1 month
Gibson 2003 0/8 11/13 64.6 % 0.01 [ 0.00, 0.30 ]
Wiesemann 1998 3/9 7/9 35.4 % 0.14 [ 0.02, 1.16 ]
Subtotal (95% CI) 17 22 100.0 % 0.06 [ 0.01, 0.30 ]
Total events: 3 (Tobramycin), 18 (Placebo)
Heterogeneity: Chi2 = 1.58, df = 1 (P = 0.21); I2 =37%
Test for overall effect: Z = 3.42 (P = 0.00063)
2 At 2 months
Gibson 2003 2/8 8/13 45.6 % 0.21 [ 0.03, 1.47 ]
Wiesemann 1998 2/9 7/9 54.4 % 0.08 [ 0.01, 0.75 ]
Subtotal (95% CI) 17 22 100.0 % 0.14 [ 0.03, 0.60 ]
Total events: 4 (Tobramycin), 15 (Placebo)
Heterogeneity: Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 2.65 (P = 0.0080)
3 At 3 months
Wiesemann 1998 2/9 6/9 100.0 % 0.14 [ 0.02, 1.16 ]
Subtotal (95% CI) 9 9 100.0 % 0.14 [ 0.02, 1.16 ]
Total events: 2 (Tobramycin), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.069)
4 At 6 months
Wiesemann 1998 1/9 7/9 100.0 % 0.04 [ 0.00, 0.48 ]
Subtotal (95% CI) 9 9 100.0 % 0.04 [ 0.00, 0.48 ]
Total events: 1 (Tobramycin), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.51 (P = 0.012)
5 At 12 months
Wiesemann 1998 1/9 9/9 100.0 % 0.01 [ 0.00, 0.26 ]
Subtotal (95% CI) 9 9 100.0 % 0.01 [ 0.00, 0.26 ]
Total events: 1 (Tobramycin), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.75 (P = 0.0059)
0.001 0.01 0.1 1 10 100 1000
Favours tobramycin Favours placebo
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Analysis 1.5. Comparison 1 Inhaled tobramycin versus placebo, Outcome 5 Positive respiratory culture for
P. aeruginosa (combined) - worst case.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 1 Inhaled tobramycin versus placebo
Outcome: 5 Positive respiratory culture for P. aeruginosa (combined) - worst case
Study or subgroup Tobramycin Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 1 month
Gibson 2003 0/8 11/13 68.6 % 0.01 [ 0.00, 0.30 ]
Wiesemann 1998 4/9 7/9 31.4 % 0.23 [ 0.03, 1.77 ]
Subtotal (95% CI) 17 22 100.0 % 0.08 [ 0.02, 0.38 ]
Total events: 4 (Tobramycin), 18 (Placebo)
Heterogeneity: Chi2 = 2.30, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 3.18 (P = 0.0015)
2 At 2 months
Gibson 2003 2/8 8/13 49.5 % 0.21 [ 0.03, 1.47 ]
Wiesemann 1998 3/9 7/9 50.5 % 0.14 [ 0.02, 1.16 ]
Subtotal (95% CI) 17 22 100.0 % 0.18 [ 0.04, 0.73 ]
Total events: 5 (Tobramycin), 15 (Placebo)
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 2.39 (P = 0.017)
3 At 3 months
Wiesemann 1998 2/9 4/9 100.0 % 0.36 [ 0.05, 2.77 ]
Subtotal (95% CI) 9 9 100.0 % 0.36 [ 0.05, 2.77 ]
Total events: 2 (Tobramycin), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.32)
4 At 6 months
Wiesemann 1998 1/9 4/9 100.0 % 0.16 [ 0.01, 1.83 ]
Subtotal (95% CI) 9 9 100.0 % 0.16 [ 0.01, 1.83 ]
Total events: 1 (Tobramycin), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
5 At 12 months
Wiesemann 1998 2/9 4/9 100.0 % 0.36 [ 0.05, 2.77 ]
Subtotal (95% CI) 9 9 100.0 % 0.36 [ 0.05, 2.77 ]
Total events: 2 (Tobramycin), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.32)
0.001 0.01 0.1 1 10 100 1000
Favours tobramycin Favours placebo
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Analysis 1.6. Comparison 1 Inhaled tobramycin versus placebo, Outcome 6 Change in weight from baseline.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 1 Inhaled tobramycin versus placebo
Outcome: 6 Change in weight from baseline
Study or subgroup Tobramycin Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 1 month
Gibson 2003 8 0.3 (0.5) 13 0.1 (0.6) 0.20 [ -0.28, 0.68 ]
2 At 2 months
Gibson 2003 8 0.4 (0.5) 13 0.3 (0.6) 0.10 [ -0.38, 0.58 ]
-4 -2 0 2 4
Favours tobramycin Favours placebo
Analysis 1.7. Comparison 1 Inhaled tobramycin versus placebo, Outcome 7 Adverse events.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 1 Inhaled tobramycin versus placebo
Outcome: 7 Adverse events
Study or subgroup Tobramycin Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cough
Gibson 2003 7/8 12/13 0.58 [ 0.03, 10.86 ]
0.01 0.1 1 10 100
Favours tobramycin Favours placebo
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Analysis 1.8. Comparison 1 Inhaled tobramycin versus placebo, Outcome 8 Change in modified
Shwachmann score from baseline.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 1 Inhaled tobramycin versus placebo
Outcome: 8 Change in modified Shwachmann score from baseline
Study or subgroup Tobramycin Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 1 month
Gibson 2003 8 0.5 (2.4) 13 -0.8 (6) 1.30 [ -2.36, 4.96 ]
2 At 2 months
Gibson 2003 8 2.4 (3.4) 13 -1.4 (6) 3.80 [ -0.22, 7.82 ]
-10 -5 0 5 10
Favours placebo Favours tobramycin
Analysis 2.1. Comparison 2 Oral ciprofloxacin and inhaled colistin versus no treatment, Outcome 1
Proportion colonised with P. aeruginosa.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 2 Oral ciprofloxacin and inhaled colistin versus no treatment
Outcome: 1 Proportion colonised with P. aeruginosa
Study or subgroup Anti-pseudo Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 3 months
Valerius 1991 1/14 0/12 2.78 [ 0.10, 74.70 ]
2 At 6 months
Valerius 1991 1/14 1/12 0.85 [ 0.05, 15.16 ]
3 At 12 months
Valerius 1991 2/14 6/12 0.17 [ 0.03, 1.09 ]
4 At 24 months
Valerius 1991 2/14 7/12 0.12 [ 0.02, 0.79 ]
0.001 0.01 0.1 1 10 100 1000
Favours anti-pseudo Favours control
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Analysis 3.1. Comparison 3 Oral ciprofloxacin and inhaled colistin versus inhaled tobramycin, Outcome 1
Positive respiratory culture for P.aeruginosa.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 3 Oral ciprofloxacin and inhaled colistin versus inhaled tobramycin
Outcome: 1 Positive respiratory culture for P.aeruginosa
Study or subgroup
Ciprofloxacin
% Inhaled
colistin Inhaled tobramycin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 In first 6 months
Proesmans 2013 10/29 16/29 0.43 [ 0.15, 1.23 ]
2 At 24 months
Proesmans 2013 (1) 9/23 11/24 0.76 [ 0.24, 2.42 ]
0.01 0.1 1 10 100
Favours cipro % colistin Favours tobramycin
(1) Only 23/29 colistin/ciproflxacin % 24/29 TSI treated patients followed up to 24 months
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Analysis 3.2. Comparison 3 Oral ciprofloxacin and inhaled colistin versus inhaled tobramycin, Outcome 2
Adverse events.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 3 Oral ciprofloxacin and inhaled colistin versus inhaled tobramycin
Outcome: 2 Adverse events
Study or subgroup
Ciprofloxacin
% Inhaled
colistin Inhaled tobramycin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Severe cough
Proesmans 2013 0/29 1/29 0.32 [ 0.01, 8.24 ]
0.01 0.1 1 10 100
Favours Ciprofloxacin % Inhaled colistin Favours Inhaled tobramycin
Analysis 4.1. Comparison 4 Nebulised tobramycin 28 days versus 56 days, Outcome 1 Time to next
isolation of P. aeruginosa from BAL, sputum or oropharyngeal cultures.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 4 Nebulised tobramycin 28 days versus 56 days
Outcome: 1 Time to next isolation of P. aeruginosa from BAL, sputum or oropharyngeal cultures
Study or subgroup Favours TIS 56 days TIS 28 days log [Hazard Ratio] Hazard Ratio Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Ratjen 2010 31 34 -0.21 (0.3963) 0.81 [ 0.37, 1.76 ]
0.05 0.2 1 5 20
Favours TIS 56 days Favours TIS 28 days
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Analysis 4.2. Comparison 4 Nebulised tobramycin 28 days versus 56 days, Outcome 2 Number of
respiratory exacerbations.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 4 Nebulised tobramycin 28 days versus 56 days
Outcome: 2 Number of respiratory exacerbations
Study or subgroup 28-day TIS 56-day TIS Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Until recurrence of P. aeruginosa
Ratjen 2010 0/44 2/43 0.19 [ 0.01, 4.00 ]
0.005 0.1 1 10 200
Favours 28-day TIS Favours 56-day TIS
Analysis 4.3. Comparison 4 Nebulised tobramycin 28 days versus 56 days, Outcome 3 Adverse events (up to
3 months).
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 4 Nebulised tobramycin 28 days versus 56 days
Outcome: 3 Adverse events (up to 3 months)
Study or subgroup 28-day TIS 56-day TIS Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cough
Ratjen 2010 9/44 2/43 5.27 [ 1.07, 26.04 ]
2 Productive cough
Ratjen 2010 1/44 2/43 0.48 [ 0.04, 5.46 ]
3 Haemoptysis
Ratjen 2010 2/44 1/43 2.00 [ 0.17, 22.91 ]
4 Rhinitis
Ratjen 2010 7/44 3/43 2.52 [ 0.61, 10.48 ]
5 Sinusitis
Ratjen 2010 0/44 0/43 Not estimable
0.005 0.1 1 10 200
Favours 28-day TIS Favours 56-day TIS
(Continued . . . )
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(. . . Continued)
Study or subgroup 28-day TIS 56-day TIS Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
6 Nasopharyngitis
Ratjen 2010 3/44 0/43 7.34 [ 0.37, 146.43 ]
7 Tonsilitis
Ratjen 2010 1/44 0/43 3.00 [ 0.12, 75.69 ]
8 Oropharyngeal pain
Ratjen 2010 2/44 0/43 5.12 [ 0.24, 109.77 ]
9 Dysphonia
Ratjen 2010 5/44 6/43 0.79 [ 0.22, 2.81 ]
10 Headache
Ratjen 2010 3/44 1/43 3.07 [ 0.31, 30.77 ]
11 URTI
Ratjen 2010 4/44 2/43 2.05 [ 0.36, 11.83 ]
12 Lung disorder
Ratjen 2010 2/44 0/43 5.12 [ 0.24, 109.77 ]
13 Bronchitis
Ratjen 2010 2/44 0/43 5.12 [ 0.24, 109.77 ]
14 P. aeruginosa infection
Ratjen 2010 2/44 1/43 2.00 [ 0.17, 22.91 ]
15 Influenza
Ratjen 2010 2/44 0/43 5.12 [ 0.24, 109.77 ]
16 Otitis media
Ratjen 2010 0/44 1/43 0.32 [ 0.01, 8.03 ]
17 Deafness
Ratjen 2010 0/44 2/43 0.19 [ 0.01, 4.00 ]
18 Drug level increased
Ratjen 2010 2/44 1/43 2.00 [ 0.17, 22.91 ]
19 Pyrexia
Ratjen 2010 3/44 4/43 0.71 [ 0.15, 3.39 ]
20 Vomiting
Ratjen 2010 1/44 1/43 0.98 [ 0.06, 16.13 ]
21 Varicella
Ratjen 2010 0/44 1/43 0.32 [ 0.01, 8.03 ]
0.005 0.1 1 10 200
Favours 28-day TIS Favours 56-day TIS
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Analysis 4.4. Comparison 4 Nebulised tobramycin 28 days versus 56 days, Outcome 4 Adverse events (over
3 months).
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 4 Nebulised tobramycin 28 days versus 56 days
Outcome: 4 Adverse events (over 3 months)
Study or subgroup 28-day TIS 56-day TIS Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cough
Ratjen 2010 9/35 7/36 1.43 [ 0.47, 4.40 ]
2 Productive cough
Ratjen 2010 0/35 1/36 0.33 [ 0.01, 8.46 ]
3 Haemoptysis
Ratjen 2010 1/35 0/36 3.17 [ 0.13, 80.58 ]
4 Rhinitis
Ratjen 2010 3/35 2/36 1.59 [ 0.25, 10.17 ]
5 Sinusitis
Ratjen 2010 2/35 0/36 5.45 [ 0.25, 117.63 ]
6 Nasopharyngitis
Ratjen 2010 0/35 2/36 0.19 [ 0.01, 4.20 ]
7 Tonsilitis
Ratjen 2010 4/35 1/36 4.52 [ 0.48, 42.59 ]
8 Oropharyngeal pain
Ratjen 2010 2/35 0/36 5.45 [ 0.25, 117.63 ]
9 Dysphonia
Ratjen 2010 0/35 0/36 Not estimable
10 Headache
Ratjen 2010 0/35 0/36 Not estimable
11 URTI
Ratjen 2010 4/35 4/36 1.03 [ 0.24, 4.50 ]
12 Lung disorder
Ratjen 2010 1/35 2/36 0.50 [ 0.04, 5.78 ]
13 Bronchitis
Ratjen 2010 3/35 4/36 0.75 [ 0.16, 3.62 ]
14 P. aeruginosa infection
Ratjen 2010 1/35 1/36 1.03 [ 0.06, 17.13 ]
0.005 0.1 1 10 200
Favours 28-day TIS Favours 56-day TIS
(Continued . . . )
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Study or subgroup 28-day TIS 56-day TIS Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
15 Influenza
Ratjen 2010 0/35 0/36 Not estimable
16 Otitis media
Ratjen 2010 3/35 2/36 1.59 [ 0.25, 10.17 ]
17 Deafness
Ratjen 2010 0/35 0/36 Not estimable
18 Drug level increased
Ratjen 2010 0/35 0/36 Not estimable
19 Pyrexia
Ratjen 2010 2/35 2/36 1.03 [ 0.14, 7.75 ]
20 Vomiting
Ratjen 2010 0/35 3/36 0.13 [ 0.01, 2.71 ]
21 Varicella
Ratjen 2010 0/35 3/36 0.13 [ 0.01, 2.71 ]
0.005 0.1 1 10 200
Favours 28-day TIS Favours 56-day TIS
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Analysis 5.1. Comparison 5 Inhaled colistin/oral ciprofloxacin versus inhaled tobramycin/oral ciprofloxacin,
Outcome 1 Positive respiratory culture for P. aeruginosa.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 5 Inhaled colistin/oral ciprofloxacin versus inhaled tobramycin/oral ciprofloxacin
Outcome: 1 Positive respiratory culture for P. aeruginosa
Study or subgroup Colistin/ciprofloxacin Tobramycin/ciprofloxacin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 In first 6 months
Taccetti 2012 39/105 41/118 1.11 [ 0.64, 1.92 ]
2 At end of follow up (median 16 months)
Taccetti 2012 36/97 34/108 1.28 [ 0.72, 2.29 ]
0.5 0.7 1 1.5 2
Favours colistin/cipro Favours tobramycin/cipro
Analysis 5.2. Comparison 5 Inhaled colistin/oral ciprofloxacin versus inhaled tobramycin/oral ciprofloxacin,
Outcome 2 Relative change in % predicted FEV1 from baseline (to mean 54 days).
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 5 Inhaled colistin/oral ciprofloxacin versus inhaled tobramycin/oral ciprofloxacin
Outcome: 2 Relative change in % predicted FEV1 from baseline (to mean 54 days)
Study or subgroup Colistin/ciprofloxacin Tobramycin/ciprofloxacin
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Taccetti 2012 60 2.15 (8.5) 68 4.55 (11.54) -2.40 [ -5.89, 1.09 ]
-10 -5 0 5 10
Favours tobramycin/cipro Favours colistin/cipro
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Analysis 5.3. Comparison 5 Inhaled colistin/oral ciprofloxacin versus inhaled tobramycin/oral ciprofloxacin,
Outcome 3 Post-trial microbiology status.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 5 Inhaled colistin/oral ciprofloxacin versus inhaled tobramycin/oral ciprofloxacin
Outcome: 3 Post-trial microbiology status
Study or subgroup Colistin/ciprofloxacin Tobramycin/ciprofloxacin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Stenotrophomonas maltophilia
Taccetti 2012 18/97 22/108 0.89 [ 0.45, 1.78 ]
2 Achromobacter xylosoxidans
Taccetti 2012 8/97 6/108 1.53 [ 0.51, 4.57 ]
3 Aspergillus species
Taccetti 2012 10/97 21/108 0.48 [ 0.21, 1.07 ]
0.05 0.2 1 5 20
Favours colistin/cipro Favours tobramycin/cipro
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Analysis 5.4. Comparison 5 Inhaled colistin/oral ciprofloxacin versus inhaled tobramycin/oral ciprofloxacin,
Outcome 4 Adverse events leading to trial discontinuation.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 5 Inhaled colistin/oral ciprofloxacin versus inhaled tobramycin/oral ciprofloxacin
Outcome: 4 Adverse events leading to trial discontinuation
Study or subgroup Colistin/ciprofloxacin Tobramycin/ciprofloxacin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vomiting
Taccetti 2012 1/105 2/118 0.56 [ 0.05, 6.24 ]
2 Photosensitivity
Taccetti 2012 1/105 0/118 3.40 [ 0.14, 84.41 ]
3 Wheeze
Taccetti 2012 0/105 1/118 0.37 [ 0.01, 9.21 ]
4 Pulmonary exacerbation during early eradication treatment
Taccetti 2012 4/105 5/118 0.90 [ 0.23, 3.42 ]
5 Lack of compliance
Taccetti 2012 11/105 13/118 0.95 [ 0.40, 2.21 ]
0.01 0.1 1 10 100
Favours colistin/cipro Favours tobramycin/cipro
Analysis 6.1. Comparison 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin, Outcome
1 Participants with one or more isolates of P. aeruginosa from respiratory tract.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin
Outcome: 1 Participants with one or more isolates of P. aeruginosa from respiratory tract
Study or subgroup Cycled Culture-based Odds Ratio Odds Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 43/148 67/150 0.51 [ 0.31, 0.82 ]
0.1 0.2 0.5 1 2 5 10
Favours cycled Favours culture-based
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Analysis 6.2. Comparison 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin, Outcome
2 Mean 70-week change in FEV1 % predicted.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin
Outcome: 2 Mean 70-week change in FEV1 % predicted
Study or subgroup Cycled Culture-based
Mean
Difference
Mean
Difference
N Mean(SD)[%] N Mean(SD)[%] IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 73 0.77 (12.65) 70 -1.61 (14.01) 2.38 [ -2.00, 6.76 ]
-10 -5 0 5 10
Favours culture-based Favours cycled
Analysis 6.3. Comparison 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin, Outcome
3 Mean 70-week change in weight from baseline.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin
Outcome: 3 Mean 70-week change in weight from baseline
Study or subgroup Cycled Culture-based
Mean
Difference
Mean
Difference
N Mean(SD)[kg] N Mean(SD)[kg] IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 152 4 (2.7) 152 3.9 (2.4) 0.10 [ -0.47, 0.67 ]
-1 -0.5 0 0.5 1
Favours culture-based Favours cycled
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Analysis 6.4. Comparison 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin, Outcome
4 Mean 70-week change in height from baseline.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin
Outcome: 4 Mean 70-week change in height from baseline
Study or subgroup Cycled Culture-based
Mean
Difference
Mean
Difference
N Mean(SD)[cm] N Mean(SD)[cm] IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 152 9.2 (2.8) 152 9.4 (3.1) -0.20 [ -0.86, 0.46 ]
-1 -0.5 0 0.5 1
Favours culture-based Favours cycled
Analysis 6.5. Comparison 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin, Outcome
5 Time to severe pulmonary exacerbation.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin
Outcome: 5 Time to severe pulmonary exacerbation
Study or subgroup Cycled Culture-based log [Hazard Ratio] Hazard Ratio Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 152 152 -0.0513 (0.286) 0.95 [ 0.54, 1.66 ]
0.5 0.7 1 1.5 2
Favours cycled Favours culture-based
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Analysis 6.6. Comparison 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin, Outcome
6 Participants with one or more severe pulmonary exacerbations.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin
Outcome: 6 Participants with one or more severe pulmonary exacerbations
Study or subgroup Cycled Culture-based Odds Ratio Odds Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 24/152 26/152 0.91 [ 0.50, 1.67 ]
0.5 0.7 1 1.5 2
Favours cycled Favours culture-based
Analysis 6.7. Comparison 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin, Outcome
7 Time to pulmonary exacerbation (any severity).
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin
Outcome: 7 Time to pulmonary exacerbation (any severity)
Study or subgroup Cycled Culture-based log [Hazard Ratio] Hazard Ratio Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 152 152 -0.223 (0.135) 0.80 [ 0.61, 1.04 ]
0.5 0.7 1 1.5 2
Favours cycled Favours culture-based
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Analysis 6.8. Comparison 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin, Outcome
8 Participants with one or more pulmonary exacerbations (any severity).
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin
Outcome: 8 Participants with one or more pulmonary exacerbations (any severity)
Study or subgroup Cycled Culture-based Odds Ratio Odds Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 70/152 81/152 0.75 [ 0.48, 1.17 ]
0.5 0.7 1 1.5 2
Favours cycled Favours culture-based
Analysis 6.9. Comparison 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin, Outcome
9 Participants with new isolates of Stenotrophomonas maltophilia.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin
Outcome: 9 Participants with new isolates of Stenotrophomonas maltophilia
Study or subgroup Cycled Culture-based Odds Ratio Odds Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 29/138 26/141 1.18 [ 0.65, 2.12 ]
0.1 0.2 0.5 1 2 5 10
Favours cycled Favours culture-based
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Analysis 6.10. Comparison 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin, Outcome
10 Participants with one or more serious adverse event.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin
Outcome: 10 Participants with one or more serious adverse event
Study or subgroup Cycled Culture-based Odds Ratio Odds Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 39/152 44/152 0.85 [ 0.51, 1.40 ]
0.5 0.7 1 1.5 2
Favours cycled Favours culture-based
Analysis 7.1. Comparison 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled
tobramycin, Outcome 1 Participants with one or more isolates of P. aeruginosa from respiratory tract.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled tobramycin
Outcome: 1 Participants with one or more isolates of P. aeruginosa from respiratory tract
Study or subgroup Ciprofloxacin Placebo Odds Ratio Odds Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 49/146 55/152 0.89 [ 0.55, 1.44 ]
0.1 0.2 0.5 1 2 5 10
Favours ciprofloxacin Favours placebo
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Analysis 7.2. Comparison 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled
tobramycin, Outcome 2 Mean 70-week change in FEV1 % predicted.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled tobramycin
Outcome: 2 Mean 70-week change in FEV1 % predicted
Study or subgroup Ciprofloxacin Placebo
Mean
Difference
Mean
Difference
N Mean(SD)[%] N Mean(SD)[%] IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 67 1.17 (13.56) 76 -1.85 (12.89) 3.02 [ -1.33, 7.37 ]
-10 -5 0 5 10
Favours placebo Favours ciprofloxacin
Analysis 7.3. Comparison 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled
tobramycin, Outcome 3 Mean 70-week change in weight from baseline.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled tobramycin
Outcome: 3 Mean 70-week change in weight from baseline
Study or subgroup Ciprofloxacin Placebo
Mean
Difference
Mean
Difference
N Mean(SD)[kg] N Mean(SD)[kg] IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 152 3.8 (2.5) 152 4.1 (2.7) -0.30 [ -0.88, 0.28 ]
-2 -1 0 1 2
Favours placebo Favours ciprofloxacin
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Analysis 7.4. Comparison 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled
tobramycin, Outcome 4 Mean 70-week change in height from baseline.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled tobramycin
Outcome: 4 Mean 70-week change in height from baseline
Study or subgroup Ciprofloxacin Placebo
Mean
Difference
Mean
Difference
N Mean(SD)[cm] N Mean(SD)[cm] IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 152 9.2 (2.8) 152 9.4 (3.1) -0.20 [ -0.86, 0.46 ]
-1 -0.5 0 0.5 1
Favours placebo Favours ciprofloxacin
Analysis 7.5. Comparison 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled
tobramycin, Outcome 5 Time to severe pulmonary exacerbation.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled tobramycin
Outcome: 5 Time to severe pulmonary exacerbation
Study or subgroup Ciprofloxacin Placebo log [Hazard Ratio] Hazard Ratio Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 152 0 0.3716 (0.439) 1.45 [ 0.61, 3.43 ]
0.02 0.1 1 10 50
Favours ciprofloxacin Favours placebo
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Analysis 7.6. Comparison 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled
tobramycin, Outcome 6 Participants with one or more severe pulmonary exacerbations.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled tobramycin
Outcome: 6 Participants with one or more severe pulmonary exacerbations
Study or subgroup Ciprofloxacin Placebo Odds Ratio Odds Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 29/152 21/152 1.47 [ 0.80, 2.72 ]
0.2 0.5 1 2 5
Favours ciprofloxacin Favours placebo
Analysis 7.7. Comparison 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled
tobramycin, Outcome 7 Time to pulmonary exacerbation (any severity).
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled tobramycin
Outcome: 7 Time to pulmonary exacerbation (any severity)
Study or subgroup Ciprofloxacin Placebo log [Hazard Ratio] Hazard Ratio Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 83 68 0.2546 (0.214) 1.29 [ 0.85, 1.96 ]
0.1 0.2 0.5 1 2 5 10
Favours ciprofloxacin Favours placebo
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Analysis 7.8. Comparison 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled
tobramycin, Outcome 8 Participants with one of more pulmonary exacerbation (any severity).
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled tobramycin
Outcome: 8 Participants with one of more pulmonary exacerbation (any severity)
Study or subgroup Ciprofloxacin Placebo Odds Ratio Odds Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 83/152 68/152 1.49 [ 0.95, 2.33 ]
0.5 0.7 1 1.5 2
Favours ciprofloxacin Favours placebo
Analysis 7.9. Comparison 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled
tobramycin, Outcome 9 Participants with new isolates of Stenotrophomonas maltophilia.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled tobramycin
Outcome: 9 Participants with new isolates of Stenotrophomonas maltophilia
Study or subgroup Ciprofloxacin Placebo Odds Ratio Odds Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 29/137 26/142 1.20 [ 0.66, 2.16 ]
0.5 0.7 1 1.5 2
Favours ciprofloxacin Favours placebo
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Analysis 7.10. Comparison 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled
tobramycin, Outcome 10 Participants with one or more serious adverse event.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled tobramycin
Outcome: 10 Participants with one or more serious adverse event
Study or subgroup Ciprofloxacin Placebo Odds Ratio Odds Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 48/152 35/152 1.54 [ 0.93, 2.57 ]
0.2 0.5 1 2 5
Favours ciprofloxacin Favours placebo
WH A T ’ S N E W
Last assessed as up-to-date: 29 October 2014.
Date Event Description
29 October 2014 New search has been performed A search of the Group’s CF Register identiﬁed 117 ref-
erences for possible inclusion in the review
Three references have been added to an already included
trial (Proesmans 2013). One trial, known as the ELITE
trial, has been moved from ’Ongoing studies’ to ’In-
cluded studies’ and the reference to the full publication
added; this trial has provided a comparison of duration
of intervention not previously available for inclusion
(Ratjen 2010). A further trial also previously listed as
ongoing with the study ID Ramsey 2005 (also known
as the EPIC trial) has been included with 11 new refer-
ences (Treggiari 2011). One new trial, with nine refer-
ences has been included (Taccetti 2012).
A total of 22 new trials (97 references) have been ex-
cluded: one reference each (Alothman2005;Goss 2009;
Prayle 2013; Postnikov 2007; Wainwright 2011b);
two references each (Alothman 2002; Kenny 2009;
Mainz 2014; Schelstraete 2010; Tramper-Stranders
2009); three references each (Coates 2011; Geller
2007; Mazurek 2012; Rietschel 2009); four references
each (Retsch-Bogart 2008; Trapnell 2012); ﬁve refer-
ences each (Clancy 2013; Konstan 2010); six refer-
ences each (Oermann 2009; Schuster 2013); 10 refer-
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(Continued)
ences (Retsch-Bogart 2009); and 32 references (Ramsey
1999).
Two trials previously listed as ’Awaiting classiﬁcation’
have now been excluded (Latzin 2008; Lenoir 2007).
One additional reference has been added to a previously
excluded study (Wainwright 2011a)
The full paper to an abstract already listed as ’Awaiting
Classiﬁcation’ has now been published and added to the
existing study ID while we await clariﬁcation regarding
participants from the authors (Noah 2010).
One new trial (with a single reference) has been added
to ’Ongoing studies’ (TORPEDO Trial).
There have been three post hoc changes to the review at
this update:
• we now include participants who have received
treatment within six months of the ﬁrst isolation of P.
aeruginosa (previously not more than two months);
• we now allow trials where all patients receive
some eradication therapy before randomisation which
reﬂects current recommended ’standard of care’ and
consequent trial design;
• we have added cost as an outcome measure, as
cost-effectiveness has become increasingly important
in CF care.
29 October 2014 New citation required but conclusions have not
changed
This review has been updated, but the conclusions re-
main the same
H I S T O R Y
Protocol ﬁrst published: Issue 2, 2003
Review ﬁrst published: Issue 1, 2006
Date Event Description
10 June 2009 New search has been performed A new search of the Group’s CF Register identiﬁed 14
new references
We have included one new study with one refer-
ence (Proesmans 2013) and excluded two new studies
with three new references (Postnikov 2000; Steinkamp
2007). Three studies with a total of ﬁve references are
listed as ’Awaiting classiﬁcation’ until we are able to
obtain further details (Latzin 2008a; Lenoir 2007a;
Noah 2007)
We have added ﬁve references to the two ongoing stud-
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(Continued)
ies: one reference to Ramsey 2005a and four references
to Ratjen 2006a
10 June 2009 New citation required but conclusions have not
changed
From the 2009 update of this review, the lead author
Dr Damian Wood has stepped down and is no longer
involved in the review. The new lead author is Dr
Simon Langton Hewer
12 November 2008 Amended Converted to new review format.
13 November 2007 Amended The review authors have addressed some comments
from the CFGD Group’s medical statistician within
this update
13 November 2007 New search has been performed The search identiﬁed four new trials; two of which
have been excluded (Gibson 2007; Griese 2002); and
two of which are still ongoing (Ramsey 2005a; Ratjen
2006a)
15 November 2006 Feedback has been incorporated The review now contains the response from the au-
thors to feedback regarding the necessity of further tri-
als received through The Cochrane Library Feedback
system.
C O N T R I B U T I O N S O F A U T H O R S
Damian Wood wrote the ﬁrst draft of the review and both Damian Wood and Alan Smyth edited it to produce the ﬁnal original review
version. Both Damian Wood and Alan Smyth have worked on updated versions of the review up until 2007. As from Issue 2, 2009 the
new lead author is Simon Langton Hewer. The most recent version of the review was jointly written by Simon Langton-Hewer and
Alan Smyth.
Simon Langton Hewer acts as guarantor of the review.
D E C L A R A T I O N S O F I N T E R E S T
Dr Langton Hewer is the lead investigator on the ongoing trial Torpedo-CF: Trial of Optimal Therapy for Pseudomonas Eradication
in Cystic Fibrosis.
Prof Smyth has received ﬁnancial support from Forest Laboratories and Gilead (both companies market a nebulised antibiotic) and
from MPEX Pharma (nebulised antibiotic in development).
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
2014
The inclusion criteria have been changed to include participants who have received study treatment within six months of the ﬁrst
isolation of P. aeruginosa (previously not more than two months). This is to reﬂect differences in clinical practice between Europe and
North America and to allow trials from earlier decades (where early treatment of P. aeruginosa was not established clinical practice) to
be included. A large trial (306 participants), published in 2011, is therefore now eligible for inclusion (Treggiari 2011). However, it is
possible that, where infection has been present for as long as six months, it may have become more difﬁcult to eradicate.
In recent years 28 days of inhaled tobramycin has been recommended as ’standard of care’ for eradication of P. aeruginosa in guidelines
(Döring 2012). This has been reﬂected in trial design, where investigators have designed their trials to ensure that all patients receive an
initial 28-day course of inhaled tobramycin before randomisation to the next stage of therapy. We have therefore altered our eligibility
criteria to allow trials where all patients receive some eradication therapy before randomisation (Treggiari 2011).
We have added cost as an outcome measure, as cost-effectiveness has become increasingly important in CF care. None of the trials
included to date have reported this outcome but future trials may do so.
2009
After new lead reviewer re-assessed the review, the section ’Objectives’ was expanded to include the sentence:
’To investigate whether there is evidence of superiority or improved cost-effectiveness between antibiotic strategies.’
Currently, we have included both P. aeruginosa free and P. aeruginosa naive patients according to the deﬁnition by Lee (Lee 2003). At
the update in 2009 we have added plans to analyse these subgroups separately if sufﬁcient data become available from included studies
in the future.
2005
Two clinically relevant additional outcomes were added at review stage to the ones we had originally listed:
1. Time to chronic infection (deﬁned as the presence of P. aeruginosa in each monthly sputum sample for six consecutive months or
the presence of precipitating antibodies to P. aeruginosa or both)
2. Clinical and radiological scores
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Pseudomonas aeruginosa; Administration, Inhalation; Administration, Oral; Anti-Bacterial Agents [administration & dosage;
∗therapeutic use]; Ciproﬂoxacin [administration &dosage; therapeutic use]; Colistin [administration & dosage; therapeutic use]; Cystic
Fibrosis [∗complications; microbiology]; Pseudomonas Infections [∗drug therapy]; Randomized Controlled Trials as Topic; Tobramycin
[administration & dosage; therapeutic use]
MeSH check words
Adult; Child; Humans
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